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ABSTRACT 
Multidrug resistant (MDR) extended-spectrum β-lactamase (ESBL)-producing and 
carbapenem-resistant Gram-negative bacteria have become an international health 
issue limiting treatment options. The objective of this study was to determine the 
prevalence of carbapenem-susceptible (CS) and carbapenem-resistant (CR) 
Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa and 
investigate clinical isolates for their resistant genes/ determinants. A total of 98 
bacterial isolates (59 CS and 39 CR) were collected between February 2012 and 
February 2013 at NHLS, after being recovered from various clinical specimens from 
PE hospital complex. Antimicrobial susceptibility testing was performed using the 
VITEK 2® system, E-test and microbroth dilution method. PCR and DNA sequencing 
were used to investigate: (i) ESBLs: CTX-M, TEM, SHV and OXA-1; (ii) plasmid-
mediated quinolone resistance (PMQR) genes: qnrA, qnrB, qnrC, qnrD, qnrS, qepA 
and aac(6’)-lb-cr; (iii) Escherichia coli sequence type 131 (ST131); (iv) 
carbapenemases: NDM, VIM, IMP, KPC, BIC, SME, IMI, NMC-A, GES, OXA-23, 
OXA-24, OXA-48, OXA-51 and OXA-58; and (v) insertion sequence ISAba1 
upstream blaOXA-23/-24/-51/-58 genes. Porin loss in CR isolates was determined by SDS-
PAGE while genetic relatedness between E. coli ST131 isolates was determined by 
pulsed-field gel electrophoresis (PFGE). MDR ESBL-producing Enterobacteriaceae 
(mainly K. pneumoniae) and CR A. baumannii isolates were recovered from 
neonatal/ infant specimens. The majority of CS and CR isolates were MDR, 
possessing multiple ESBL genotypes (CTX-M, TEM, SHV and OXA-1). ESBL 
variants identified included: CTX-M-1, CTX-M-3, CTX-M-15, CTX-M-22, CTX-M-9, 
CTX-M-14, TEM-1, SHV-1, SHV-11 and OXA-1. PMQRs identified included: aac(6’)-
lb-cr, qnrB1, qnrB2, qnrB13 and qnrS1. Twelve of 21 (57.1%) E. coli isolates 
belonged to the ST131 clonal complex and were genetically diverse, mainly 
producing CTX-M-15. Carbapenem resistance mechanisms identified included: (i) 
OXA-23 preceded by ISAba1 in 10 A. baumannii and 2 P. aeruginosa isolates; (ii) 
IMI-2 carbapenemase in an E. asburiae isolate; and (iii) combination of porin loss 
and ESBL production in 1 K. pneumoniae and 1 E. coli isolate. This is the first report 
in South Africa describing the occurrence of CTX-M-9, CTX-M-22 and IMI-2 among 
Enterobacteriaceae; CTX-M-15 in A. baumannii; and OXA-23 in combination with 
OXA-51 in P. aeruginosa. However, resistance determinants could not be detected 
for 24 carbapenem-resistant isolates which requires further investigation. 
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CHAPTER ONE 
 
LITERATURE REVIEW 
 
1.1 INTRODUCTION 
The emergence and dissemination of multidrug resistant (MDR), extended-spectrum 
β-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae, A. 
baumannii, and P. aeruginosa has become a worldwide health concern, posing 
enormous threat to the feasibility of currently available antibiotics (Zarrilli et al., 2009; 
Nordmann et al., 2011; Brink et al., 2012b; Marchaim et al., 2012; Bush, 2013a). 
Carbapenem-resistant bacteria are limiting the use of carbapenems, which are the 
most potent, broad-spectrum β-lactam antibiotics used as last line of defense to treat 
life-threatening infections (e.g. bacteraemia and septicaemia) caused by MDR Gram-
negative bacteria (El Gamal and Oh, 2010; Patel and Bonomo, 2013).  
 
Global emergence of carbapenemases (i.e. carbapenem-hydrolyzing enzymes) 
among Gram-negative bacteria is a serious threat both in clinical and community 
settings (Patel and Bonomo, 2013). Carbapenemase molecular families include 
serine carbapenemases (representatives include KPC “Klebsiella pneumoniae 
carbapenemase” and OXA-48 “Oxacillinase-48”) and metallo-β-lactamases (MBLs) 
such as NDM (New Dehli metallo-β-lactamase), VIM (Verona-integron mediated 
metallo-β-lactamase) and IMP (Imipenemase) (Walsh, 2010; Bush, 2013a). 
Mechanisms that may be responsible for carbapenem resistance in the absence of 
carbapenemases include efflux pump over-expression, or porin loss/ modification in 
combination with over-production of ampicillin cephalosporinase (AmpC)/ ESBL type 
enzyme (Lu et al., 2009; Lee et al., 2010a; Lynch et al., 2013). 
 
Among the ESBL enzymes, the rising problem is the emergence of cefotaxime (CTX-
M) β-lactamases both in clinical and community settings and these have become the 
most prevalent ESBLs worldwide (Livermore and Woodford, 2006; D’Andrea et al., 
2013; Lynch et al., 2013). CTX-M-15 variant has been reported as the most 
prevalent CTX-M-type enzyme worldwide conferring acquired resistance to the 
oxyimino-cephalosporins such as cefotaxime, ceftriaxone and ceftazidime (Canton 
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and Coque, 2006; Livermore et al., 2007; D’Andrea et al., 2013). Other common 
ESBL genes include TEM (Temoneira) and SHV (Sulfhydryl variable) (Rawat and 
Nair, 2010; El Salabi et al., 2013). Another global health threat is the widespread 
dissemination of the Escherichia coli sequence type 131 (ST131) clone, which is 
often associated with community-acquired urinary tract infections (UTIs) and 
harbours a wide range of antimicrobial resistance determinants (Pitout et al., 2005; 
Peirano and Pitout, 2010). 
 
CTX-M enzymes previously described in South Africa include CTX-M-1, CTX-M-2, 
CTX-M-3, CTX-M-14, CTX-M-15 and CTX-M-37 (Paterson et al., 2003; Govinden et 
al., 2006; Govinden et al., 2008; Ehlers et al., 2009; Peirano et al., 2011). 
Carbapenemases previously described include KPC-2, GES-5 (Guiana extended-
spectrum β-lactamase), NDM-1, IMP, VIM-2, OXA-23, OXA-51, OXA-58, OXA-48 
and OXA-181 (Labuschagne et al., 2008; Brink et al., 2012a; Brink et al., 2012b; 
Jacobson et al., 2012; Brink et al., 2013; Govind et al., 2013; Kock et al., 2013; 
Perovic, 2013). There is only one published study in South Africa describing the 
emergence of the E. coli ST131 clone predominantly producing CTX-M-14 and CTX-
M-15 (Peirano et al., 2011). 
 
There are two published reports from Port Elizabeth describing the occurrence of 
carbapenemases in Enterobacteriaceae such as GES (Serratia marcescens) and 
OXA-48 (K. pneumoniae and S. marcescens) from private hospitals (Brink et al., 
2013) while OXA-48 variants (E. cloacae) and IMP (E. cloacae) were detected in 
public hospitals (Perovic, 2013). Furthermore, there are no reports describing the 
prevalence of ESBLs and E. coli ST131 clone in Port Elizabeth. The purpose of this 
study was to provide information on the resistance determinants of carbapenem-
resistant and –susceptible Enterobacteriaceae, A. baumannii and P. aeruginosa 
clinical isolates. 
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1.2  ENTEROBACTERIACEAE, Acinetobacter baumannii AND Pseudomonas 
aeruginosa 
 
1.2.1 Taxonomy 
The family Enterobacteriaceae contains inhabitants of the intestinal flora that are 
Gram-negative, peritrichously flagellated or non-motile, facultative anaerobic, straight 
rods with simple nutritional requirements (Nordmann et al., 2011; Lynch et al., 2013). 
This family belongs to the phylum Proteobacteria, class Gammaproteobacteria, order 
Enterobacteriales which has only one family, Enterobacteriaceae, with 44 genera 
(Prescott et al., 2008). Representative species include E. coli, Shigella spp., 
Salmonella spp., Citrobacter spp., Klebsiella spp., Enterobacter spp., S. marcescens 
and Proteus spp. (Prescott et al., 2008; Lynch et al., 2013).  
 
Acinetobacter baumannii is a non-fermentative, strictly aerobic, non-motile, non-
pigmented, catalase-positive and oxidase-negative Gram-negative coccobacillus that 
belongs to the phylum Proteobacteria, class Gammaproteobacteria, order 
Pseudomonadales, family Moraxellaceae and under genus Acinetobacter 
(Giamarellou et al., 2008). The genus Acinetobacter currently contains up to 26 
named and 9 unnamed species (Dijkshoorn et al., 2007). Three clinically significant 
Acinetobacter spp. include A. baumannii, genomic species 3 and 13TU, and are 
genetically and phenotypically similar to an environmental species, A. calcoaceticus, 
hence differentiation is difficult and the species are often grouped together as A. 
calcoaceticus - A. baumannii complex (Dijkshoorn et al., 2007).  
 
Pseudomonas aeruginosa is a non-fermentative, versatile, motile Gram-negative rod 
forming straight or slightly curved rods (Prescott et al., 2008). This bacterium 
belongs to the phylum Proteobacteria, class Gammaproteobacteria, order 
Pseudomonadales, family Pseudomonaceae and under genus Pseudomonas 
(Prescott et al., 2008). 
 
1.2.2 Community- and hospital-acquired infections 
ESBL- and carbapenemase-producing Enterobacteriaceae, A. baumannii and P. 
aeruginosa are known to be the most common and important human pathogens 
responsible for various community and hospital-acquired infections (Azap et al., 
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2010; Nordmann et al., 2011; Piednoir et al., 2011; Song et al., 2011). These 
include: cystitis, pyelonephritis with fever, surgical-site infections, intra-abdominal 
abscesses, septicaemia, pneumonia, peritonitis, pseudomonal infections in cystic 
fibrosis patients, meningitis, wound infections, skin and soft tissue infections, 
bacterial prostatitis, ulcerative colitis and device-associated infections (Paterson, 
2000; Giamarellou, 2002; Guerin et al., 2005; Scott et al., 2007; Lowman et al., 
2008; Sacha et al., 2008; Nordmann et al., 2011; Nordmann et al., 2012). 
Carbapenemase-producing bacteria are frequently implicated in life-threatening 
infections such as bacteremia and septicemia in immunocompromised patients 
(Bratu et al., 2005; Marchaim et al., 2008).  
 
Carbapenemase-producing Enterobacteriaceae isolates have been associated with 
increased mortality in several healthcare institutions (Marchaim et al., 2008; 
Nordmann et al., 2011; Brink et al., 2012b). In South Africa, cases of patient demise 
following infection with carbapenemase-producing K. pneumoniae and E. cloacae 
have been reported (Brink et al., 2012a; Brink et al., 2013). E. coli strains expressing 
CTX-M β-lactamases are frequently implicated in community-acquired UTIs 
(particularly ST131 strains), and often lead to nosocomial and community outbreaks 
(Pitout et al., 2005). Clinical settings have been shown to be a preferential 
environment for A. baumannii isolates since they adapt easily and survive for 
prolonged periods in such environments (Bergogne-Berezin and Towner, 1996; 
Cisneros and Rodriguez-Bano, 2002; Kempf and Rolain, 2012).  
 
Risk factors associated with colonization/ infection with an ESBL- or 
carbapenemase-producing pathogen include previous antibiotic exposure 
(particularly β-lactams, fluoroquinolones and aminoglycosides), prolonged stay in the 
intensive care unit (ICU) or long-term care facility, in-dwelling devices, mechanical 
ventilation, severe comorbidities and immunosuppression (Ben-Ami et al., 2009; 
Gupta et al., 2011; Kritsotakis et al., 2011).  
 
1.2.3 Treatment 
There are still controversies concerning treatment of MDR Gram-negative bacteria 
(Brink, 2013). Nonetheless, carbapenems (particularly ertapenem) remain the only 
viable treatment option for severe infections caused by ESBL-producing bacteria 
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(Collins et al., 2012; El Salabi et al., 2013). Carbapenem resistance may still develop 
during therapy via loss/ modification of porins, over-expression of AmpC or efflux 
pumps, or combination of these mechanisms (Kochar et al., 2009; Lynch et al., 
2013).  
 
ESBL-producing bacteria may be susceptible to the following drugs: cephamycins 
(e.g. cefoxitin, cefotetan and cefepime) and β-lactam-β-lactamase inhibitors (e.g. 
piperacillin-tazobactam and amoxicillin-clavulanate); however, resistance 
development to these antimicrobials during therapy has been reported (Endimiani 
and Paterson, 2007; Peterson, 2008). Resistance to fluoroquinolones and 
aminoglycosides has increased over the past years among ESBL-producing bacteria 
(Coque et al., 2008a; El Salabi et al., 2013). As a result, fluoroquinolone therapy 
usually leads to poor clinical outcomes while aminoglycoside monotherapy is not 
recommended for ESBL infections (Endimiani and Paterson, 2007; El Salabi et al., 
2013).  
 
Optimal treatment for carbapenem-resistant Enterobacteriaceae, A. baumannii and 
P. aeruginosa infections has not been established and treatment options remain 
limited (Li et al., 2006; Kanj and Kanafani, 2011; Kempf and Rolain, 2012). Currently, 
colistin, fosfomycin, temocillin and tigecycline are the only feasible treatment choices 
(Carmeli et al., 2010; Livermore et al., 2011; Schultsz and Geerlings, 2012). 
However, several Enterobacteriaceae species (e.g. P. mirabilis) and P. aeruginosa 
are inherently resistant to tigecycline, further limiting therapeutic alternatives 
(Lowman et al., 2011; Tawfik et al., 2012). Another concern is the emergence of 
colistin resistance during therapy among KPC-producing Enterobacteriaceae in the 
United States of America (USA), Italy, Greece, Israel and Korea (Kontopoulou et al., 
2010; Zarkotou et al., 2010; Marchaim et al., 2011; Mammina et al., 2012); NDM-
producing K. pneumoniae in France (Arpin et al., 2012); and recently in OXA-181-
producing K. pneumoniae in South Africa (Brink et al., 2013). Colistin resistance has 
also been observed worldwide in A. baumannii and P. aeruginosa (Kempf and 
Rolain, 2012). 
 
Combination therapy with two or three active drugs for the treatment of infections 
caused by carbapenem-resistant bacteria has proven effective and recommended as 
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an optimal treatment strategy compared to monotherapy (Carmeli et al., 2010; Kanj 
and Kanafani, 2011; Qureshi et al., 2012; Tumbarello et al., 2012; Brink, 2013). 
Combination therapy with tigecycline, colistin and meropenem has been associated 
with higher clinical success relative to colistin monotherapy (Tumbarello et al., 2012). 
Double carbapenem therapy that includes ertapenem has been recommended 
(Hirsch and Tam, 2010). Other effective treatment alternatives include: rifampicin 
with doripenem and colistin or with intravenous fosfomycin (Endimiani et al., 2010; 
Urban et al., 2010; Kempf and Rolain, 2012; Durante-Mangoni et al., 2013). There is 
only one published case report of successful treatment of prostatitis due to VIM-2-
producing P. aeruginosa with the combination of fosfomycin and aztreonam (Guerin 
et al., 2005).  
 
 
1.3 ANTIMICROBIAL SUSCEPTIBILITY TESTING 
Antimicrobial susceptibility testing is crucial as it facilitates - (i) administration of 
appropriate treatment; (ii) detection of microorganisms with exceptional resistance 
(e.g. ESBL- or carbapenemase-producers); (iii) determination of the rate of 
resistance development using epidemiological cut-off values (ECOFFs) and clinical 
breakpoints; and (iv) development of strategies to reduce antimicrobial resistance 
development (Kahlmeter, 2013). 
 
Internationally recommended guidelines for susceptibility testing of 
Enterobacteriaceae, A. baumannii and P. aeruginosa are available as there are for 
other prokaryotes under the Clinical and Laboratory Standards Institute (CLSI) and 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST). The 
CLSI recommended and FDA (Food and Drug Administration) approved phenotypic 
methods for antibiotic susceptibility testing in Gram-negative bacteria include agar 
disk diffusion, E-test, microbroth dilution method and automated systems such as the 
Vitek® 2 system (bioMérieux), Phoenix (BD Diagnostics) and MicroScan (Siemans) 
(Paterson and Bonomo, 2005). These methods can also be used for screening and 
detection of ESBL/ carbapenemase-producing bacteria by noting specific zone 
diameters or minimal inhibitory concentrations (MIC) (Paterson and Bonomo, 2005).  
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MICs play an important role in antibiotic stewardship and dose optimization/ 
individual antimicrobial management, therefore optimizing clinical outcome (Dellit et 
al., 2007). MICs and zone diameters of various antimicrobial agents against Gram-
negative bacteria can be interpreted according to CLSI and EUCAST clinical 
breakpoints. However, there are discrepancies (only 32.5% agreement) between 
CLSI and EUCAST clinical breakpoints (Miriagou et al., 2010; Kahlmeter, 2013).  
 
The uptake of EUCAST guidelines has increased since 2012 while the uptake of 
CLSI guidelines is rapidly decreasing (Kahlmeter, 2013). Recently, South Africa has 
decided to follow the guidelines for susceptibility testing and clinical breakpoints set 
by the EUCAST (Kahlmeter, 2013). The EUCAST makes decisions by consensus, 
rationale for decisions are published, and documents are freely accessible online 
including clinical breakpoints and ECOFFs (Kahlmeter, 2013). In contrast, CLSI 
makes decisions by vote, the rationale for decisions are not published, and 
documents are for sale (Kahlmeter, 2013). The CLSI (2013) and EUCAST (2013) 
MIC interpretive criteria for carbapenems against Enterobacteriaceae, A. baumannii 
and P. aeruginosa are presented in Table 1.1.  
 
Table 1.1:   CLSI and EUCAST carbapenem clinical breakpoints (MIC values, mg/L). 
Organism 
 
Carbapenem CLSI breakpoints (mg/L)  EUCAST breakpoints (mg/L) 
 S I R  S R 
Enterobacteriaceae Doripenem ≤1 2 ≥4  ≤1  >4
 Ertapenem ≤0.5 1 ≥2  ≤0.5  >1
 Imipenem ≤1 2 ≥4  ≤2  >8
 Meropenem ≤1 2 ≥4  ≤2  >8
P. aeruginosa Doripenem ≤2 4 ≥8  ≤1  >4
 Ertapenem ND ND ND ND ND
 Imipenem ≤2 4 ≥8  ≤4  >8
 Meropenem ≤2 4 ≥8  ≤2  >8
Acinetobacter spp. Doripenem ND ND ND  ≤1  >4
 Ertapenem ND ND ND ND ND
 Imipenem ≤4 8 ≥16  ≤2  >8
 Meropenem ≤4 8 ≥16  ≤2  >8
S, susceptible; I, intermediate; R, resistant; ND, not defined; CLSI - http://www.clsi.org; EUCAST -  http://www.eucast.org. 
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1.4 MECHANISMS OF DRUG RESISTANCE  
 
1.4.1 β-lactam resistance mechanisms 
There are four groups of β-lactam drugs: penicillins, cephalosporins, monobactams, 
and carbapenems. β-lactam drugs exert their bactericidal effect by binding to the 
penicillin-binding proteins (PBPs) in the periplasmic space, thereby inhibiting 
synthesis of the peptidoglycan layer of bacterial cell walls, which consequently leads 
to cell lysis (Nordmann et al., 2012). β-lactam resistance can result from one or more 
of the following mechanisms (Fig. 1.1): (i) β-lactamase (i.e. ESBL or 
carbapenemase) production which leads to β-lactam hydrolysis/ inactivation due to 
cleavage of the β-lactam ring; (ii) loss/ modification of porins (which allow entry of β-
lactam drugs into the cell) usually in combination with over-production of AmpC/ 
ESBL enzyme; (iii) augmented drug efflux (i.e. over-expression of efflux pumps); and 
(iv) modification of target site (i.e. PBPs) (Nordmann et al., 2012; Patel and Bonomo, 
2013). 
 
 
 
Figure 1.1: β-lactam resistance mechanisms in Gram-negative bacteria (Image extracted from 
Nordmann et al., 2012). 
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1.4.1.1 Extended-spectrum β-lactamases (ESBLs) 
ESBLs are enzymes with an ability to hydrolyze and inactivate all the commercially 
available β-lactam drugs excluding carbapenems and cephamycins such as cefoxitin 
and cefotetan (Paterson and Bonomo, 2005; El Salabi et al., 2013). The majority of 
ESBLs (TEM, SHV and CTX-M) belong to Ambler class A β-lactamases (Paterson 
and Bonomo, 2005; El Salabi et al., 2013). ESBL-producing Enterobacteriaceae 
have been reported in literature with increasing frequency worldwide due to the 
emergence of CTX-M enzymes encoded by blaCTX-M gene (Bonnet, 2004; Lynch et 
al., 2013).  
 
CTX-M-type ESBLs are divided into five groups (Group I, II, III, IV and V) based on 
their amino acid sequence identities (Bonnet, 2004). The CTX-M group I β-
lactamase has been reported to be the most frequent in Enterobacteriaceae, with 
CTX-M-15 reported as the most prevalent ESBL worldwide and the primary cause of 
acquired resistance to the extended-spectrum cephalosporins (Priyadharsini et al., 
2011; Ben-Sallem et al., 2012; Lonchel et al., 2012). Over the past few years, CTX-
M-15 has become the most predominant ESBL in many parts of the world in which 
TEM and SHV were dominant including many European (Livermore et al., 2007), 
Asian (Ling et al., 2006; Kiratisin et al., 2008) and Latin American countries (Rossi, 
2011). TEM and SHV are still dominant over CTX-M in North America; however, with 
the rapid dissemination of the latter, the former will soon be replaced (Doi et al., 
2007; Lewis et al., 2007; Johnson et al., 2010a; Peirano et al., 2010a). 
 
Rapid dissemination of CTX-M enzymes is associated with highly efficient mobile 
genetic elements including insertion sequences, integrons, transposons and MDR 
IncFII (incompatibility type FII) plasmids (Poirel et al., 2008). However, certain clonal 
complexes are responsible for the global dissemination of CTX-M enzymes (Lynch et 
al., 2013). An example is the E. coli ST131 clone, which is frequently associated with 
CTX-M-15 enzyme and plasmid-mediated quinolone resistance (PMQR) 
determinants (Coque et al., 2008b; Nicolas-Chanoine et al., 2008). 
 
TEM-, SHV-, Pseudomonas-extended-resistance β-lactamase (PER), Vietnam 
extended-spectrum β-lactamase (VEB), Belgium extended-spectrum β-lactamase 
(BEL) and CTX-M-type ESBLs have been described in A. baumannii and P. 
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aeruginosa (Vila et al., 1993; Poirel et al., 2003; Yong et al., 2003; Huang et al., 
2004; Nagano et al., 2004; Poole, 2004; Paterson and Bonomo, 2005). CTX-M-15 
and CTX-M-2 β-lactamases were reported in A. baumannii clinical isolates in Japan, 
Bolivia, India and Haiti (Nagano et al., 2004; Celenza et al., 2006; Shakil and Khan, 
2010; Potron et al., 2011). ESBLs are less common in P. aeruginosa (Poole, 2011). 
OXA-2 and OXA-10 ESBLs have been identified in P. aeruginosa isolates from 
Turkey and France (Livermore and Woodford, 2006). 
 
1.4.1.2 Carbapenemases 
Carbapenemases are intricate β-lactamases that exhibit significantly diverse variants 
and highly variable hydrolytic activity against carbapenems (Currie, 2012). These 
enzymes can hydrolyze and confer resistance to all the commercially available β-
lactam drugs including penicillins, cephalosporins and carbapenems (Bush, 2013a; 
Bush, 2013b). Bacteria expressing carbapenemases usually exhibit MDR phenotype 
since plasmids carrying carbapenemase genes usually harbour other additional 
resistance genes (Patel and Bonomo, 2013). Carbapenemases belong to two major 
molecular families distinguished by the hydrolytic mechanism at the active site, 
namely serine (active site serine - metal-independent) and metallo- (Zn2+-requiring - 
metal-dependent) carbapenemases (Walsh, 2010). Carbapenemases can be further 
classified into three molecular classes: Ambler class A, B and D based on amino 
acid sequence homology (Table 1.2) (Ambler, 1980; Bush and Jacoby, 2010).  
 
Table 1.2: Clinically significant carbapenemases in Gram-negative bacteria (Table adapted from Perovic, 2013). 
Classification Clinically significant enzymes Most common bacteria 
Class A 
(Serine carbapenemases) 
KPC, SME, IMI, NMC, GES Enterobacteriaceae 
(rare in P. aeruginosa and A. 
baumannii) 
Class B 
(Metallo-β-lactamases) 
NDM, IMP, VIM, GIM, SPM P. aeruginosa 
Enterobacteriaceae 
A. baumannii 
Class D 
(Serine carbapenemases) 
OXA-48, OXA-48 variants, OXA-23, 
OXA-24, OXA-58 
A. baumannii (recently in 
Enterobacteriaceae) 
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The rapid emergence and worldwide dissemination of carbapenemases is 
associated with mobile genetic elements (plasmids, transposons and insertion 
sequences) and specific clones (e.g. K. pneumoniae ST258 clone carrying KPC 
enzymes). The blaKPC, blaNDM-1 and blaOXA-48 genes with associated mobile genetic 
elements are shown in Fig. 1.2 (Patel and Bonomo, 2013). These elements facilitate 
inter- or intra-species transfer of carbapenemase genes (Walsh, 2010).  
 
 
 
Figure 1.2: Basic genetic construct of blaKPC, blaNDM-1 and blaOXA-48 (Adapted from Patel and Bonomo, 
2013). A: The blaKPC gene is associated with Tn4401 type of transposon which includes a 
transposase gene (tnpA), a resolvase gene (tnpR), as well as insertion sequences ISKpn6 and 
ISKpn7. B: The blaNDM-1 gene is associated with an insertion sequence ISAba125 upstream 
and a novel bleomycin resistance (bleMBL) gene downstream. C: The blaOXA−48 gene is mapped 
to a Tn1999 composite transposon where it is bracketed between two copies of the same 
insertion sequence IS1999 and lysR gene which encodes for a regulatory protein is located 
downstream blaOXA−48. 
 
 
1.4.1.3 Class A serine carbapenemases 
Class A serine carbapenemases are predominantly found in Enterobacteriaceae and 
less frequently in A. baumannii and P. aeruginosa (Queenan and Bush, 2007). 
These enzymes are effective at hydrolyzing carbapenems but are partially inhibited 
by β-lactamase inhibitors such as clavulanic acid and tazobactam (Queenan and 
Bush, 2007; Nordmann et al., 2009; Tsakris et al., 2010). KPC is the most clinically 
significant class A carbapenemase and is disseminated worldwide due to its 
association with a Tn3-like transposon, Tn4401, which can be inserted into different 
12 
plasmids (Naas et al., 2008; Nordmann et al., 2009; Cuzon et al., 2010a; Walsh, 
2010).  
 
KPC enzyme in combination with porin loss/ modification has been reported to 
confer high-level carbapenem resistance (Woodford et al., 2004; Leavitt et al., 2007; 
Zhang et al., 2008; Davies et al., 2011). Co-production of KPC with other acquired 
carbapenemases such as NDM, VIM, and IMP has been reported among 
Enterobacteriaceae in India (Kumarasamy and Kalyanasundaram, 2012), USA (Bush 
et al., 2012) and China (Li et al., 2011), respectively. Several studies have shown 
KPC-producers with plasmids co-harbouring one or more ESBLs (Baraniak et al., 
2009; Giani et al., 2009; Qi et al., 2011; Lauderdale et al., 2012). Other class A 
carbapenemases include chromosomally encoded Serratia marcescens enzyme 
(SME), IMI (imipenem-hydrolyzing β-lactamase), NMC (non-metallo-enzyme 
carbapenemase) and plasmid-encoded GES (Walsh, 2010).  
 
1.4.1.4 Class B metallo-β-lactamases (MBLs) 
Metallo-β-lactamases can hydrolyse all β-lactams except monobactams (e.g. 
aztreonam) and their activity is inhibited by metal-ion chelators such as ethylene-
diamine-tetra-acetate (EDTA) (Walsh et al., 2005; Tsakris et al., 2010). However, 
MBLs are resistant to the commercially available β-lactamase inhibitors (Queenan 
and Bush, 2007). MBLs were previously predominant in P. aeruginosa and A. 
baumannii, and less frequent in Enterobacteriaceae (Bush, 2013a). However, certain 
MBLs (e.g. NDM-1) are now widespread in Enterobacteriaceae, with increasing 
reports of  NDM-1 worldwide amongst Enterobacteriaceae and now also in A. 
baumannii and P. aeruginosa showing genetic dexterity of the plasmid carrying 
blaNDM-1 gene (Patel and Bonomo, 2013). IMP and VIM are disseminated worldwide 
but less compared to NDM (Bush, 2013a). Similar to KPC-producers, isolates 
producing MBLs usually express other β-lactamases such as TEM, SHV or CTX-M 
(Bush, 2013a). 
 
 
 
 
 
13 
1.4.1.5 Carbapenem-hydrolyzing class D β-lactamases (CHDLs) 
CHDLs hydrolyse carbapenems and are not inhibited by EDTA or clavulanic acid 
(Nordmann et al., 2011). Most CHDLs are mainly reported in Acinetobacter spp. but 
the acquired OXA-48 and OXA-48 variants (e.g. OXA-162, OXA-163, OXA-181, 
OXA-204 and OXA-232) CHDLs are most frequently identified in Enterobacteriaceae 
(mostly in K. pneumoniae and E. coli) (Nordmann et al., 2011; Glupczynski et al., 
2012; Patel and Bonomo, 2013). CHDLs can either be plasmid-borne or 
chromosomally encoded (Kempf and Rolain, 2012).  
 
OXA-48 is a weaker carbapenemase - in order to confer high-level/ clinically 
significant carbapenem resistance an isolate producing this enzyme requires other 
resistance determinants such as ESBLs, AmpC, porin loss/ modification or over-
expression of efflux pumps (Gulmez et al., 2008). This is evident in several studies 
where OXA-48 in combination with an ESBL and loss of porins conferred very high 
MICs for carbapenems (Cuzon et al., 2010b; Nordmann et al., 2011). Rapid global 
dissemination of blaOXA-48 gene is associated with a 63 kb conjugative IncL/M-type 
plasmid and certain clones (Glupczynski et al., 2012).  
 
A. baumannii has intrinsic β-lactamases in their genome, namely AmpC and OXA-51 
(Peleg et al., 2008; Kempf and Rolain, 2012). There are three major clusters of 
CHDLs described in A. baumannii worldwide and these include OXA-23-, OXA-24-, 
and OXA-58-like carbapenemases (Poirel and Nordmann, 2006; Mugnier et al., 
2010; Poirel et al., 2010). The OXA-24 cluster is less widespread than the OXA-23 
cluster, with high prevalence of OXA-24 reported in Europe and USA (Mendes et al., 
2009). Contribution of OXA-51 to carbapenem resistance is often overlooked since 
this enzyme is normally expressed at very low levels (Zarrilli et al., 2009; Davies et 
al., 2011). However, when an insertion sequence ISAba1 is located upstream of 
blaOXA-51, it acts as a strong promoter and leads to gene over-expression, resulting in 
increased carbapenemase activity of OXA-51 enzyme - followed by elevated 
carbapenem MICs; the same applies to OXA-23, OXA-24 and OXA-58 enzymes 
(Mak et al., 2009).  
 
Co-existence of CHDLs with acquired carbapenemases such as KPC, NDM, IMP in 
clinical isolates of A. baumannii has been reported (Karthikeyan et al., 2010; 
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Robledo et al., 2010; Yamamoto et al., 2011). Although exclusively reported among 
A. baumannii, OXA-40 has been reported in P. aeruginosa clinical isolates (Sevillano 
et al., 2009). A novel CHDL, OXA-198, has been identified in P. aeruginosa isolate in 
Belgium (Garch et al., 2011). 
 
 
1.4.1.6 Reduced permeability: efflux pump over-expression and porin loss/ 
modification 
Reduction of outer membrane permeability is an intrinsic non-enzymatic mechanism 
that Gram-negative bacteria possess to withstand the pressure exerted by 
antimicrobial agents. This can be achieved by (i) over-expression of efflux pumps 
which extrude antimicrobial agents outside the cell; and (ii) by loss/ alteration of 
porins which form hydrophilic channels allowing selective entry of essential nutrients 
and antimicrobial agents into the cell (Nordmann et al., 2012). Carbapenem-resistant 
isolates with no carbapenemase genes are considered of less clinical concern since 
their carbapenem resistance trait is not transferable (Nordmann et al., 2012). Porin 
loss/ modification as a carbapenem resistance mechanism is considered unstable 
since it could be as a result of lower fitness and decreased growth ability (Doumith et 
al., 2009).  
 
Porins associated with carbapenem resistance in Enterobacteriaceae include 
OmpK35 and OmpK36 in K. pneumoniae (Shin et al., 2012), OmpF and OmpC in E. 
coli and Enterobacter spp. (Chia et al., 2009). Ertapenem resistance associated with 
a combination of porin loss/ modification and ESBL production has been reported in 
Enterobacteriaceae (Lartigue et al., 2007; Garcia-Fernandez et al., 2010). Efflux 
pump over-expression in association with carbapenem resistance is underestimated 
in Enterobacteriaceae clinical isolates (Pages et al., 2009), or is rather not a frequent 
or major contributor to carbapenem resistance (Doumith et al., 2009). However, 
over-expression of efflux pump AcrAB-TolC has been reported in association with 
imipenem resistance in E. aerogenes in France (Bornet et al., 2003; Chevalier et al., 
2008). A combination of porin loss/ modification and efflux pump over-expression 
was suggested to confer ertapenem resistance in E. cloacae (Szabo et al., 2006). In 
contrast, Doumith et al. (2009) did not detect over-expression of AcrAB-TolC efflux 
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pump in any of the ertapenem-resistant K. pneumoniae and Enterobacter spp. 
isolates screened from the United Kingdom.  
 
Lee et al. (2010a) reported carbapenem resistance in A. baumannii isolates due to 
interplay between AdeABC efflux pump over-expression and production of 
chromosomal OXA-23 carbapenemase. Reduced expression/ loss of porin CarO, a 
25- to 29 kDa porin protein, in conjunction with production of OXA-type 
carbapenemases has previously been reported as a mechanism responsible for 
carbapenem resistance in A. baumannii isolates (Bou et al., 2000; Lu et al., 2009). 
Imipenem resistance solely due to loss of CarO was reported by Limansky et al. 
(2002). Carbapenem resistance via insertional inactivation of porin gene (carO gene) 
by insertion sequences (ISAba825, ISAba125 or ISAba10) has also been reported 
(Mussi et al., 2005; Poirel and Nordmann, 2006; Lee et al., 2011). There are few 
reports on the role of PBPs in carbapenem resistance in A. baumannii (Poirel and 
Nordmann, 2006). Loss of a 73.2 kDa PBP was reported to be associated with 
imipenem resistance in conjunction with carbapenemase production in A. baumannii 
isolates from Spain (Fernandez-Cuenca et al., 2003).  
 
Over-expression of endogenous AmpC cephalosporinase or efflux pumps in 
combination with loss or modification of a carbapenem-specific porin OprD is a 
common intrinsic carbapenem resistance mechanism in non-carbapenemase-
producing P. aeruginosa (Poole, 2004; Poole, 2011). The efflux pumps MexAB-OprM 
(“Multi-drug efflux system AB- Outer membrane protein M”), MexCD-OprJ and 
MexXY-OprM have been shown to extrude antipseudomonal antibiotics including β-
lactams and confer β-lactam resistance in clinical isolates (Poole, 2004; Vettoretti et 
al., 2009; Tomas et al., 2010). Over-expression of these efflux pumps may be 
induced by mutational events in their operons (Piddock, 2006). Mutations in the 
mexR gene which encodes MexR repressor protein were shown to induce over-
expression of mexAB-oprM operon, thus leading to over-expression of MexAB-OprM 
efflux pump (Saito et al., 1999).  
 
Mutational inactivation of OprD and over-expression of the efflux pump MerAB-OprM 
was reported as the most widespread carbapenem resistance mechanism in 
Chinese clinical isolates of P. aeruginosa (Wang et al., 2010). P. aeruginosa strains 
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with mutated OprD are reported to be more resistant to imipenem and meropenem 
(Quale et al., 2006; Rodriguez-Martinez et al., 2009), while strains that are over-
expressing MerAB-OprM are reported to be more resistant to meropenem (Quale et 
al., 2006).  
 
 
1.4.2 Quinolone resistance 
Quinolones are broad spectrum antibiotics that act as DNA synthesis inhibitors by 
inhibiting the activity of enzymes involved in DNA replication, namely DNA gyrase 
(topoisomerase II) and topoisomerase IV (Drlica and Zhao, 1997). Quinolone 
resistance is increasingly being reported among clinical isolates worldwide due to 
their wide clinical use (Cattoir and Nordmann, 2009). Quinolone resistance can be 
chromosome-encoded or plasmid-mediated. Chromosome-encoded quinolone 
resistance mechanisms include: (i) mutations in the quinolone resistance 
determining regions (QRDRs) of gyrA and gyrB (genes encoding DNA gyrase 
subunits) and topoisomerase IV genes (parC and parE); and (ii) decreased uptake 
due to porin defects or efflux pump over-expression (Cattoir and Nordmann, 2009). 
Plasmid-mediated quinolone resistance (PMQR) determinants include: (i) quinolone 
resistance proteins (Qnr proteins) which protect DNA gyrase and type IV 
topoisomerase from quinolone inhibition; (ii) aminoglycoside acetyltransferase for 
ciprofloxacin resistance (AAC(6’)-lb-cr) which acetylates fluoroquinolones such as 
norfloxacin and ciprofloxacin but not levofloxacin; and (iii) efflux pump QepA (for 
quinolone efflux pump A) that extrudes hydrophilic fluoroquinolones such as 
norfloxacin, ciprofloxacin and enrofloxacin (Cattoir and Nordmann, 2009).  
 
The emergence of PMQR genes among clinical isolates is worrisome since PMQRs 
are carried by broad-host range conjugative plasmids and often lead to elevated 
quinolone MICs in combination with chromosomal quinolone resistance mutations 
(Muller et al., 2011). PMQRs have been reported largely in Enterobacteriaceae, and 
less frequently in Pseudomonas spp. and A. baumannii (Peleg et al., 2008; Cattoir 
and Nordmann, 2009).  
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1.5 EPIDEMIOLOGY OF CARBAPENEMASE-PRODUCING 
ENTEROBACTERIACEAE, A. baumannii AND P. aeruginosa 
 
Carbapenem-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae are on 
the rise worldwide including South Africa, contributing to patient morbidity and 
mortality (Patel and Bonomo, 2013). Multiple factors play an important role in 
intercontinental dissemination of carbapenem-resistant Gram-negative bacteria and 
these include: transfer of patients between countries, travel, medical tourism and 
refugees (Perovic, 2013). The epidemiology of carbapenem-resistant clinical isolates 
depends on multiple factors including the country, local antibiotic usage, dosing 
regimens and historical/ cultural relationships (Perovic, 2013).  
 
In South Africa, NDM (175/377) has been reported as the most predominant 
carbapenemase among carbapenem-resistant clinical Enterobacteriaceae (mainly K. 
pneumoniae) since 2012 and including current data from the majority of South 
African public and private sector laboratories, followed by OXA-48 (64/377), VIM 
(47/377), OXA-48-like (30/377), GES (28/377), IMP (18/377) and KPC (15/377) 
(Perovic, 2013). The most common source of carbapenem-resistant isolates is urine, 
followed by blood, pus, wound swabs and sputa (Perovic, 2013).  
 
Carbapenem-resistant Enterobacteriaceae producing KPC enzymes were previously 
predominant in USA and Israel, and are often associated with endemic regional 
outbreaks (Nordmann et al., 2009; Walsh, 2010; Gupta et al., 2011). The first case of 
KPC was reported in 2001 in North Carolina in a K. pneumoniae isolate. Currently, 
KPC-producing Enterobacteriaceae isolates are prevalent worldwide, associated 
with nosocomial infections and outbreaks in acute and long-term care facilities (Patel 
and Bonomo, 2013). Worldwide prevalence of KPC enzymes is facilitated by 
plasmids and specific clones (such as K. pneumoniae ST258 clone) (Kitchel et al., 
2009).  
 
KPC enzymes have been reported in various Enterobacteriaceae clinical isolates 
including E. coli from China (Du et al., 2013), K. pneumoniae from Italy (Giuffere et 
al., 2013), K. oxytoca from Austria (Hoenigl et al., 2012), S. marcescens from China 
(Cai et al., 2008), Enterobacter cloacae from USA (Bennet et al., 2010), Proteus 
18 
mirabilis from China (Hu et al., 2012), Salmonella enterica serotype Cubana from 
USA (Miriagou et al., 2003) and Citrobacter freundii from Spain (Gomez-Gil et al., 
2010). SME in S. marcescens and GES in Enterobactericeae are distributed 
worldwide while IMI in Enterobacter spp. is scattered in various geographical regions 
(Queenan and Bush, 2007; Patel and Bonomo, 2013).  
 
KPC- and GES-producing A. baumannii isolates were reported occasionally in 
Puerto Rico in acute and chronic care facilities and in Belgium are associated with 
nosocomial outbreaks, respectively (Bogaerts et al., 2010; Robledo et al., 2010). 
Class A carbapenemases previously described in P. aeruginosa clinical isolates 
include: KPC in Puerto Rico, Colombia and USA (Villegas et al., 2007; Wolter et al., 
2009; Robledo et al., 2011) and GES with worldwide prevalence (Vourli et al., 2004; 
Zhao and Hu, 2010).  
 
NDM is endemic in the Indian subcontinent but to date cases have been reported 
worldwide predominantly in Enterobacteriaceae with a direct link to the Indian 
subcontinent (i.e. India, Pakistan, and Bangladesh) (Nordmann et al., 2011). NDM-1-
positive strains of Enterobacteriaceae have been reported worldwide including K. 
pneumoniae in Canada (Mataseje et al., 2012), E. coli in Germany (Pfeifer et al., 
2011), C. freundii in Thailand (Rimrang et al., 2012), E. cloacae in Belgium (Bogaerts 
et al., 2011), P. mirabilis in Switzerland (Poirel et al., 2011a), Providencia stuartii in 
Afghanistan (McGann et al., 2012) and Morganella morganii in Belgium (Bogaerts et 
al., 2011).  
 
Integron-associated MBLs such as IMP and VIM were first reported in P. aeruginosa 
from Japan and Italy, respectively, but are also found in several Enterobacteriaceae 
species (Currie, 2012). Both VIM and IMP are now endemic in Greece, Italy, Spain, 
Taiwan, Japan and Europe (Currie, 2012). IMP is distributed worldwide and has 
been found in E. aerogenes (Biendo et al., 2008), C. freundii (Yang et al., 2010), E. 
cloacae (Yang et al., 2010), E. coli (Yan et al., 2013), K. oxytoca (Chen et al., 2009) 
and K. pneumoniae (Yu et al., 2012). VIM has also been detected worldwide in 
Citrobacter amalonaticus (Aschbacher et al., 2011), E. aerogenes (Biendo et al., 
2008), E. cloacae (Miro et al., 2010), E. coli (Coelho et al., 2012), K. oxytoca (Miro et 
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al., 2010), K. pneumoniae (Samuelsen et al., 2011) and P. mirabilis (Galani et al., 
2012). 
 
The following MBLs have been reported infrequently in A. baumannii isolates mainly 
infecting patients hospitalized in the ICU: VIM in Korea, Greece and Taiwan (Yum et 
al., 2002, Tsakris et al., 2006; Lee et al., 2008); IMP in Italy, Portugal, South Korea, 
Hong Kong, Brazil, Australia and Japan (Cornaglia et al., 1999; Chu et al., 2001; Da 
Silva et al., 2002; Gales et al., 2003; Lee et al., 2003; Peleg et al., 2006; Yamamoto 
et al., 2011); SIM “Seoul imipenemase” in Korea (Lee et al., 2005); and NDM in 
China, India and Egypt (Karthikeyan et al., 2010; Chen et al., 2011; Kaase et al., 
2011). 
 
The following common and uncommon MBLs have been reported in P. aeruginosa 
clinical isolates: NDM in Serbia (Jovcic et al., 2011); IMP reported worldwide 
(Sanchez-Martinez et al., 2010); VIM reported worldwide (Mataseje et al., 2012); 
SPM “Sao Paulo metallo-β-lactamase” reported in Brazil and Europe (Picao et al., 
2009; El Salabi et al., 2010); GIM “German imipenemase” only in Germany 
(Castanheira et al., 2004); AIM “Australian imipenemase” in Australia (Yong et al., 
2007; Yong et al., 2012); and FIM “Florence imipenemase” in Italy (Pollini et al., 
2013).  
 
The first case of OXA-48 was reported in a K. pneumoniae isolate from Turkey in 
2003. Since then this enzyme has been documented among Enterobacteriaceae in 
the following parts of the world: Turkey, Middle East, North Africa, Europe (Carrer et 
al., 2010), USA (Lascols et al., 2013; Mathers et al., 2013) and recently in South 
Africa (Brink et al., 2013). OXA-181 has been identified in Indian patients and in 
several European countries in association with sporadic cases and/or outbreaks and 
recently in South Africa associated with nosocomial infections and mortality (Kalpoe 
et al., 2011; Nordmann et al., 2011; Currie, 2012; Poirel et al., 2012; Brink et al., 
2013). 
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1.6 SCOPE AND OBJECTIVES 
ESBL-producing and carbapenem-resistant Enterobacteriaceae, A. baumannii and 
P. aeruginosa have become an international health issue posing a challenge to the 
current diagnostic approaches (Nordmann et al., 2011). One of the major threats in 
South African hospitals (including Eastern Cape public and private sector hospitals) 
is the emergence of carbapenem-resistant bacteria producing clinically significant 
carbapenemases including KPC, NDM, IMP, GES, OXA-48 and OXA-48-variants 
and are often associated with severe infections and high mortality rates 
(Labuschagne et al., 2008; Brink et al., 2012a; Brink et al., 2012b; Jacobson et al., 
2012; Brink et al., 2013; Govind et al., 2013; Kock et al., 2013; Perovic, 2013). 
However, there is little information on ESBL-producing and carbapenem-resistant 
clinical isolates in Port Elizabeth, hence this study was conducted to provide 
information on the resistance determinants in carbapenem-susceptible and -resistant 
Enterobacteriaceae, A. baumannii and P. aeruginosa clinical isolates. 
 
1.6.1 Hypotheses to be tested 
It was hypothesized that: 
i) there was a high prevalence of CTX-M enzymes among carbapenem-
susceptible and -resistant Enterobacteriaceae, A. baumannii and P. 
aeruginosa clinical isolates; 
ii) the resistance determinants included ESBL enzymes, plasmid-mediated 
quinolone resistance (PMQR) genes, carbapenemases and porin loss, and 
iii) E. coli isolates belonging to the ST131 clone were present.  
 
1.6.2 Objectives 
The following objectives were established to test the above hypotheses: 
i. To screen the carbapenem-susceptible Enterobacteriaceae for CTX-M, 
TEM, SHV and OXA-1 and PMQR genes by PCR and DNA sequencing, 
ii. To detect genes encoding metallo-β-lactamases (blaVIM, blaIMP, blaNDM-1) 
and serine-β-lactamases (blaKPC, blaBIC, blaGES, blaIMI, blaNMC-A, blaSME, 
blaOXA-23, blaOXA-24, blaOXA-48, blaOXA-51, blaOXA-58) in carbapenem-resistant 
Enterobacteriaceae, A. baumannii and P. aeruginosa by PCR and DNA 
sequencing, 
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iii. To establish loss of porins in carbapenem-resistant isolates by SDS-
PAGE, and 
iv. To screen for E. coli ST131 among E. coli isolates by PCR and determine 
their genetic relatedness using PFGE. 
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CHAPTER TWO 
 
PREVALENCE OF CARBAPENEM-SUSCEPTIBLE AND -RESISTANT 
ESBL-PRODUCING ENTEROBACTERIACEAE, Acinetobacter 
baumannii AND Pseudomonas aeruginosa 
 
2.1 INTRODUCTION 
The emergence of ESBL-producing and carbapenem-resistant Gram-negative 
pathogens is a serious problem in both clinical and community settings worldwide 
(Currie, 2012). ESBLs are a diverse group of plasmid-mediated β-lactamases 
produced by Gram-negative bacteria, primarily Enterobacteriaceae (in particular 
Klebsiella pneumoniae and Escherichia coli) which are of great clinical and 
microbiological significance (Dhillon and Clark, 2011). ESBLs are also produced by 
non-fermenters such as Pseudomonas aeruginosa and Acinetobacter baumannii 
(Dhillon and Clark, 2011). ESBLs belong to Ambler class A β-lactamases based on 
their molecular structure, exhibiting hydrolytic activity against oxyimino-
cephalosporins (i.e. cefotaxime, ceftazidime and ceftriaxone) and monobactams but 
not to cephamycins and carbapenems (Paterson and Bonomo, 2005). As a result, 
healthcare facilities that incorporate cephalosporins in empiric treatment for ESBL-
infections, commonly septicaemia, usually experience poor therapeutic outcomes 
(Dhillon and Clark, 2011).  
 
Bacteria exhibiting carbapenem resistance usually express carbapenemases which 
are β-lactamases with a potent activity against carbapenems (Walsh et al., 2010). 
Carbapenems are potent β-lactam antibiotics used as drugs of last resort for 
treatment of life-threatening infections (Patel and Bonomo, 2013). ESBL- and 
carbapenemase-producing bacteria are usually associated with severe infections 
such as bactaeremia, nosocomial pneumonia and meningitis, cholangitis, intra-
abdominal abscesses, peritonitis and UTIs (mainly community-acquired) with 
mortality rates ranging from 42% to 100% (Paterson, 2000; Colodner, 2005). 
Infections due to ESBL-producing bacteria are often treated with carbapenems as 
drugs of first choice or with fluoroquinolones and aminoglycosides, provided that 
susceptibility to these agents is confirmed (Samaha-Kfoury and Araj, 2003).  
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Treatment of infections due to carbapenem-resistant bacteria is very difficult since 
there are very few effective drugs against these pathogens. Carbapenem-resistant 
infections may be treated with colistin, tigecycline and sometimes fosfomycin (Currie, 
2012). Suggested management options for multidrug/ extensive drug resistant Gram-
negative infections in complicated patients in South Africa include doripenem, 
infusion of β-lactams, fosfomycin, tigecyline and colistin (Brink, 2011).  
 
Carbapenem-resistant and –susceptible ESBL-producing bacteria have been 
described in both private and public sector institutions in South Africa. SMART 
(Study for the Monitoring of Antimicrobial Resistance Trends) analysed 1218 ESBL-
producing Gram-negative isolates in intra-abdominal infections in South Africa during 
2004 to 2009 (Brink et al., 2012c). In this surveillance study, K. pneumoniae and E. 
coli were the most frequent ESBL-producers with prevalence rates of 41.2% and 
7.6%, respectively. The highest resistance rate was observed for ceftriaxone 
(29.7%), followed by cefotaxime (28.7%), ciprofloxacin (22.5%) and lastly 
levofloxacin (21.1%). The multidrug resistance (MDR) rate (i.e. resistance to ≥ 3 
antibiotic classes) was highest among K. pneumoniae (27.9%), followed by 
Enterobacter spp. (14.9%) and E. coli (4.9%). Comparative analysis of international 
ESBL rates in complicated intra-abdominal infections from 2002 to 2009 revealed 
Africa to be a region with the highest ESBL rate among K. pneumoniae (41%) and 
North America having the lowest ESBL rate (8%) (Brink et al., 2012c). On the other 
hand, Asia had the highest ESBL rate among E. coli while North America and South 
Pacific region had the lowest ESBL rate (6%). The ESBL rates for K. pneumoniae 
and E. coli globally were found to be 17% and 22%, respectively (Brink et al., 
2012c).  
 
Among carbapenem-resistant (mostly ertapenem-resistant) Enterobacteriaceae 
submitted for molecular screening in the private sector nationally, K. pneumoniae 
(63.5%) was the most predominant, followed by Serratia marcescens (13.9%), 
Enterobacter cloacae (10.4%), Citrobacter freundii (6.0%), E. coli (4.3%) and 
Morganella morganii (1.7%) (Perovic, 2013). Specimen types included urine (48.6%), 
pus and wound swabs (18.3%), sputa (15.7%), blood (6.1%), intra-abdominal fluid/ 
pus (4.3%) and miscellaneous (7%). Vermaak and Partners together with Lancet 
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laboratories have also confirmed K. pneumoniae to be the predominant species 
among carbapenem-resistant Enterobacteriaceae in South Africa (Perovic, 2013).  
 
Meropenem-resistant A. baumannii isolates were reported in association with 
colonisation/ infection of HIV-infected and HIV-uninfected patients admitted into the 
adult respiratory and surgical ICUs in Cape Town, South Africa (Ntusi et al., 2012). 
In this setting, A. baumannii was associated with high “in-ICU” mortality and 
multidrug resistance. High resistance rates were noted against cotrimoxazole, 
ciprofloxacin, meropenem, ceftazidime, cefepime, gentamycin, amikacin and 
pipericillin-tazobactam. However, these isolates remained susceptible to colistin 
(Ntusi et al., 2012). MDR P. aeruginosa isolates exhibiting high level resistance to 
meropenem (≥128 mg/L) and imipenem (≥128 mg/L) have been reported in a 
haematology unit of a tertiary academic hospital in Cape Town (Jacobson et al., 
2012). Three carbapenem-resistant isolates (1 S. marcescens from tissue and 2 K. 
pneumoniae isolates from urine) positive for carbapenemase genes were recently 
identified in two private hospitals in Port Elizabeth (Brink et al., 2013). These isolates 
were multidrug resistant and only susceptible to colistin (MIC <0.5 mg/L). In contrast, 
a carbapenem-resistant K. pneumoniae urinary isolate exhibiting colistin resistance 
(MIC = 4 mg/L) was identified in a Cape Town institution in the same study (Brink et 
al., 2013). 
 
Demise of two patients in association with infections due to carbapenemase-
producing K. pneumoniae and E. cloacae has been reported in South Africa (Brink et 
al., 2012a). These pathogens were recovered from various specimen types including 
urine, blood, tracheal aspirate and central venous catheter (Brink et al., 2012a). The 
reported risk factors associated with the acquisition of these pathogens include 
prolonged hospitalization and ICU stay, invasive devices, immunosuppression and 
previous antibiotic exposure (Nordmann et al., 2009). 
 
The focus of this chapter was to collate the demographic and clinical data (where 
available) to establish the prevalence of ESBL-producing and carbapenem-resistant 
bacteria from clinical isolates.  
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2.2 MATERIALS AND METHODS 
 
2.2.1 Patients and bacterial isolates 
Carbapenem-susceptible Enterobacteriaceae cultures (n=59) and carbapenem-
resistant (n=39) Enterobacteriaceae, A. baumannii and P. aeruginosa identified by 
the VITEK® 2 system version 06.01 (bioMérieux) were supplied by the Bacteriology 
Laboratory manager at the National Health Laboratory Services (NHLS) in Port 
Elizabeth during February 2012 to February 2013. Data request approval from NHLS 
and authorization from the Department of Health was granted. Ethics approval for 
this project was obtained from the Nelson Mandela Metropolitan University Research 
Ethics Committee (Human) [Ref.: H13-SCI-BCM-008]. Patient information was 
recorded where available; however, clinical information concerning patient history 
was not available. 
 
MacConkey agar (Merck) and Cetrimide agar (Conda) were used to cultivate both 
Enterobacteriaceae and A. baumannii, and P. aeruginosa, respectively. Bacterial 
cultures were stored in MicroBankTM beads (Davies Diagnostics) at -80oC until 
required for DNA (deoxyribonucleic acid) extraction or other tests. 
 
2.2.2 Antimicrobial susceptibility testing 
2.2.2.1 Vitek® 2 system 
Antimicrobial susceptibility profiles with MICs and resistance phenotype reports from 
the VITEK® 2 system were used. Susceptibilities of the clinical isolates to 20 different 
antimicrobial agents were tested. The MICs of the following antimicrobial agents 
were determined: ampicillin (AMP), amoxicillin-clavulanic acid (AMC), piperacillin-
tazobactam (TZP), cefuroxime (CXM), cefuroxime axetil (CAE), cefoxitin (FOX), 
cefotaxime (CTX), ceftazidime (CAZ), cefepime (FEP), ertapenem (ETP), imipenem 
(IPM), meropenem (MEM), amikacin (AMK), gentamicin (GEN), nalidixic acid (NAL), 
ciprofloxacin (CIP), tigecycline (TGC), nitrofurantoin (NIT), colistin (CST) and 
trimethoprim-sulfamethoxazole (SXT). The recommended quality control strains 
were used by NHLS in the VITEK® 2 system tests: E. coli ATCC 25922, P. 
aeruginosa ATCC 27853 and E. coli ATTC 35218. Throughout this study, antibiotic 
susceptibility profiles were interpreted using the Clinical and Laboratory Standards 
Institute interpretive criteria (CLSI, 2013) breakpoints for broth dilution. At the 
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Federation of Infectious Diseases Societies of Southern Africa (FIDSSA) meeting in 
October 2013, it was decided that the use of EUCAST was preferred and would be 
further investigated. Strains were designated as multidrug resistant (MDR) when 
exhibiting resistance to three or more antibiotic classes (Brink et al., 2012c). 
 
2.2.2.2 Microbroth dilution method (carbapenem-resistant isolates) 
MIC values for IPM (Sigma) and MEM (Sigma) were determined using the 
microbroth dilution method to confirm carbapenem resistance. The bacterial isolates 
were grown on a Mueller-Hinton (MH) plate overnight at 37ºC. A phosphate buffer 
saline (PBS) suspension (inoculum) was prepared from an overnight culture and the 
turbidity was adjusted to a 0.5 McFarland standard (1.175% BaCl2 + 1% H2SO4). 
Determination of the MICs was carried out using the p-Iodonitrotetrazolium chloride 
(INT) assay (Eloff, 1998). Muller-Hinton broth (50 µL) was added to wells 2 – 8. Drug 
concentration ranges were: IPM (0.5 - 128 µg/mL) and MEM (0.5 - 128 µg/mL). To 
wells 1 and 2, 50 µL antibiotic containing MH broth was added. Doubling dilutions 
were then performed across wells 2 to 8. The inoculum (50 µL per well) was derived 
by comparison with 0.5 McFarland standard (absorbance at 600 nm = 0.08 – 0.1 
equivalent to ~1.5 x 108 cells/mL). Controls comprised of well 9: positive control (50 
µL inoculum + 50 µL MH broth); well 10: antibiotic control (50 µL antibiotic + 50 µL 
MH broth); and well 11: negative control (100 µl MH broth). The plates were sealed 
with microplate sealing tape and incubated overnight at 37oC. After the incubation, 
50 µL of 0.2 mg/mL INT dye (Sigma) was added into each well and the plates were 
further incubated for 30 – 60 min until there was a colour change. A colour change 
from yellow (dye) to a purple/ pink colour indicated the presence of viable bacteria 
which are able to reduce the yellow dye to a purple/ pink colour. If there was no 
colour change, that indicated inhibition of bacterial growth.  
 
2.2.2.3 E-test (carbapenem-resistant isolates) 
MIC values for ETP (Liofilchem®) in carbapenem-resistant isolates were determined 
using the MIC test strips (0.002 – 32 µg/mL) (Liofilchem®), as described by the 
manufacturer. Bacterial inoculum was prepared as described above in Section 
2.2.2.2. The inoculum (100 µL) was spread evenly on the MH plate and left to dry for 
30 min. This was followed by application of MIC test strips on the surface of the 
plate. The plate was incubated overnight at 37ºC in an inverted position. At the end 
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of incubation, MIC values were read where the edge of the inhibition ellipse 
intersected the strip (intersection between two scale segments was rounded up to 
the higher value).  
 
2.2.3 Statistical analysis 
Statistical analysis was performed using Pearson chi-square and P-values were 
determined where applicable.  
 
2.3 RESULTS 
2.3.1 Collection of bacterial isolates 
Fifty nine non-duplicate carbapenem-susceptible Enterobacteriaceae and 39 non-
duplicate carbapenem-resistant bacteria (including Enterobacteriaceae, A. 
baumannii and P. aeruginosa) analysed in this study were recovered from 
specimens collected from public hospitals and community clinics in Port Elizabeth 
and identified by the Vitek® 2 system at NHLS. A further 13 samples were “repeats” 
which constituted multiple samples from the same patients who had visited different 
clinics/ hospitals and were excluded from the data analysis. 
 
A substantial number of carbapenem-susceptible ESBL-producing 
Enterobacteriaceae isolates (34/59, 57.6%) were collected during October and 
November, 2012. Carbapenem-resistant ESBL-producing isolates were collected 
throughout the year except for the months of June, November and December, 2012 
(Fig. 2.1).  
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Figure 2.1: Collection of bacterial isolates (n=98) during the period of February 2012 to February 2013. 
 
The prevalence of carbapenem-susceptible ESBL-producers was relatively higher 
from specimens obtained at Dora Nginza (13/59, 22%) and Livingstone (12/59, 
20.3%) hospitals, followed by Provincial hospital (5/59, 8.5%), and lower at the 
following community clinics: Algoa Park clinic (1/59, 1.7%), KwaDwesi clinic (1/59, 
1.7%) and Masakhane clinic (1/59, 1.7%) (Fig. 2.2). Carbapenem-resistant ESBL-
producers were mainly isolated from specimens obtained at Livingstone hospital 
(18/39, 46.2%), Dora Nginza hospital (14/39, 35.9%) and less frequently from 
Provincial hospital (1/39, 2.5%). However, hospital names were unknown for 44.1% 
(26/59) and 15.4% (6/39) of carbapenem-susceptible and –resistant isolates, 
respectively.  
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Figure 2.2: Distribution of bacterial isolates (n=98) in public hospitals and clinics in Port Elizabeth. 
 
2.3.2 Demographic information (Gender, Age) 
 
Patient history information (i.e. nature of infection, clinical symptoms, whether the 
patient was hospitalized or was an outpatient, length of stay in the healthcare facility, 
ward unit, previous antibiotic exposure, history of hospitalization in the previous year, 
comorbidities, previous history of nosocomial infection, empiric and definitive 
treatment administered) could not be included in this study since some of the patient 
medical records were missing and some of the patients were apparently outpatients 
hence the Department of Medical Records could not locate their records.  
In total, 95 patients were colonized/ co-infected with either a carbapenem-
susceptible (58) or –resistant (37) isolate and as a result of co-infection/ co-
colonization cases (n=3) with different bacterial species, a sum of 98 bacterial 
isolates were analysed in this study. The majority of carbapenem-susceptible ESBL-
producing Enterobacteriaceae were isolated from females (28/58, 48.3%), 
predominantly in the 31-40 year age group (5/28), 21-30 year age group (5/28) and 
less than 10 year age group (5/28) (Figs. 2.3 and 2.4). These isolates were relatively 
less in males (21/58, 36.2%) (Fig. 2.3). One male patient (1/58, 1.7%) was co-
colonized/ co-infected with two different carbapenem-susceptible isolates (i.e. E. coli 
and P. mirabilis) hence 59 carbapenem-susceptible isolates from 58 patients. 
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Gender information for 15.5% (9/58) patients with carbapenem-susceptible isolates 
could not be obtained.  
 
On the contrary, the majority of carbapenem-resistant isolates were isolated from the 
male population (24/37, 64.9%) predominantly in the 31-40 year age group (8/24), 
21-30 year age group (5/24) and less than 10 year age group (5/24) (Figs. 2.3 and 
2.4). Carbapenem-resistant isolates were relatively less in female population (11/37, 
29.7%). Two male patients (2/37, 5.4%) were co-colonized/ co-infected with two 
different carbapenem-resistant isolates, hence 39 carbapenem-resistant isolates 
from 37 patients. Gender information for 5.4% (2/37) patients with carbapenem-
resistant isolates was unavailable.  
 
 
Figure 2.3: Distribution of patients (n=95) colonized/ infected with carbapenem-susceptible and –resistant bacterial 
isolates based on gender. Gender ratio for carbapenem-susceptible and -resistant isolates: 0.75 and 
0.45, respectively. 
 
 
The median age of the patients with carbapenem-susceptible and -resistant isolates 
was 33 years (range = 2 days to 88 years) and 28 years (range 9 days – 63 years), 
respectively (Fig. 2.4). An unexpectedly high number of patients with carbapenem-
susceptible ESBL-producers was noted in the age group of 0 – 10 years (13/58, 
22.4%) with the majority of individuals in this age group being neonates/ infants (age 
31 
range = 2 days to 2 years) (12/13, 92.3%). Age for 15.5% (9/58) patients with 
carbapenem-susceptible isolates remained unknown.  
 
Only 16.2% (6/37) of carbapenem-resistant ESBL-producers were detected in 
neonatal/ infant specimens and were predominantly from males (5/6, 83.3%) (Fig. 
2.4). However, the majority of patients with carbapenem-resistant isolates were in 
the age groups of 21 – 30 years (10/37, 27%) and 31 – 40 years (9/37, 24.3%). Age 
for 5.4% (2/37) patients with carbapenem-resistant isolates was unavailable.  
 
 
Figure 2.4: Distribution of patients (n=95) colonized/ infected with carbapenem-susceptible and –
resistant bacterial isolates based on age.   
 
 
2.3.3 Distribution of clinical isolates  
Carbapenem-susceptible ESBL-producing pathogens were predominantly recovered 
from urine (22/59, 37.3%), followed by pus (17/59, 28.8%), blood (11/59, 18.6%) and 
sputa (9/59, 15.3%) (Fig. 2.5). The majority of carbapenem-resistant ESBL-
producing isolates were detected from pus (18/39, 46.2%), followed by sputa (11/39, 
28.2%), urine (6/39, 15.4%) and blood (4/39, 10.2%).  
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Figure 2.5: Distribution of bacterial isolates (n=98) based on specimen type.  
 
Among carbapenem-susceptible ESBL-producing isolates, K. pneumoniae (25/59, 
42.4%) and E. coli (21/59, 35.6%) were the most predominant, followed by 
Enterobacter cloacae (4/59, 6.8%), Citrobacter freundii (4/59, 6.8%), Serratia 
marcescens (2/59, 3.3%), Klebsiella oxytoca (1/59, 1.7%), Proteus mirabilis (1/59, 
1.7%) and Enterobacter aerogenes (1/59, 1.7%) (Fig. 2.6-A). Among carbapenem-
resistant isolates, Acinetobacter baumannii (14/39, 35.9%) was the most 
predominant, followed by K. pneumoniae (10/39, 25.6%), Pseudomonas aeruginosa 
(9/39, 23.1%), E. cloacae (4/39, 10.2%), Enterobacter asburiae (1/39, 2.6%) and E. 
coli (1/39, 2.6%) (Fig. 2.6-B). Notably, all A. baumannii and P. aeruginosa isolates 
were carbapenem-resistant in this study.  
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Figure 2.6: Predominant bacterial species among: [A] carbapenem-susceptible (n=59) and [B] 
carbapenem-resistant (n=39) isolates.  
 
 
2.3.4 Antimicrobial resistance profiles of carbapenem-susceptible and -
resistant isolates  
Overall resistance rates of clinical isolates analysed in this study to a variety of 
antimicrobial agents tested are shown in Tables 2.1 and 2.2. Detailed antimicrobial 
resistance profiles (including MIC ranges for each species) are attached in the 
Appendix section (Tables A.1 – A.14).  
A 
B 
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Carbapenem-resistant Enterobacteriaceae isolates exhibited higher resistance rates 
(P < 0.05) relative to carbapenem-susceptible Enterobacteriaceae isolates to the 
following antimicrobial agents (n=11) (Table 2.1): NIT (93.8% vs. 49.2%), AMC 
(100% vs. 67.8%), CAZ (93.8% vs. 45.8%), TZP (93.8% vs. 30.5), NAL (93.8 vs. 
52.5%), CIP (87.5% vs. 52.5%), FEP (93.8% vs. 30.5%), FOX (100% vs. 22%), and 
the carbapenems – ETP (100% vs. 0%), IPM (100% vs. 0%) and MEM (100% vs. 
0%). However, both carbapenem-resistant and –susceptible Enterobacteriaceae 
isolates exhibited 100% resistance to the following antimicrobial agents: AMP, CXM 
and CAE. Low resistance rates were observed for both carbapenem-resistant and –
susceptible Enterobacteriaceae isolates against TGC (43.8% vs. 5.1%), AMK (0% 
vs. 3.4%) and CST (0% vs. 5.1%). Carbapenem-resistant Enterobacteriaceae 
isolates had a higher resistance rate against ETP (100%) compared to carbapenem-
resistant A. baumannii (64.3%) and P. aeruginosa (55.6%).  
 
Table 2.1: Enterobacteriaceae resistance rates to various antimicrobial agents tested in this study. 
Antimicrobial Agent 
MIC range 
(mg/L) 
Carbapenem-susceptible 
(n=59) 
Carbapenem-resistant 
(n=16) 
% Resistance 
AMP 16 - ≥32 100.0 100.0 
CXM ≥64 100.0 100.0 
CAE ≥64 100.0 100.0 
CTX 2 - ≥64 100.0 93.8 
GEN 8 - ≥16 54.2 68.8 
SXT 76 - ≥320 83.1 87.5 
NIT 64 - ≥512 49.2 93.8 
AMC 16 - ≥32 67.8 100.0 
CAZ 16 - ≥32 45.8 93.8 
TZP 64 - ≥128 30.5 93.8 
NAL ≥32 52.5 93.8 
CIP 2 - ≥4 52.5 87.5 
FEP 16 - ≥32 30.5 93.8 
FOX 16 - ≥32 22.0 100.0 
TGC* ≥8 5.1 43.8 
AMK 32 - ≥64 3.4 0.0 
CST* ≥16 5.1 0.0 
ETP 1 - >32 0.0 100.0 
IPM 8 - 32 0.0 100.0 
MEM 16 - 32 0.0 100.0 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; TZP = piperacillin-tazobactam; 
CXM = cefuroxime; CAE = cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; 
FEP = cefepime; ETP = ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = 
gentamicin; NAL = nalidixic acid; CIP = ciprofloxacin; TGC = tigecycline; NIT = nitrofurantoin; CST = 
colistin; SXT = trimethoprim-sulfamethoxazole. (*) indicates that the MICs were interpreted using 
EUCAST since not provided by CLSI. 
 
The prevalence of multidrug resistance (MDR), defined as resistance to three or 
more antibiotic classes (Brink et al., 2012c) among carbapenem-susceptible and -
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resistant isolates was extremely high, 98.3% (58/59) and 100% (39/39), respectively. 
The MDR carbapenem-susceptible isolates included K. pneumoniae (24/25, 96%), 
E. coli (21/21, 100%), E. cloacae (4/4, 100%), C. freundii (4/4, 100%), S. 
marcescens (2/2, 100%), K. oxytoca (1/1, 100%), E. aerogenes (1/1, 100%) and P. 
mirabilis (1/1, 100%). The MDR carbapenem-resistant isolates included of A. 
baumannii (14/14, 100%), P. aeruginosa (9/9, 100%), K. pneumoniae (10/10, 100%), 
E. cloacae (4/4, 100%), E. asburiae (1/1, 100%) and E. coli (1/1, 100%).  
 
Some antimicrobial agents have no CLSI and EUCAST breakpoints (such are 
indicated with ‘ab or b’ superscript in Table 2.2); for such agents MIC breakpoints 
given by the Vitek® 2 system were used instead. The two non-fermenters, A. 
baumannii and P. aeruginosa were highly resistant and exhibited 100% resistance to 
the following antimicrobial agents (Table 2.2): AMP, CXM, CAE, CTX, NIT, AMC, 
FOX and MEM. A. baumannii exhibited relatively higher resistance to the following 
antimicrobial agents compared to P. aeruginosa: CAZ (100% vs. 11.1%), TZP (100% 
vs. 55.6%), CIP (92.9% vs. 44.4%) and FEP (100% vs. 55.6%). Noticeably, A. 
baumannii and P. aeruginosa had relatively higher resistance rate against TGC 
(64.3% and 100%, respectively) compared to Enterobacteriaceae (both 
carbapenem-resistant [43.8%] and –susceptible [5.1%]). Non-fermenters exhibited 
low levels of resistance to AMK (A. baumannii = 21.4% and P. aeruginosa = 44.4%) 
and remained susceptible to CST. 
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Table 2.2: A. baumannii and P. aeruginosa resistance rates to various antimicrobial agents tested in this study. 
  A. baumannii (n=14) P. aeruginosa (n=9) 
Antimicrobial Agent MIC range (mg/L) % Resistance 
AMPab 16 - ≥32 100.0 100.0 
CXMab ≥64 100.0 100.0 
CAEab ≥64 100.0 100.0 
CTXb ≥64 100.0 100.0 
GEN 8 - ≥16 92.9 77.8 
SXTb 160 - ≥320 100.0 77.8 
NITab 64 - ≥512 100.0 100.0 
AMCab 16 - ≥32 100.0 100.0 
CAZ 16 - ≥32 100.0 11.1 
TZP 64 - ≥128 100.0 55.6 
NALab ≥32 92.9 100.0 
CIP 2 - ≥4 92.9 44.4 
FEP 16 - ≥32 100.0 55.6 
FOXab 16 - ≥32 100.0 100.0 
TGCab ≥8 64.3 100.0 
AMK 32 - ≥64 21.4 44.4 
CST ≤0.5 0.0 0.0 
ETPab 2 - >32 64.3 55.6 
IPM 16 - 64 100.0 88.9 
MEM 16 - 64 100.0 100.0 
(ab) indicates that there are no CLSI or EUCAST breakpoints for these agents for both A. baumannii and P. 
aeruginosa; (b) indicates that there are no CLSI or EUCAST breakpoints for these agents for P. aeruginosa. 
 
2.3.5 Characteristics of carbapenem-susceptible and -resistant ESBL-
producing isolates in paediatric population  
 
Alarmingly, a relatively high number of neonates/ infants (12/58, 20.7%) were 
colonized/ infected with carbapenem-susceptible MDR ESBL-producers (7 neonates 
defined as 1 – 28 days old and 5 infants defined as 1 month – 2 years old) (Table 
2.3) and less frequently with carbapenem-resistant isolates (6/37, 16.2% [4 neonates 
and 2 infants]). Most of the neonates/ infants with carbapenem-susceptible ESBL-
producing isolates were from Dora Nginza (8/12, 66.7%) and the hospital names for 
the remaining four (4/12, 33.3%) remained unknown (Table 2.3). All the neonates/ 
infants colonized/ infected with carbapenem-resistant isolates were from Dora 
Nginza (6/6, 100%). The number of male neonates/ infants with carbapenem-
susceptible (58.3%) and –resistant (83.3%) isolates was higher compared to female 
neonates/ infants, 41.7% and 16.7%, respectively. K. pneumoniae (9/12, 75%) was 
the most predominant carbapenem-susceptible species from neonatal/ infant 
specimens, followed by S. marcescens (1/12, 8.3%), E. aerogenes (1/12, 8.3%) and 
E. coli (1/12, 8.3%). On the other hand, A. baumannii (6/6, 100%) was the only 
carbapenem-resistant species colonizing/ infecting neonates/ infants at Dora Nginza 
hospital. Sources/ risk factors associated with the transmission of these pathogens 
37 
amongst neonates/ infants in this study could not be identified due to lack of clinical 
data. 
 
Carbapenem-susceptible isolates in neonates/ infants were mainly recovered from 
sputa (4/12, 33.3%), blood (4/12, 33.3%), urine (3/12, 25%) and very rarely from pus 
(1/12, 8.4%) (Table 2.3). In contrast, carbapenem-resistant isolates were mainly 
recovered from pus (3/6, 50%) and rarely from sputa (1/7, 16.7%), blood (1/7, 
16.7%) and urine (1/7, 16.7%). K. pneumoniae isolates were all susceptible to FOX, 
TGC, AMK, CST and carbapenems (Table A.1 in the Appendix). E. coli, E. 
aerogenes and S. marcescens were susceptible to the quinolones (CIP and NAL), 
TGC, AMK and the carbapenems (Tables A3, A6 and A8 in the Appendix, 
respectively). Interestingly, only S. marcescens and P. mirabilis exhibited CST 
resistance (MIC ≥ 16 mg/L). All A. baumannii isolates in neonates/ infants were 
susceptible to CST and only 2 exhibited resistance to AMK. A. baumannii isolates in 
neonates/ infants exhibited 100% resistance rate for 80% (16/20) of antimicrobial 
agents tested in this study (Table 2.2; Table A.9 in the Appendix). The MDR rate 
among carbapenem-susceptible and –resistant isolates in this population was 
extremely high, 91.7% (11/12) and 100% (6/6), respectively. 
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Table 2.3: Characteristics of carbapenem-susceptible and –resistant isolates (n=18) from paediatric specimens. 
 
 Isolate No. Isolate/species Specimen Hospital Age Gender MDR 
Carbapenem-susceptible (n=12) CS 1 K. pneumoniae Urine Dora Nginza 60 days Female Yes 
 CS 6 K. pneumoniae Urine Dora Nginza 20 days Female Yes 
 CS 9 K. pneumoniae Sputum Dora Nginza 23 days Male Yes 
 CS 10 K. pneumoniae Sputum ND 13 months Male No 
 CS 11 K. pneumoniae Sputum ND 17 days Male Yes 
 CS 12 K. pneumoniae Sputum ND 5 months Female Yes 
 CS 20 K. pneumoniae Blood Dora Nginza 3 days Male Yes 
 CS 21 K. pneumoniae Blood Dora Nginza 2 days Male Yes 
 CS 23 K. pneumoniae Pus Dora Nginza 2 years Male Yes 
 CS 34 S. marcescens Urine Dora Nginza 8 days Female Yes 
 CS 37 E. aerogenes Blood ND 5 months Male Yes 
 PE 11 E. coli Blood Dora Nginza 10 months Female Yes 
Carbapenem-resistant (n=6) CR 2 A. baumannii Urine Dora Nginza 9 days Male Yes 
 CR 4 A. baumannii Pus Dora Nginza 2 years Female Yes 
 CR 5 A. baumannii Pus Dora Nginza 11 months Male Yes 
 CR 8 A. baumannii Blood Dora Nginza 15 days  Male Yes 
 CR 9 A. baumannii Sputum Dora Nginza 16 days  Male Yes 
 CR 12 A. baumannii Pus Dora Nginza 11 days  Male Yes 
(CS): Carbapenem-susceptible; (CR): Carbapenem-resistant; (PE): Port Elizabeth; MDR: indicates multidrug resistance; (ND) indicates no data; PE 
11 is an E. coli isolate which is further discussed in Chapter 4. 
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2.4 DISCUSSION  
Healthcare systems are currently faced with a major problem, the rapid emergence 
and global spread of ESBLs and carbapenemases in clinical as well as community 
settings. These are usually associated with multidrug resistant Gram-negative 
pathogens thus complicating treatment of associated infections (Pitout et al., 2005; 
Papadimitriou-Olivgeris et al., 2013). This problem is exacerbated by the high 
mortality rates associated with infections due to ESBL- and carbapenemase-
producing bacteria compared to non-β-lactamase infections (Brink, 2007; 
Papadimitriou-Olivgeris et al., 2013). This study highlights the prevalence of 
carbapenem-susceptible and -resistant ESBL-producing bacteria among patients 
from Port Elizabeth hospital complex. Carbapenem-susceptible and -resistant ESBL-
producing bacteria were frequently recovered from clinical specimens from Dora 
Nginza and Livingstone hospitals.  
 
Retrieval of patient medical records was a major challenge presenting limitations in 
this study. As a result of insufficient demographic data, there was lack of distinction 
between hospital- and community-acquired infections or whether the patients were 
colonized/ infected with ESBL-producing and carbapenem-resistant bacteria. 
However, ethics and data request approval from NHLS and authorization from the 
Department of Health was granted to access patient medical records. This challenge 
highlights the insufficiencies of the healthcare system in Port Elizabeth including 
inefficient method of capturing and storing patient clinical data resulting in loss of 
patient folders, folders with missing pages and a lack of co-operation between the 
hospital personnel.  
 
In our locale, most female patients were frequently colonized/ infected with 
carbapenem-susceptible isolates relative to carbapenem-resistant isolates. In 
contrast, male patients were predominantly colonized/ infected with carbapenem-
resistant bacteria compared to carbapenem-susceptible bacteria. Male gender has 
previously been reported as an independent risk factor for transmission of ESBL-
producing E. coli and K. pneumoniae in an Israeli long-term care facility and more 
recently KPC-producing K. pneumoniae in an ICU of University Hospital of Patras, 
Greece (Mendelson et al., 2005; Papadimitriou-Olivgeris et al., 2013).  
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K. pneumoniae and E. coli remain the major MDR ESBL-producing species among 
carbapenem-susceptible isolates with a prevalence of 42.4% and 35.6%, 
respectively (Fig. 2.6-A) consistent with the findings from other South African public 
sector hospitals (Bamford et al., 2007; Ehlers et al., 2009; Bamford et al., 2011; 
Crowther-Gibson et al., 2011). Other carbapenem-susceptible ESBL-producing 
enterobacterial species were very rare constituting 22% of carbapenem-susceptible 
isolates analysed in this study and these were E. cloacae, C. freundii, S. 
marcescens, K. oxytoca, E. aerogenes and P. mirabilis. It is uncertain whether the 
emergence of these carbapenem-susceptible ESBL-producing bacteria (particularly 
K. pneumoniae) in Port Elizabeth is due to cross-infection or clonal spread, since 
these isolates were not typed.  
 
A. baumannii was the most predominant species (35.9%) among carbapenem-
resistant isolates, followed by K. pneumoniae (25.6%) and P. aeruginosa (23.1%) 
(Fig. 2.6-B). A. baumannii and P. aeruginosa are typical ICU pathogens thus their 
prevalence reflects possible emergence of carbapenem resistance in the ICU in the 
Port Elizabeth hospital complex. Other carbapenem-resistant species were very rare 
constituting 15.4% of carbapenem-resistant isolates and these included E. cloacae, 
E. asburiae and E. coli. Of great concern is the rapid emergence of carbapenem-
resistant K. pneumoniae in our locale as this organism is the most widespread 
nosocomial pathogen with high levels of resistance, thus it would limit treatment 
options of common (mild-to-severe) K. pneumoniae infections.  
 
Carbapenem-resistant Enterobacteriaceae exhibited significantly higher resistance 
rates (P < 0.05) compared to carbapenem-susceptible Enterobacteriaceae and this 
could be due to additional resistance mechanisms (porin deficiency/ reduced 
permeability, efflux pump overexpression, carbapenemase production and ESBL 
over-production) which will be described in the subsequent chapters. High resistance 
(≥83.1%) was recorded for AMP, CXM, CAE, CTX and SXT in both carbapenem-
resistant and –susceptible Enterobacteriaceae (Table 2.1). CTX resistance rate 
among Enterobacteriaceae (carbapenem-resistant [93.8%] and –susceptible [100%]) 
was extremely high compared to the 28.7% CTX resistance rate in 
Enterobacteriaceae reported by Brink et al. (2012c). This data discourages the use 
of commonly prescribed cephalosporins (CTX and CXM) and AMP in the 
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management and prophylaxis of nosocomial infections due to ESBL-producing 
Enterobacteriaceae in our locale.  
 
Cephamycins (i.e. FOX) are generally known to be stable against ESBLs (Babic et 
al., 2006) and this was true in this study only for carbapenem-susceptible ESBL-
producing Enterobacteriaceae. Only 22% of carbapenem-susceptible 
Enterobacteriaceae exhibited resistance against FOX. In contrast, all carbapenem-
resistant Enterobacteriaceae, A. baumannii and P. aeruginosa isolates exhibited 
100% resistance rate against FOX.  
 
Aminoglycosides are a group of very potent antimicrobial agents usually used in 
empiric treatment for serious infections caused by MDR Enterobacteriaceae with 
AMK and GEN being the most frequently prescribed (Bassetti et al., 2013). Moderate 
resistance rate towards GEN was observed: 68.8% and 54.2% for carbapenem-
resistant and –susceptible Enterobacteriaceae, respectively. In comparison, low 
resistance rate towards AMK of 3.4% and 0% was noted for carbapenem-susceptible 
and –resistant Enterobacteriaceae, respectively. Low AMK resistance rates relative 
to GEN were also noted for A. baumannii (21.4% vs. 92.9%) and P. aeruginosa 
(44.4% vs. 77.8%).  
 
Comparable resistance rates were reported in ESBL-producing Enterobacteriaceae 
nasopharyngeal and blood isolates from HIV-infected children in Cape Town with 
higher GEN resistance rate (56%) and lower AMK resistance rate (15.6%) (Cotton et 
al., 2008). Recently, a comparable resistance profile was also reported in Saudi 
Arabia where ESBL-producing K. pneumoniae isolates were more resistant to GEN 
(87.3%) compared to AMK (10%) (Tawfik et al., 2013). In contrast, recent report by 
Eftekhar et al. (2012) showed a higher AMK resistance rate (49.02%) relative to 
GEN (29.42%) in ESBL-producing K. pneumoniae isolates from Iran. However, 
antimicrobial resistance patterns are expected to differ between different 
geographical regions due to local antibiotic usage and dosing regimens (Sannes et 
al., 2004). In South Africa, AMK is recommended as an empiric treatment for UTIs 
(National Essential Drug List Committee, 2012), therefore, in our locale it could still 
be an effective therapeutic option based on our findings.  
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Comparison of susceptibility data obtained in this study with the 2009 NHLS public 
sector susceptibility data (including 8 laboratories: 3 in Cape Town, 2 Johannesburg, 
2 Pretoria and 1 Bloemfontein) revealed both a degree of consistency and 
discrepancy in the susceptibility rates (Crowther-Gibson et al., 2011). For 
carbapenem-susceptible K. pneumoniae (Table A.1 in the Appendix), susceptibility 
rates for GEN (28% vs. 32 - 63%), AMK (100% vs. 63 - 98%) and CIP (48% vs. 54 - 
80%) were more or less consistent with 2009 reported NHLS rates (Crowther-Gibson 
et al., 2011). Carbapenem-resistant K. pneumoniae had comparable susceptibility 
rates (Table A.10 in the Appendix) for GEN (30%) and AMK (100%), but the CIP 
susceptibility rate of 0% varied greatly with that recorded for carbapenem-
susceptible K. pneumoniae in this study (48%) and the NHLS study (54 - 80%) 
(Crowther-Gibson et al., 2011).  
 
For carbapenem-susceptible E. coli (Table A.3 in the Appendix), susceptibility rates 
for GEN (81% vs. 76 - 91%) and AMK (95.2% vs. 69 - 98%) were consistent with 
2009 reported NHLS rates (Crowther-Gibson et al., 2011). Carbapenem-resistant E. 
coli had comparable susceptibility rate for AMK (100% vs. 69 - 98%), but the CIP 
and GEN susceptibility rate of 0% was inconsistent with that recorded for 
carbapenem-susceptible E. coli in the present study (33.3%) (Tables A.3 and A.14) 
and the NHLS study (70 - 93%) (Crowther-Gibson et al., 2011). 
 
Similar to previous studies (Brink et al., 2008), carbapenem-susceptible E. coli 
exhibited lower GEN resistance (81% susceptible) compared to carbapenem-
susceptible K. pneumoniae (28% susceptible). In contrast, carbapenem-susceptible 
K. pneumoniae exhibited lower CIP resistance rate (48% susceptible) compared to 
carbapenem-susceptible E. coli (33.3% susceptible).  
 
A. baumannii susceptibility rates recorded in this study are comparable to those 
recently reported by NHLS in Pretoria (Ahmed et al., 2012) except for TGC, 35.7% 
(present study: Tables 2.2 and A.9) vs. 75.8% (NHLS study). NHLS findings in 
Pretoria suggested TGC and AMK as effective treatment options for infections due to 
carbapenem-resistant A. baumannii (Ahmed et al., 2012). Our findings support the 
use of AMK (78.6% susceptible) but discourage the use of TGC (only 35.7% 
susceptible). High resistance rate towards TGC in carbapenem-resistant A. 
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baumannii (64.3% resistant) is disturbing since TGC has recently been licensed in 
South Africa as an additional treatment option for these infections (Ahmed et al., 
2012). Thus continued monitoring of A. baumannii susceptibility to TGC is crucial. 
 
P. aeruginosa showed consistency with susceptibility rates previously reported by 
NHLS (Crowther-Gibson et al., 2011). However, disparity in susceptibility rate for 
MEM was noted. P. aeruginosa showed 0% susceptibility to MEM (Tables 2.2 and 
A.11) which is below the reported range (13% - 97%) (Crowther-Gibson et al., 2011). 
 
According to our findings, the only antimicrobial agents with a potent activity 
(resistance rate ranging from 0% - ≤ 5.1%) against carbapenem-susceptible ESBL-
producers in our locale were TGC, CST, AMK and the carbapenems (i.e. ETP, IPM 
and MEM). ETP empiric therapy (and possibly TGC) has been recommended for 
mild-to-moderate infections due to ESBL-producing K. pneumoniae (Brink, 2007). 
For severe infections, IPM and MEM therapy has been recommended (Brink, 2007), 
provided susceptibility to these drugs has been confirmed.  
 
Alarmingly, the MDR rate among carbapenem-susceptible and -resistant isolates 
was extremely high, with 98.3% and 100% of the isolates exhibiting MDR phenotype, 
respectively. MDR rates recorded in this study for carbapenem-susceptible K. 
pneumoniae (96%), E. coli (100%) and Enterobacter spp. (100%) (Highlighted in the 
Results: Section 2.3.4) were extremely high compared to those reported by Brink et 
al. (2012c) (K. pneumoniae = 27.9%, E. coli = 4.9% and Enterobacter spp. = 14.9%). 
Elevated MDR rates highlight increased transmission and circulation of highly 
resistant nosocomial/ community-acquired strains in our locale. In addition, these 
figures also indicate a challenge that clinicians may be faced with in prescribing and 
choice of empiric therapy as MDR phenotype severely limits therapeutic options and 
may lead to therapeutic failure (Brink et al., 2012c).  
 
Generally, high MDR rates were expected in carbapenem-resistant A. baumannii 
and P. aeruginosa isolates since they are known for frequently exhibiting MDR 
phenotype in the clinical settings due to their ability to easily acquire resistance 
determinants and their multiple innate resistance determinants (Poirel and 
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Nordmann, 2006; Bamford et al., 2011; Poole, 2011). As was expected, high MDR 
rates were recorded for A. baumannii and P. aeruginosa isolates.  
 
A disturbing finding in this study was the emergence and predominance of MDR 
ESBL-producing Enterobacteriaceae (particularly K. pneumoniae) and carbapenem-
resistant A. baumannii in neonatal/ infant specimens mainly collected at Dora Nginza 
hospital (Table 2.3). This poses a threat of intra-household transmission of these 
pathogens since neonates/ infants have been reported to be long-term faecal 
carriers of ESBL-producing nosocomial pathogens (Lohr et al., 2013; Strenger et al., 
2013).  
 
MDR K. pneumoniae and carbapenem-resistant A. baumannii were the most 
predominant pathogens recovered from neonatal/ infant specimens. A. baumannii 
was reported to be the most common VAP (ventilator-associated pneumonia) 
pathogen, followed by K. pneumoniae in a paediatric intensive care unit in Cape 
Town (Morrow and Argent, 2009). A high mortality rate associated with infections 
due to ESBL-producing K. pneumoniae in neonatal units has been reported in 
KwaZulu-Natal (85%) while relatively low mortality rate was observed in Gauteng 
(30%) (Moodley et al., 2005; Velaphi et al., 2009). In the present study, quinolone 
resistance was observed in the isolates recovered from neonatal/ infant specimens 
raising therapeutic concerns even though quinolones are usually contra-indicated in 
neonates/ infants (Mshana et al., 2013). These bacterial strains might be transmitted 
by an older household member from the colonized/ infected neonate/ infant and in 
that case quinolone therapy would be empirically administered (Cantey et al., 2013; 
Lohr et al., 2013). All the isolates from neonatal/ infant specimens in the present 
study were resistant to CTX and AMP, while 66.7% carbapenem-susceptible 
Enterobacteriaceae and of 92.9% carbapenem-resistant A. baumannii exhibited 
resistance to GEN. AMP and GEN are frequently used as first line antibiotics in 
empiric therapy in neonatal units and CTX as a second line antibiotic treatment 
(Cassettari et al., 2009), hence high resistance rates were observed in the present 
study similar to other studies (Miranda et al., 2004; Bedenic et al., 2010; Mshana et 
al., 2013). 
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A. baumannii, K. pneumoniae, S. marcescens, E. coli and E. aerogenes have been 
reported in other parts of the world in association with neonatal infections and 
outbreaks: A. baumannii associated with VAP in China (Zhou et al., 2013); K. 
pneumoniae associated with neonatal sepsis in Tanzania (Mshana et al., 2013); S. 
marcescens associated with neonatal sepsis and pneumonia in Italy (Casolari et al., 
2013); E. coli associated with UTIs and bloodstream infections in Turkey and France, 
respectively (Birgy et al., 2013; Mutlu et al., 2013) and E. aerogenes associated with 
bloodstream infection in Fiji (Narayan et al., 2009). 
 
In the neonatal unit of a regional hospital in KwaZulu-Natal, intravenous glucose 
preparation used for multiple dosing was reported as a source of an outbreak of 
ESBL-producing K. pneumoniae bloodstream infections among the neonates 
(Moodley et al., 2005). Interestingly, cockroaches were implicated in a nosocomial 
outbreak caused by ESBL-producing K. pneumoniae in the neonatal unit at 
Tygerberg hospital in Cape Town (Cotton et al., 2000). Other reported sources/ risk 
factors associated with transmission of these pathogens in neonatal units include 
increased levels of colonisation of the neonates (especially colonisation of the gut), 
disinfectant solutions (Reiss et al., 2000), dextrose containing intravenous solutions 
(Lalitha et al., 1999), contaminated breast milk (Rettedal et al., 2012), high use of 
third-generation cephalosporins (such as cefotaxime) (Mshana et al., 2013), low birth 
weight (or prematurity) (Cantey et al., 2013; Rettedal et al., 2013), overcrowding 
(Cantey et al., 2013), mechanical ventilation (Boo et al., 2005), total parenteral 
nutrition (Huang et al., 2007), delivery by caesarean section (Lohr et al., 2013), 
longer hospital stay (Crivaro et al., 2007) and use of central venous catheters (Kuo 
et al., 2007).  
 
The following critical clinical information was lacking in this study: type of delivery, 
birth weight and type of feeding (breast feeding or parenteral), co-morbidities and 
whether the neonates/ infants were discharged, recovered or demised. This 
information is essential for investigating potential risk factors associated with the 
emergence and transmission of ESBL-producers in the paediatric units and to decide 
upon intervention strategies. As a result, the risk factors could not be clearly 
identified in this study. 
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This study illustrates the emergence and dissemination of MDR ESBL-producing 
Enterobacteriaceae and carbapenem-resistant A. baumannii in Port Elizabeth 
hospital complex, particularly in the paediatric unit at Dora Nginza hospital which 
requires a great deal of attention. 
 
47 
CHAPTER THREE 
 
DETECTION OF RESISTANCE DETERMINANTS: ESBL-PRODUCING 
CARBAPENEM-SUSCEPTIBLE ISOLATES 
 
3.1 INTRODUCTION 
 
There are several extended-spectrum β-lactamase (ESBL) enzymes described and 
the most common include CTX-M (Cefotaximase), TEM (Temoneira) and SHV 
(Sulfhydryl variable) encoded by blaCTX-M, blaTEM and blaSHV genes, respectively 
(Dhillon and Clark, 2011). Less common ESBLs include VEB (Vietnam extended-
spectrum β-lactamase), PER (Pseudomonas-extended-resistance β-lactamase) and 
BEL (Belgium extended β-lactamase) (Dhillon and Clark et al., 2011). CTX-M 
enzymes are currently the most clinically dominant and widespread ESBL-type 
worldwide distinguished by their potent activity against cefotaxime displacing 
previously dominant TEM and SHV among Enterobacteriaceae worldwide (Canton et 
al., 2012).  
 
CTX-M β-lactamases are divided into five groups (i.e. CTX-M group I/1, II/2, III/8, 
IV/9 and V/25) based on their amino acid sequence identities (Bonnet, 2004). There 
are over 100 CTX-M variants described so far and few representative variants in 
each CTX-M group are highlighted here: CTX-M group I variants include CTX-M-1, 
CTX-M-3, CTX-M-15 and CTX-M-22; CTX-M group II variants include CTX-M-2; 
CTX-M group III variants include CTX-M-8; CTX-M group IV variants include CTX-M-
9 and CTX-M-14; and CTX-M group V variants include CTX-M-25 (D’Andrea et al., 
2013). Novel CTX-M variants (often with enhanced activity) arise very rapidly mainly 
by point mutation of their gene or by recombination events (Fursova et al., 2013). 
The CTX-M group I is the most dominant group in clinical isolates with CTX-M-15 
reported as the most prevalent CTX-M variant worldwide (Canton and Coque, 2006; 
Livermore et al., 2007; Priyadharsini et al., 2011).  
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Mobile genetic elements and specific lineages (e.g. E. coli ST131 clone) play an 
important role in the emergence and dissemination of CTX-M enzymes between 
different hosts (Canton and Coque, 2006). Mobile genetic elements include insertion 
sequences (for mobilization), integrons (for maintenance), transposons and plasmids 
(for dissemination) (Canton and Coque, 2006; Canton et al., 2012).  
 
CTX-M-producing bacteria pose a threat in both community and healthcare facilities 
due to their MDR phenotype (Canton et al., 2012). Plasmids carrying CTX-M 
enzymes often carry other resistance determinants that confer co-resistance to 
multiple antimicrobial agents (frequently fluoroquinolones and aminoglycosides) 
(Bonnet, 2004; Canton et al., 2012). These resistance determinants include plasmid-
mediated quinolone resistance (PMQR) genes such as aac(6′)-Ib-cr, qnr genes and 
efflux pump qepA (Martinez-Martinez et al., 2008; Cattoir and Nordmann, 2009; 
Cavaco et al., 2009).  
 
PMQR genes previously described in South African fluoroquinolone-resistant 
isolates from patients presenting with different infections include qnrA in E. coli UTI 
pathogens (Chenia et al., 2006), qnrB2 in invasive Salmonella enterica serovar 
Typhimurium from a blood culture of an HIV–seropositive patient that was 
hospitalized due to tuberculosis with chronic diarrhoea (Govender et al., 2009), 
qnrS1 in Salmonella enterica serotype Typhi from a blood culture of a patient with 
typhoid fever in Cape Town (Keddy et al., 2010) and aac(6′)-Ib-cr in CTX-M-
producing E. coli from patients presenting predominantly with UTIs in Cape Town 
community hospitals (Peirano et al., 2011). Although when alone PMQR genes 
confer low-level resistance, the presence of the PMQR genes in these infections 
could facilitate selection of highly resistant mutants (Govender et al., 2009). 
Therefore, the emergence of PMQRs in the above-mentioned infections illustrates 
possible treatment challenges and could force change to the currently used 
treatment guidelines for some of the infections (e.g. typhoid fever and UTIs) (Keddy 
et al., 2010).  
 
CTX-M group I has been reported as the most predominant CTX-M group among 
clinical Enterobacteriaceae pathogens (C. freundii, E. coli, M. morganii spp. 
morganii, E. cloacae, K. pneumoniae and Proteus penneri) in two South African 
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cities: Pretoria (Ehlers et al., 2009) and Cape Town (Peirano et al. 2011) with CTX-
M-15 being the most predominant CTX-M group I variant. Co-expression of two or 
three ESBLs was also observed in these studies with a combination of CTX-M, TEM 
and SHV being the most predominant in isolates from Pretoria and combination of 
CTX-M, TEM and OXA-1 predominant in isolates from Cape Town (Ehlers et al., 
2009; Peirano et al., 2011). CTX-M-3 has been reported in E. coli causing UTI from 
Cape Town (Peirano et al., 2011), K. pneumoniae causing bactaeremia from 
Johannesburg (Paterson et al., 2003) and Salmonella enterica serotype Kivu causing 
acute diarrhoea in neonates from Durban (Govinden et al., 2008). CTX-M-14 has 
only been described in Cape Town in E. coli associated with UTIs (Peirano et al., 
2011). CTX-M-15 and CTX-M-37 have also been described among S. enterica 
serotypes cultured from stool samples from neonates at a tertiary hospital in Durban 
(Govinden et al., 2006; Govinden et al., 2008). CTX-M-14- and CTX-M-15-producing 
Shigella isolates (Shigella flexneri, Shigella sonnei phase II and Shigella 
dysenteriae) carrying other ESBLs such as TEM, SHV, and CMY (Cephamycin β-
lactamase) from humans were reported in South Africa (Tau et al., 2012).  
 
Although CTX-M enzymes have been described before, none of the CTX-M group III 
and V variants have been reported in South Africa. To date, there is no report on the 
prevalence of CTX-M enzymes as well as PMQR genes among clinical isolates from 
Port Elizabeth. This chapter investigated the presence of antibiotic resistance genes 
in ESBL-producing carbapenem-susceptible isolates.  
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3.2 MATERIALS AND METHODS 
 
The following carbapenem-susceptible bacterial species were the focus of this 
chapter: K. pneumoniae, E. cloacae, C. freundii, S. marcescens, K. oxytoca, E. 
aerogenes and P. mirabilis.  
 
3.2.1 DNA extraction and primers 
Chromosomal and plasmid DNA (deoxyribonucleic acid) was extracted from a 200 
µL bacterial culture (grown on a MacConkey/ Cetrimide agar plate overnight and 
suspended in PBS) using the QIAprep Spin Miniprep kit (Qiagen) and Plasmid Mini 
kit (Qiagen), respectively, as described by the manufacturer. Extracted DNA was 
quantified using the NanoDropTM Spectrophotometer (Thermo Scientific) at 260 nm.  
Primers were synthesised by Integrated DNA Technologies (WhiteSci) and re-
constituted in TE buffer (Lonza) according to manufacturer’s instructions. 
 
3.2.2 Detection of resistance determinants in carbapenem-susceptible 
isolates 
 
3.2.2.1 ESBLs 
PCR screening for blaCTX-M, blaTEM, blaSHV and blaOXA-1 genes was performed using 
plasmid DNA as a template with the primers and PCR conditions shown in Table 3.1. 
All the PCR reactions were performed using the TopTaqTM Master Mix kit (Qiagen) 
with an iCyclerTM Thermal cycler (Bio-Rad). The PCR reactions were performed twice 
to verify that correct amplicons were obtained and no contamination had occurred 
including negative controls in all the reactions. Resulting amplicons (10 µL) were 
confirmed using agarose gel electrophoresis.  
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Table 3.1:   Primers and PCR conditions employed for detection of ESBLs. 
Gene 
 
Primer Sequence Size 
(bp) 
GenBank 
reference 
Reference 
CTX-M 
group I 
CTXM1-F3 5’-GACGATGTCACTGGCTGAGC-3’ 499 X92506 Pitout et al. (2004) 
and Priyadharsini et 
al. (2011) 
 CTXM1-R2 5’-AGCCGCCGACGCTAATACA-3’    
      
CTX-M 
group II 
TOHO1-2F 5’-GCGACCTGGTTAACTACAATCC-3’ 351 X92507 Pitout et al. (2004) 
and Priyadharsini et 
al. (2011) 
 TOHO1-1R 5’-CGGTAGTATTGCCCTTAAGCC-3’    
      
CTX-M 
group III/V 
CTXM825-F 5’-CGCTTTGCCATGTGCAGCACC-3’ 307 AF189721 Pitout et al. (2004) 
and Priyadharsini et 
al. (2011) 
 CTXM825-R 5’-GCTCAGTACGATCGAGCC-3’    
      
CTX-M 
group IV 
CTXM914-F 5’-GCTGGAGAAAAGCAGCGGAG-3’ 474 AF252622 Pitout et al. (2004) 
and Priyadharsini et 
al. (2011) 
 CTXM914-R 5’-GTAAGCTGACGCAACGTCTG-3’    
      
blaTEM TEM-F 5’-ATGAGTATTCAACATTTCCGTG–3’ 861 JX129212.1 
 
Essack et al. (2001) 
 TEM-R 5’-TTACCAATGCTTAATCAGTGAG-3’ 
(Initial denaturation: 3 min at 95°C; 30 
cycles of 60 s at 95°C, 60 s at 55°C and 
60 s at 72°C; and 5 min at 72°C for the 
final extension) 
   
      
blaSHV SHV-F 5’-ATGCGTTATATTCGCCTGTG–3’ 865 AF117743.1 Essack et al. (2001) 
 SHV-R 5’-GTTAGCGTTGCCAGTGCTCG-3’ 
(Initial denaturation: 3 min at 95°C; 30 
cycles of 15 s at 94°C, 60 s at 60°C and 
60 s at 72°C and 5 min at 72°C for the 
final extension) 
   
      
blaOXA-1 OXA-F 5’-CCAAAGACGTGGATG–3’ 420 AF255921.1 Siu et al. (2000)
 OXA-R 5’-GTTAAATTCGACCCCAAGTT-3’ 
(Initial denaturation: 3 min at 95°C; 35 
cycles of 60 s at 94°C, 60 s at 57°C and 
60 s at 72°C and 5 min at 72°C for the 
final extension) 
   
      
PCR conditions: blaCTX-M I-IV 
[Pitout et al. (2004) and 
Priyadharsini et al. (2011)] 
 
Initial denaturation: 3 min at 94ºC. 25 cycles:  30 s at 94ºC, 30 s  at 55ºC (Group I, II, and 
III) or 62ºC (Group IV), 30 s  at 72ºC. Final extension: 5 min at 72oC 
 
3.2.2.2 qnr genes, qepA, and aac(6’)-Ib-cr  
All the isolates in this study, including NAL- and CIP-susceptible, were screened for 
qnr, qepA and aac(6’)-Ib genes employing specific primers and PCR conditions 
outlined in Tables 3.2 and 3.3.  
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Table 3.2: Primers and PCR conditions employed for the amplification of qnr genes. 
 
Gene Primer Sequence Size (bp) 
GenBank 
Reference Reference 
qnrA qnrA-F 5’-ATTTCTCACGCCAGGATTTG–3’ 516 AY070235 Robicsek et al. (2006) 
 qnrA-R 5’-GATCGGCAAAGGTTAGGTCA-3’   
      
qnrB qnrB-F 5’-GATCGTGAAAGCCAGAAAGG-3’ 469 DQ351241 Robicsek et al. (2006) 
 qnrB-R 5’-ACGATGCCTGGTAGTTGTCC-3’   
      
qnrS qnrS-F 5’-ACGACATTCGTCAACTGCAA-3’ 359 JQ619636.1 Robicsek et al. (2006) 
 qnrS-R 5’-TAAATTGGCACCCTGTAGGC-3’   
      
qnrC qnrC-F 5’-GGGTTGTACATTTATTGAATC–3’ 447 EU917444.1 Wang et al. (2009) 
 qnrC-R 5’-TCCACTTTACGAGGTTCT-3’ 
(3 min at 94°C; 30 cycles of 30 s at 94°C, 
30 s at 50°C, and 30 s at 72°C and 5 min 
at 72°C for the final extension) 
   
      
qnrD qnrD-F 5’-CGAGATCAATTTACGGGGAATA–3’ 582 FJ228229.1 Cavaco et al. (2009) 
 qnrD-R 5’-AACAAGCTGAAGCGCCTG-3’ 
(5 min at 94°C; 30 cycles of 60 s at 94°C, 
60 s at 50°C, and 60 s at 72°C and 10 min 
at 72°C for the final extension) 
   
      
PCR conditions: qnrA, qnrB, qnrS 
(Robicsek et al., 2006) 
                                                    Initial denaturation: 3 min at 94ºC 
32 cycles:               45 s  at 94ºC 
                               45 s  at 53ºC 
                               60 s  at 72ºC 
Final extension:      5 min at 72oC 
 
 
 
 
Table 3.3: Primers and PCR conditions employed for the amplification of aac(6’)-Ib and qepA genes. 
 
Gene Primer Sequence Size (bp) 
GenBank 
Reference Reference 
aac(6’)-Ib aac(6’)Ib-F 5’-TTGCGATGCTCTATGAGTGGCTA–3’ 482 JQ065040.1 Park et al. (2006) 
 aac(6’)Ib-R 5’-CTCGAATGCCTGGCGTGTTT-3’   
      
qepA qepA-F 5’-GCAGGTCCAGCAGCGGGTAG–3’ 199 AB263754.2  
 
Yamane et al. 
(2008) 
 qepA-R 5’-CTTCCTGCCCGAGTATCGTG-3’ 
(1 min at 96°C; 30 cycles of 60 s at 96°C, 
60 s at 60°C, and 60 s at 72°C and 5 min 
at 72°C for the final extension) 
 
   
      
PCR conditions: aac(6’)-Ib 
(Park et al., 2006) 
 
                                                   Initial denaturation: 3 min at 94ºC;  
                                                   34 cycles:                45 s at 94ºC,   
                                                                                   45 s  at 55ºC,  
                                                                                   45 s at 72ºC 
Final extension:      5 min at 72oC 
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3.2.3 Agarose gel electrophoresis (AGE) 
A 2% (w/v) agarose gel containing 0.3 µg/mL ethidium bromide (Promega) was used 
for confirmation and analysis of PCR products. Tris-acetate EDTA buffer (Lonza) 
was used as a running buffer. Each well was loaded with 10 µL of the respective 
PCR reaction mixture and electrophoresis was conducted at 100 V and 400 mA for 
45 min. Ethidium bromide-stained DNA products were visualised by UV 
transillumination and images captured using an Alpha ImagerTM 3400 gel system 
(Alpha Innotech). A 100 base pair (bp) molecular weight marker (ranging from 100 
bp to 1 kb) (Bioline) was included in the gels to verify amplicon size. 
 
3.2.4 Sequencing 
PCR products were prepared for sequencing using Wizard SV gel PCR clean-up kit 
(Promega) in accordance with the manufacturer’s instructions. Purified DNA samples 
were sequenced at the Central Analytical Facility, University of Stellenbosch. 
Sequence analyses were performed using Chomas 1.45 and BioEdit 7.0.5. The 
ESBL and PMQR variants were obtained through BLAST search (GenBank 
accession numbers are indicated in Tables 3.1 – 3.3).  
 
 
3.3 RESULTS 
3.3.1 ESBLs 
ESBL-producing carbapenem-susceptible Enterobacteriaceae (excluding all E. coli 
isolates which are discussed in Chapter 4) were PCR-positive for one or more ESBL 
genes as shown in Fig. 3.1.  
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Figure 3.1: ESBL genes identified among carbapenem-susceptible isolates in this study on a 2% agarose 
gel following PCR amplification and electrophoresis. Lane 1: Molecular weight marker (100 bp 
Bioline DNA ladder); Lane 2: Negative control (ddH2O); Lane 3: blaCTX-M-group I (499 bp); 
Lane 4: blaCTX-M-group IV (474 bp); Lane 5: blaSHV (865 bp); Lane 6: blaTEM (861 bp); Lane 7: 
blaOXA-1 (420 bp).  
 
ESBL genes identified include CTX-M, TEM, SHV and OXA-1. Only CTX-M groups I 
and IV were identified with CTX-M group 1 variants including: CTX-M-3, CTX-M-15, 
CTX-M-22 and CTX-M group IV variant: CTX-M-14. While there have been reports of 
other ESBL-producing Enterobacteriaceae in South Africa, CTX-M-22 variant 
identified from K. pneumoniae isolates in this study has not been described 
previously. The sequence alignment for CTX-M-22 is shown in Fig. 3.2 while 
sequence alignments for other CTX-M variants are indicated in the Appendix section: 
Figs. A.1 – A.3. 
 
Other ESBL variants found were TEM-1, SHV-1, SHV-11 and OXA-1 (sequence 
alignments are shown in the Appendix section: Figs. A.4 – A.7).  
 
 
      1           2         3         4         5         6          7 
OXA-1 (420 bp) 
500 bp 
TEM (861 bp) SHV (865 bp)
CTX-M group I 
(499 bp) 
CTX-M group IV 
(474 bp)
400 bp 
800 bp 
900 bp 
100 bp 
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Figure 3.2: DNA sequence of CTX-M group I: CTX-M-22 variant (blaCTX-M-22) from a carbapenem-susceptible K. pneumoniae isolate CS2 aligned with a 
GenBank CTX-M-22 sequence (sequence corresponding to position 401 - 855 of blaCTX-M-22 with accession number: AY080894.1). Sequence 
identity = 99%.  
 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. AY080894.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. AY080894.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. AY080894.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. AY080894.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. AY080894.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. AY080894.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. AY080894.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. AY080894.1 
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3.3.2 Plasmid-mediated quinolone resistance (PMQR) genes  
PMQR variants identified in this study were qnrS1, qnrB1, qnrB13 and aac(6′)-lb-cr 
(Fig. 3.3). None of the isolates were positive for qnrA, qnrC, qnrD and qepA genes. 
While there have been reports of other PMQR variants among Enterobacteriaceae in 
South Africa, qnrB1 and qnrB13 variants identified from the Enterobacteriaceae 
isolates in this study have not been described previously. The sequence alignments 
for qnrB1 and qnrB13 are shown in Figs. 3.4 and 3.5 while sequence alignments for 
other PMQR variants are indicated in the Appendix (Figs. A.8 – A.9). 
 
Figure 3.3: PMQR genes identified among carbapenem-susceptible isolates in this study on a 2% 
agarose gel following PCR amplification and electrophoresis. Lane 1: Molecular weight 
marker (100 bp Bioline DNA ladder); Lane 2: Negative control (ddH2O); Lane 3: qnrB (469 
bp); Lane 4: qnrS (359 bp); Lane 5: aac(6’)-lb-cr (482 bp).  
 
 
       1          2        3          4         5        
100 bp 
500 bp 
400 bp 
qnrB 
(469 bp)
qnrS 
(359 bp)
aac(6′)-lb-cr 
(482 bp) 
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Figure 3.4: DNA sequence of QnrB1 variant from a carbapenem-susceptible K. pneumoniae isolate CS7 aligned with a GenBank 
QnrB1 sequence (sequence corresponding to position 181 - 595 of qnrB1 with accession number: JN193528.1). 
Sequence identity = 99%.  
 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. JN193528.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. JN193528.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. JN193528.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. JN193528.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. JN193528.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. JN193528.1 
Clinical isolate: K. pneumoniae 
GenBank strain: Acc. No. JN193528.1 
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Figure 3.5: DNA sequence of QnrB13 variant from a carbapenem-susceptible Citrobacter freundii isolate CS30 aligned with 
a GenBank QnrB13 sequence (sequence corresponding to position 203 - 642 of qnrB13 with accession number: 
EU273756.1). Sequence identity = 97%.  
 
Clinical isolate: C. freundii 
GenBank strain: Acc. No. EU273756.1 
Clinical isolate: C. freundii 
GenBank strain: Acc. No. EU273756.1 
Clinical isolate: C. freundii 
GenBank strain: Acc. No. EU273756.1 
Clinical isolate: C. freundii 
GenBank strain: Acc. No. EU273756.1 
Clinical isolate: C. freundii 
GenBank strain: Acc. No. EU273756.1 
Clinical isolate: C. freundii 
GenBank strain: Acc. No. EU273756.1 
Clinical isolate: C. freundii 
GenBank strain: Acc. No. EU273756.1 
Clinical isolate: C. freundii 
GenBank strain: Acc. No. EU273756.1 
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3.3.3 Prevalence of ESBL and PMQR genes 
 
3.3.3.1 K. pneumoniae  
 
ESBL-producing K. pneumoniae isolates (n=25) were predominantly recovered from 
sputa (8/25, 32%) and urine (8/25, 32%) specimens, and relatively less from blood 
(5/25, 20%) and pus (4/25, 16%) specimens (Table 3.4). The majority of K. 
pneumoniae isolates (16/25, 64%) possessed two or more ESBL genes and only a 
minority possessed one ESBL gene (9/25, 36%). PCR screening revealed that 80% 
(20/25) of K. pneumoniae isolates were CTX-M-positive with CTX-M group I (19/20, 
95%) being the most predominant CTX-M group and only 1 isolate (CS11) positive 
was for CTX-M group IV (1/20, 5%). Five K. pneumoniae isolates (5/25, 20%) were 
negative for CTX-M enzymes but positive for SHV-1 (4/25, 16%) and TEM-1+SHV-1 
(1/25, 4%).  
 
CTX-M-15 variant (12/20, 60%) was the most predominant CTX-M variant found in 
combination with TEM-1+SHV-1+OXA-1+qnrB1+aac(6’)-lb-cr (2/12), TEM-1+SHV-
1+OXA-1+aac(6’)-lb-cr (1/12), TEM-1+SHV-1+OXA-1 (1/12); TEM-1+OXA-
1+qnrB1+aac(6’)-lb-cr (1/12), TEM-1+OXA-1+aac(6’)-lb-cr (1/12); SHV-1+OXA-
1+qnrB1+aac(6’)-lb-cr (1/12), SHV-1+OXA-1 (1/12), TEM-1+SHV-1+ qnrB1+aac(6’)-
lb-cr (1/12), TEM-1+SHV-1 (1/12) and SHV-1 (2/12).  
 
Interestingly, CTX-M-3 variant (4/20, 20%) was not found in combination with any of 
the other ESBL or PMQR genes in K. pneumoniae. The CTX-M-22 variant (3/20, 
15%) was found in combination with TEM-1+SHV-1+qnrS1 (1/3), OXA-1+qnrS1 (1/3) 
and qnrS1 (1/3), while the CTX-M-14 variant (1/20, 5%) was found in combination 
with SHV-11 (1/1).  
 
Of major concern, three patients from whom ESBL-producing K. pneumoniae 
isolates CS3, CS4 and C19 were recovered demised. However, it could not be 
confirmed if mortality was associated with ESBL-producing K. pneumoniae isolates. 
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Table 3.4: Summary of antibiotic resistance profiles and resistance genes in ESBL-producing K. pneumoniae (n=25). 
 
Isolate 
No. Isolate/species Specimen 
Antimicrobial resistance 
PMQR 
CTX-M 
group β-lactamases Resistant Intermediate 
CS1n K. pneumoniae Urine AMP, CXM, CAE, CTX, GEN, NAL, CIP, SXT  aac(6′)-lb-cr I CTX-M-15, TEM-1, SHV-1; 
OXA-1 
CS2 K. pneumoniae Urine AMP, CXM, CTX, GEN, SXT NIT qnrS1 I CTX-M-22 
CS3d K. pneumoniae Urine AMP, CXM, CAE, NAL, CIP CTX  I CTX-M-15, SHV-1; OXA-1 
CS4d K. pneumoniae Urine AMP, CXM, CAE, CTX, CAZ, GEN, SXT AMC  I CTX-M-15; TEM-1; SHV-1; 
OXA-1 
CS5 K. pneumoniae Urine AMP, AMC, TZP, CXM, CAE, CTX, CAZ, GEN, NIT    SHV-1  
CS6n K. pneumoniae Urine AMP, TZP, CXM, CAE, CTX, GEN NIT    SHV-1  
CS7 K. pneumoniae Urine AMP, TZP, CXM, CAE, CTX, CAZ, GEN, NAL, CIP, 
TGC, NIT, SXT 
AMC, FOX qnrB1; 
aac(6′)-lb-cr 
I CTX-M-15; TEM-1; SHV-1; 
OXA-1 
CS8 K. pneumoniae Urine AMP, AMC, TZP, CXM, CAE, CTX, CAZ, FEP, NAL, 
NIT, SXT 
TGC aac(6′)-lb-cr I CTX-M-15; TEM-1; OXA-1 
CS9n K. pneumoniae Sputum AMP, CXM, CAE, CTX, GEN, NIT, SXT  qnrS1 I CTX-M-22, TEM-1, SHV-1  
CS10n K. pneumoniae Sputum AMP, CXM, CAE, CTX  AMC qnrS1 I CTX-M-22; OXA-1 
CS11n K. pneumoniae Sputum AMP, CXM, CAE, CTX, NIT   IV CTX-M-14, SHV-11 
CS12n K. pneumoniae Sputum AMP, CXM, CAE, CTX AMC, NIT  I CTX-M-3 
CS13 K. pneumoniae Sputum AMP, CXM, CAE, CTX NIT  I CTX-M-3 
CS14 K. pneumoniae Sputum AMP, CXM, CAE, CTX, GEN, SXT NIT  I CTX-M-3 
CS15 K. pneumoniae Sputum AMP, CXM, CAE CTX, NIT   I CTX-M-3 
CS16 K. pneumoniae Sputum AMP, CXM, CAE, CTX, CAZ, GEN, NIT, SXT AMC, CIP qnrB1; 
aac(6′)-lb-cr 
I CTX-M-15; TEM-1; OXA-1 
CS17  K. pneumoniae Blood AMP, AMC, TZP, CXM, CAE, CTX, CAZ, GEN, NAL, 
CIP, NIT, SXT 
FEP   TEM-1; SHV-1 
CS18 K. pneumoniae Blood AMP, AMC, CXM, CAE, CTX, CAZ, GEN, NAL, CIP, 
NIT 
TZP, FEP aac(6′)-lb-cr  SHV-1 
CS19d K. pneumoniae Blood AMP, AMC, CXM, CAE, CTX, CAZ, GEN, NAL, CIP, 
NIT, SXT 
TZP, FEP qnrB1; 
aac(6′)-lb-cr 
I CTX-M-15; SHV-1; OXA-1 
CS20n K. pneumoniae Blood AMP, CXM, CAE, CTX, CAZ, FEP, GEN, NAL, CIP, 
NIT, SXT 
AMC  I CTX-M-15; TEM-1; SHV-1 
CS21n  K. pneumoniae Blood AMP, CXM, CAE, CTX, CAZ, FEP, GEN, NAL, CIP, 
NIT, SXT 
  I CTX-M-15; SHV-1 
CS22 K. pneumoniae Pus AMP, CXM, CAE, CTX, CAZ, GEN, NAL, SXT AMC, CIP qnrB1; 
aac(6′)-lb-cr 
I CTX-M-15; TEM-1; SHV-1; 
OXA-1 
CS23n K. pneumoniae Pus AMP, AMC, CXM, CAE, CTX, CAZ, GEN, NIT, SXT TZP, CIP qnrB1; 
aac(6′)-lb-cr 
 SHV-1  
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 Table 3.4 Continued…. 
 
     
Isolate 
No. Isolate/species Specimen 
Antimicrobial resistance 
PMQR 
CTX-M 
group β-lactamases Resistant Intermediate 
CS24 K. pneumoniae Pus AMP, CXM, CAE, CTX, CAZ, FEP, GEN, NAL, CIP, 
NIT, SXT 
  I CTX-M-15; SHV-1   
CS25 K. pneumoniae Pus AMP, AMC, CXM, CAE, CTX, CAZ, FEP, GEN, SXT TZP, CIP qnrB1; 
aac(6′)-lb-cr 
I CTX-M-15; TEM-1; SHV-1 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; TZP = piperacillin-tazobactam; CXM = cefuroxime; CAE = cefuroxime axetil; FOX = 
cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = 
gentamicin; NAL = nalidixic acid; CIP = ciprofloxacin; TGC = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = trimethoprim-sulfamethoxazole. (n) 
indicates isolates from neonatal/ infant specimens; (d) indicates that the patients demised. 
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3.3.3.2 Other Enterobacteriaceae species 
 
ESBL-producing Enterobacter cloacae isolates (n=4) were mainly recovered from blood (2/4, 
50%) and urine (2/4, 50%) specimens (Table 3.5). E. cloacae isolates possessed one (1/4, 
25%), two (2/4, 50%) or three (1/4, 25%) ESBL genes. CTX-M group I (4/4, 100%) was the 
only CTX-M group identified in E. cloacae isolates. CTX-M-15 variant (3/4, 75%) was the 
most predominant CTX-M variant in E. cloacae and was found in combination with TEM-
1+OXA-1 (1/4), OXA-1+qnrB1+aac(6’)-lb-cr (1/4) and OXA-1+aac(6’)-lb-cr (1/4). In contrast 
to K. pneumoniae, CTX-M-3 (1/4, 25%) in E. cloacae was found in combination with qnrS1.  
 
ESBL-producing Citrobacter freundii isolates (n=4) were mainly recovered from urine (2/4, 
50%) and pus (2/4, 50%) specimens (Table 3.5). All the C. freundii isolates possessed at 
least two ESBL genes. Similar to E. cloacae, CTX-M group I (4/4, 100%) was the only CTX-
M group identified in C. freundii. CTX-M-15 variant (3/4, 75%) was the most predominant 
CTX-M variant and found in combination with OXA-1+qnrB1+aac(6’)-lb-cr (1/4), TEM-
1+SHV-1+OXA-1+qnrB13 (1/4) and OXA-1 (1/4). CTX-M-3 (1/4, 25%) was identified in 
combination with TEM-1+qnrS1 (1/1).  
 
ESBL-producing S. marcescens isolates (n=2) were recovered from urine (1/2, 50%) and 
pus (1/2, 50%) specimens (Table 3.5). Both S. marcescens isolates possessed two ESBL 
genes. Similar to other species, CTX-M group I (2/2, 100%) was the only CTX-M group 
identified in S. marcescens. CTX-M-15 variant (2/2, 100%) was the only CTX-M variant 
identified and mainly found in combination with OXA-1 (2/2). S. marcescens isolates were 
not positive for any of the PMQR genes as was expected since they exhibited susceptibility 
to the quinolones (NAL and CIP). 
 
ESBL-producing K. oxytoca (n=1), E. aerogenes (n=1) and P. mirabilis (n=1) isolates were 
recovered from sputum, blood and pus specimens, respectively. K. oxytoca was positive for 
CTX-M-15+OXA-1 and negative for PMQR genes (susceptible to the quinolones). E. 
aerogenes was positive for CTX-M-15+TEM-1+OXA-1 and also negative for PMQR genes 
(susceptible to the quinolones). In contrast, P. mirabilis was negative for CTX-M gene,  
but positive for TEM-1+OXA-1+qnrB1 (resistant to NAL). 
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Table 3.5: Summary of antibiotic resistance profiles and resistance genes in selected ESBL-producing Enterobacteriaceae. 
 
Isolate 
No. Isolate/species Specimen 
Antimicrobial resistance 
PMQR 
CTX-M 
group β-lactamases Resistant Intermediate 
CS26 E. cloacae Blood AMP, AMC, CXM, CAE, FOX, CTX, CAZ, GEN, SXT TZP, NIT  I CTX-M-15; TEM-1; OXA-1 
CS27 E. cloacae Blood AMP, AMC, CXM, CAE, FOX, CTX, CAZ, FEP, GEN, 
NAL, CIP, SXT 
TZP, NIT qnrB1; 
aac(6′)-lb-cr 
I CTX-M-15; OXA-1 
CS28 E. cloacae  Urine AMP, AMC, CXM, CAE, FOX, CTX, SXT TZP, NIT qnrS1 I CTX-M-3 
CS29 E. cloacae Urine AMP, AMC, CXM, CAE, FOX, CTX, CAZ, NAL, CIP, 
SXT 
 aac(6′)-lb-cr I CTX-M-15; OXA-1 
CS30 C. freundii Urine AMP, AMC, CXM, CAE, CTX, CAZ, GEN, NAL, CIP, 
SXT 
TZP qnrB13 I CTX-M-15; TEM-1; SHV-1; 
OXA-1 
CS31 C. freundii Urine AMP, CXM, CAE, CTX, CAZ, GEN, NAL, SXT AMC qnrB1; 
aac(6′)-lb-cr 
I CTX-M-15; OXA-1 
CS32 C. freundii Pus AMP, AMC, CXM, CAE, FOX, CTX, NAL, CIP, SXT  qnrS1 I CTX-M-3; TEM-1 
CS33 C. freundii Pus AMP, AMC, CXM, CAE, FOX, CTX, CAZ, FEP, GEN, 
SXT 
TZP  I CTX-M-15; OXA-1 
CS34n Serratia 
marcescens 
Urine AMP, AMC, CXM, CAE, CTX, CAZ, GEN, NIT, CST, 
SXT 
TZP, FOX, 
FEP  
 I CTX-M-15; OXA-1 
CS35 Serratia 
marcescens 
Pus AMP, AMC, TZP, CXM, CAE, CTX, CAZ, FEP, GEN, 
NIT, CST 
FOX  I CTX-M-15; OXA-1 
CS36 K. oxytoca Sputum AMP, CXM, CAE, CTX, CAZ, FEP, GEN, SXT AMC, TZP  I CTX-M-15; OXA-1 
CS37n E. aerogenes Blood AMP, AMC, CXM, CAE, FOX, CTX, CAZ, FEP, GEN, 
SXT 
TZP, NIT  I CTX-M-15; TEM-1; OXA-1 
CS38* P. mirabilis Pus AMP, CXM, CAE, CTX, CAZ, FEP, NAL, NIT, CST, 
SXT 
AMK, GEN, 
TGC 
qnrB1  TEM-1; OXA-1 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; TZP = piperacillin-tazobactam; CXM = cefuroxime; CAE = cefuroxime axetil; FOX = 
cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = 
gentamicin; NAL = nalidixic acid; CIP = ciprofloxacin; TGC = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = trimethoprim-sulfamethoxazole.  
(n) indicates isolates from neonatal/ infant specimens; (*) indicates isolate that was co-colonizing/ co-infecting one male patient with E. coli isolate PE21. 
 
 
 
 
 
 
64 
3.4  DISCUSSION  
The presence of multiple ESBL genes in combination with PMQR genes, a common 
phenomenon for members of the Enterobacteriaceae is often associated with 
extended spectrum of antimicrobial resistance and severely limits β-lactam treatment 
options (Huang et al., 2005; Rankin et al., 2005; Ehlers et al., 2009). A similar 
observation was made for the isolates described in this study (Tables 3.4 and 3.5). 
The wide range of different ESBL gene combinations highlights the role played by 
mobile genetic elements (i.e. integrons, transposons and insertions sequences), 
genetic interactions among different plasmids (resulting in mosaic plasmids) or 
recombinatorial shuffling of sequences in the process of evolving plasmids with 
multiple resistance determinants (Canton and Coque, 2006). For future studies, it 
would be interesting to type plasmids carrying ESBLs and PMQR genes especially 
those carrying four different ESBL genes since the evolution of plasmids carrying 
four different ESBL genes in combination with PMQR genes, is a major threat in the 
medical community as it increases the spectrum of antimicrobial activity of these 
organisms (Canton et al., 2012). These findings have clinical implications for 
selecting empiric antimicrobial drug therapy when infection caused by ESBL-
producing K. pneumoniae or other Enterobacteriaceae species is suspected. 
 
The emergence and distribution of various CTX-M enzymes in South Africa is 
illustrated below in Fig. 3.6. Only CTX-M group I and IV variants have been identified 
from the Port Elizabeth region namely CTX-M-1, CTX-M-3, CTX-M-15, CTX-M-22 
and CTX-M-14 similar to the pattern observed in Cape Town (Peirano et al., 2011). 
CTX-M group I variants have been described mainly among Enterobacteriaceae 
isolates in five South African cities: Johannesburg (Paterson et al., 2003; Tau et al., 
2012), Pretoria (Ehlers et al., 2009), Durban (Govinden et al., 2006; Govinden et al., 
2008; Mocktar et al., 2009), Cape Town (Peirano et al., 2011) and Port Elizabeth 
(Present study, 2013). CTX-M-2 variant which belongs to CTX-M group II was 
reported in K. pneumoniae isolate detected in Johannesburg (Paterson et al., 2003). 
No other part of the country has reported CTX-M group II variants except 
Johannesburg. CTX-M group III and V variants have never been described in South 
Africa. 
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Figure 3.6: Emergence and distribution of CTX-M type enzymes in South Africa. Map adapted from Brink et al. 
(2012b). Data extracted from Paterson et al. (2003), Govinden et al. (2006), Govinden et al. (2008), 
Ehlers et al. (2009), Mocktar et al. (2009), Peirano et al. (2011) and Tau et al. (2012). 
 
 
TEM-1, OXA-1, SHV-1 and SHV-11 were identified in the present study. TEM-1 and 
OXA-1 have been reported frequently among South African clinical isolates whereas 
SHV-1 is rarely reported and SHV-11 has never been reported. TEM and SHV 
variants previously described in South Africa include: TEM-1, TEM-10, TEM-12, 
TEM-53, TEM-55, TEM-63, TEM-131, TEM-145, TEM-146, SHV-1, SHV-2, SHV-5, 
SHV-19, SHV-20, SHV-21 and SHV-22 (Pitout et al., 1998; Essack et al., 2001; 
Paterson et al., 2003; Kruger et al., 2004; Govinden et al., 2008; Mocktar et al., 
2009; Peirano et al., 2011).  
 
CTX-M group I was the most predominant CTX-M group (31/32, 96.9%) among 
CTX-M-positive Enterobacteriaceae similar to findings of Enterobacteriaceae species 
in Cape Town [66.7%] (Peirano et al., 2011), Pretoria [100%] (Ehlers et al., 2009) 
and nationally [94.7%] (Tau et al., 2012). Only one K. pneumoniae isolate was 
positive for CTX-M group IV (isolate CS11) comparable to the findings from a 
national study carried out by the reference centre, Enteric Diseases Reference Unit 
(EDRU) of the National Institute for Communicable Diseases (NICD) where only one 
Shigella dysenteriae 3 isolate produced CTX-M IV group variant (Tau et al., 2012).  
 
CTX-M GROUP 
GROUP 1 
GROUP 2 
GROUP 3 
GROUP 4 
GROUP 5 
CTX-M-3, -15 
CTX-M-14 
CTX-M-1; -3, -15, -37 
CTX-M-15 
CTX-M-3, -15
CTX-M-2 
CTX-M-1, -3, -15, -
22 
CTX-M-14, -9 Present Study 
Cape Town 
Port Elizabeth 
Durban
Johannesburg 
Pretoria 
CTX-M-14
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CTX-M-15 was the most predominant variant (22/32, 68.8%) similar to other studies 
(Ehlers et al., 2009; Peirano et al., 2011; Tau et al., 2012; Wang et al., 2013) and 
was frequently found in combination with ESBLs such as OXA-1, TEM-1 and SHV-1 
with PMQR genes such as aac(6’)-lb-cr, qnrB1 and rarely with qnrB13 (Tables 3.4 
and 3.5). The gene encoding CTX-M-15 (i.e. blaCTX-M-15) has been shown to co-exist 
on the same plasmid with blaTEM-1, blaOXA-1 and aac(6’)-lb-cr (Carattoli, 2009) and that 
correlates with the results of this study which showed that most of the CTX-M-15-
producing isolates possessed both TEM-1 and OXA-1 while quinolone-resistant 
isolates also contained aac(6’)-lb-cr, qnrB1+aac(6’)-lb-cr or qnrB13. Similar findings 
have been reported in Cape Town except for the presence qnrB (Peirano et al., 
2011). CTX-M-15 enzyme has been identified in other parts of the country (Fig. 3.6) 
including Cape Town (Peirano et al., 2011), Pretoria (Ehlers et al., 2009), Durban 
(Govinden et al., 2008) and in a national study by Enteric Diseases Reference Unit 
(Tau et al., 2012). 
 
The rapid mobilization and convergence of CTX-M enzymes with plasmid backbones 
of all major incompatibility groups is facilitated by insertion sequences (particularly 
ISEcp1 or ISCR1) located upstream of the blaCTX-M gene (Canton et al., 2012). 
Analysis of plasmids carrying CTX-M-15 (either by plasmid replicon typing or 
conjugation experiments) or genotyping of the isolates producing CTX-M-15 variant 
using PFGE would reveal whether the observed predominance of this variant in our 
locale is associated with epidemic plasmids or is merely disseminated by clonal 
dispersion. However, several studies have shown that CTX-M-15-producing K. 
pneumoniae are genetically heterogeneous using PFGE (Rossolini et al., 2008; 
Wang et al., 2013), thus the emergence and spread of these isolates in our locale is 
likely due to polyclonal spread of isolates with diverse genetic background or due to 
horizontal transfer of a mobile genetic element carrying blaCTX-M gene. Various 
sequence types of CTX-M-15-producing K. pneumoniae have been reported, 
however, none are as successful as E. coli ST131 clone in terms of worldwide 
dissemination of CTX-M enzymes (Damjanova et al., 2008; Oteo et al., 2009; Shin et 
al., 2011; Wang et al., 2013). 
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Most CTX-M-15-producers (15/22, 68.2%) exhibited quinolone resistance with 46.7% 
(7/15) positive for aac(6’)-lb-cr+qnrB1, 20% (3/15) positive for aac(6’)-lb-cr, 6.6% 
(1/15) positive for qnrB13 and 26.7% (4/15) PMQR-negative. Quinolone resistance in 
PMQR-negative isolates (i.e. CS3, CS20, CS21 and CS24) implies the presence of 
chromosomal mutations in the QRDR of DNA gyrase (gyrA and gyrB) and 
topoisomerase IV (parC and parE) or chromosomal-encoded active efflux pumps. A 
limitation in this study was that mutations in the quinolone target regions were not 
investigated. The emergence of PMQR genes in clinical isolates is an emerging 
threat as they are frequently associated with mobile genetic elements that facilitate 
rapid emergence and inter- or intra-species dissemination of quinolone resistance 
(Cattoir and Nordmann, 2009).  
 
Co-expression of qnrB1+aac(6’)-lb-cr has been described previously in CTX-M-15-
producing Enterobacteriaceae (particularly K. pneumoniae) in other parts of the 
world (Perilli et al., 2009; Peirano et al., 2010b; Meradi et al., 2011; Aibinu et al., 
2012; Peirano et al., 2012). This study reports the first description of simultaneous 
carriage of qnrB1+aac(6’)-lb-cr in CTX-M-15-producing Enterobacteriaceae 
(particularly K. pneumoniae) in South Africa. The qnrS1 gene was relatively common 
among K. pneumoniae isolates as previously described in similar studies conducted 
in Norway and Sweden (Karah et al., 2010), China (Jiang et al., 2008), France 
(Poirel et al., 2006), Spain (Lavilla et al., 2008) and the United States (Robicsek et 
al., 2006). An interesting feature noted about qnrS1 allele in this study is that it was 
exclusively detected occurring alone and not in combination with other PMQR genes. 
However, simultaneous carriage of qnrS1+aac(6’)-lb-cr and qnrS+qnrB has been 
reported in Sweden (Karah et al., 2010) and China (Zhang et al., 2012), respectively.  
 
qnrB has the greatest number of variants and is the most common qnr type 
worldwide (Strahilevitz et al., 2009) as has been observed in this study and in other 
studies elsewhere (Silva-Sanchez et al., 2011; Zhang et al, 2012). Rare qnrB13 
variant was found in a C. freundii urinary isolate (isolate CS30). This is a first 
description of qnrB13 in South Africa. qnrB13 was only reported in C. freundii clinical 
isolates in a Korean hospital (Tamang et al., 2008). Citrobacter spp. has been 
described as a source of qnrB alleles and indeed many novel qnrB variants have 
been discovered in this genus (Sanchez-Cespedes et al., 2009; Jacoby et al., 2011). 
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Interestingly, qnrB1 was also identified in one NAL-resistant P. mirabilis (isolate 
CS38). Previously described PMQR genes in P. mirabilis include qnrA1, qnrB, qnrC, 
qnrD, qnrS1 and aac(6’)-lb-cr (Ahmed et al., 2007; Pitout et al., 2008; Wang et al., 
2009; Guo et al., 2010; Hu et al. 2012; Siebor and Neuwirth, 2011; Mokracka et al., 
2012). 
 
CTX-M-3 was detected alone in K. pneumoniae isolates. In contrast, 1 E. cloacae 
(isolate CS28) and 1 C. freundii (isolate CS32) possessed CTX-M-3+qnrS1 and 
CTX-M-3+TEM-1+qnrS1, respectively. This is a first description of CTX-M-3 in E. 
cloacae and C. freundii in South Africa. However, a combination of CTX-M-3+TEM-1 
has been identified in E. coli and CTX-M-3+TEM-1+SHV-1 in K. pneumoniae in 
Cape Town and Johannesburg, respectively (Paterson et al., 2003; Peirano et al., 
2011). Interestingly, the qnrS1-positive CTX-M-3-producing C. freundii isolate was 
resistant to the quinolones while qnrS1-positive CTX-M-3-producing E. cloacae 
isolate was susceptible to the quinolones. The observed quinolone susceptibility in 
qnrS1-positive E. cloacae may be due to insufficient quinolone resistance mutations 
since PMQRs alone confer low-level quinolone resistance (Martinez-Martinez et al., 
2008). A combination of qnrS with CTX-M-3 in E. cloacae was previously reported in 
Japan (Kanamori et al., 2012). Notably, all the CTX-M-3-producing K. pneumoniae, 
E. cloacae and C. freundii isolates were susceptible to CAZ, FEP and carbapenems.  
 
CTX-M-22 was mainly detected among quinolone-susceptible qnrS1-positive K. 
pneumoniae isolates (isolates CS2, CS9 and CS10) and this study describes the first 
occurrence of CTX-M-22 in South Africa. CTX-M-22 has been described in E. coli 
and K. pneumoniae isolates in Korea and China, respectively (Song et al., 2009; 
Wang et al., 2012). All the CTX-M-22-producing K. pneumoniae isolates were 
susceptible to the following β-lactam drugs: CAZ, FEP, FOX and carbapenems 
similar to CTX-M-22-producing K. pneumoniae from a pus specimen reported in 
China (Wang et al., 2012). A noteworthy feature of CTX-M-22-producing K. 
pneumoniae is their susceptibility to the quinolones albeit possessing qnrS1 gene, 
thus confirming that PMQR expression alone is not sufficient to confer clinically 
significant quinolone resistance. A similar phenomenon has been described in 
quinolone-susceptible, qnrA-positive E. coli, qnrS1-positive isolates of Salmonella 
enterica, E. coli and K. pneumoniae, and qnrB7-positive K. pneumoniae from 
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different geographical regions (Cavaco et al., 2007; Hopkins et al., 2007; Karah et 
al., 2010). Additionally, detection of qnr genes among quinolone-susceptible isolates 
highlights the cryptic spread of these genes (Karah et al., 2010), and underscore the 
importance of screening all CTX-M-positive isolates (quinolone-susceptible or -
resistant) for qnr determinants in order to obtain accurate prevalence. Thus, NAL 
and CIP MICs are not reliable markers for detection of PMQR genes.  
 
The prevalence of quinolone resistance mutations in gyrA and parC genes were 
reported to increase in PMQR-positive isolates over time leading to higher levels of 
quinolone resistance but in PMQR-negative isolates these mutations remained 
stable over time (Kim et al., 2009). This is contrary to the findings of other 
researchers (Cavaco et al., 2007; Hopkins et al., 2007; Govender et al., 2009; Karah 
et al., 2010) and the present study where qnrS1-positive isolates were susceptible to 
quinolones while PMQR-negative isolates showed quinolone resistance.  
 
CTX-M-14 variant was rare and detected in combination with an uncommon SHV 
variant, SHV-11 in a fluoroquinolone-susceptible, PMQR-negative K. pneumoniae 
(isolate CS11). CTX-M-14-producing K. pneumoniae was susceptible to the following 
β-lactam drugs: CAZ, FEP, FOX and carbapenems similar to CTX-M-22- and CTX-
M-3-producing isolates. SHV-11 variant has been reported in E. coli and K. 
pneumoniae isolates possessing CTX-M-14, CTX-M-15 and CTX-M-55 variants in 
Thailand (Kiratisin et al., 2008). On the other hand, CTX-M-14 has been described in 
E. coli urinary isolates in Cape Town (Peirano et al., 2011) and in Shigella 
dysenteriae 3 stool isolate in a national study by the Enteric Diseases Reference 
Unit, Johannesburg (Tau et al., 2012). Rodriguez-Bano et al. (2006) hypothesized 
that CTX-M-14-producing isolates are acquired from the community. This hypothesis 
could be true as observed in Cape Town where CTX-M-14 variant had a prevalence 
of 33% (7/21) from E. coli urinary isolates from the community (Peirano et al., 2011). 
However, due to lack of clinical information, it was not possible to confirm this 
hypothesis in this study.  
 
Emergence of ESBL-producing Enterobacteriaceae among neonates/ infants was 
mentioned earlier in Chapter 2. CTX-M-15 was the most prevalent CTX-M variant 
among isolates from neonatal/ infant specimens (Tables 3.4 and 3.5) similar to 
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previous studies (Lohr et al., 2013; Mshana et al., 2013). An interesting observation 
was that 2/3 qnrS1-positive CTX-M-22-producing K. pneumoniae were among 
isolates recovered from neonatal/ infant specimens. Future large-scale surveillance 
studies will confirm this association between CTX-M-22 and neonatal/ infant 
specimens.  
 
This study highlights the emergence of MDR Enterobacteriaceae (predominantly K. 
pneumoniae) with multiple ESBL genes and simultaneous carriage of PMQR genes.  
Emergence of MDR CTX-M-producing Enterobacteriaceae in clinical as well as 
community-onset infections poses a challenge to the currently used treatment 
guidelines (D’Andrea et al., 2013). Therefore, longitudinal surveillance of these 
pathogens and their susceptibility patterns is essential to guide recommendations for 
empiric treatment (both in hospital and outpatient/ primary healthcare settings) and 
implementation of effective infection control strategies.  
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CHAPTER FOUR 
 
CHARACTERIZATION OF ESBL-PRODUCING Escherichia coli 
SEQUENCE TYPE 131 ISOLATES 
 
4.1  INTRODUCTION 
E. coli sequence type 131 (ST131) is a global, highly virulent, pandemic MDR clone 
that has been described in various geographical regions worldwide and these include 
Europe, America, Asia and the Middle East, Australia and Africa (Nicolas-Chanoine et 
al., 2008; Rogers et al., 2011). ST131 infections have been described in patients of all 
ages (Rogers et al., 2011). Similar to other E. coli, the clone is associated with many 
clinical and community-acquired infections but more especially UTIs (Hidron et al., 
2008; Pitout et al., 2009; Peirano et al., 2011). Some of these infections include 
uncomplicated cystitis (Cagnacci et al., 2008; Vincent et al., 2010), emphysematous 
pyelonephritis (Ender et al., 2009), neonatal sepsis (Johnson et al., 2010b), 
bactaeremia (Bert et al., 2010; Courpon-Claudinon et al., 2010) and pyomyositis (Vigil 
et al., 2010). The clone has been isolated from other body sites including intra-
abdominal abscess (Bert et al., 2010), respiratory tract (Suzuki et al., 2009) and 
bones/joints (Johnson et al., 2010b).  
 
ST131 is frequently associated with the following phenotypic and molecular resistance 
features in isolation or combination: fluoroquinolone resistance, CTX-M-15 enzyme and 
aac(6’)-lb-cr (Coque et al., 2008b; Nicolas-Chanoine et al., 2008).  A number of other 
CTX-M variants described in ST131 include CTX-M-2, CTX-M-3, CTX-M-9, CTX-M-14, 
CTX-M-27, CTX-M-32 and CTX-M-61 (Clermont et al., 2009; Suzuki et al., 2009; Mora 
et al., 2010). TEM, SHV and other β-lactamases (e.g. AmpC enzymes) are less 
frequent in ST131 clone (Rogers et al., 2011). SHV and TEM variants reported in 
association with the clone include SHV-12, SHV-5, SHV-7, TEM-1, TEM-24 and TEM-
116 (Clermont et al., 2009; Sidjabat et al., 2009; Cerquetti et al., 2010; Ewers et al., 
2010; Peirano et al., 2011). The plasmid carrying CTX-M genes is usually large (64 – 
160 kb) and often carries genes encoding for TEM-1, OXA-1 and Aac(6’)-lb-cr (Boyd et 
al., 2004; Coque et al., 2008b; Nicolas-Chanoine et al., 2008; Pitout et al., 2009).   
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ESBL and non-ESBL-producing E. coli isolates belonging to the ST131 clone often 
exhibit fluoroquinolone resistance which may serve as a marker for ST131-positive E. 
coli (Cagnacci et al., 2008; Jones et al., 2008; Johnson et al., 2010a; Uchida et al., 
2010). Fluoroquinolone resistance mechanisms include chromosomal mutations in 
genes encoding fluoroquinolone targets: gyrA, gyrB, parC and parE; and PMQR genes: 
qnrA, qnrB, qnrC, qnrD, qnrS, qepA and aac(6’)-lb-cr (Rogers et al., 2011).  
 
E. coli O25b-ST131 has three major characteristics which play a significant role in 
identification of the clone, viz., serogroup (O25b), phylogenetic group (B2) and 
sequence type (ST131) (Rogers et al., 2011). ST131 clone can only be detected using 
molecular techniques such as multilocus sequence typing (MLST) and PCR; 
phenotypic detection is impossible (Rogers et al., 2011). MLST is regarded as a ‘gold 
standard’ for ST131 clone identification but it is labour-intensive hence rapid and simple 
detection methods have been developed to easily identify members of the clone/ group 
(Rogers et al., 2011). One such method is a PCR-based assay which uses allele-
specific PCR assay for the pabB gene specific to the B2 subgroup I isolates of O 
serotype 25b (Clermont et al., 2009). This method has been successfully applied in 
several laboratories worldwide for rapid detection of the clone (Hussain et al., 2012; 
Morris et al., 2012; Sennati et al., 2012; Mnif et al., 2013; Rakotonirina et al., 2013). 
 
Treatment options for E. coli ST131 infections are similar to those of other E. coli 
sequence types (Rogers et al., 2011). Carbapenem monotherapy or combination 
therapy with amikacin has been used to treat infections caused by CTX-M-producing E. 
coli isolates with high success rate (Ender et al., 2009; Vigil et al., 2010). Tigecycline 
has been demonstrated to have a good in vitro activity against ESBL-producing E. coli 
but there is still doubt about the in vivo activity of this drug (Morosini et al., 2006; Nix 
and Matthias, 2010). Third-generation cephalosporins (cefotaxime and ceftriaxone) 
remain effective against non-ESBL- or non-AmpC-producing isolates (Johnson et al., 
2009; Lee et al., 2010b). Oral combination amoxicillin-clavulanate or trimethoprim-
sulfamethoxazole has been used successfully to treat uncomplicated UTI caused by 
either non-ESBL- or ESBL-producers, provided that susceptibility to these agents is 
confirmed (Rodriguez-Bano et al., 2008; Rogers et al., 2011).  
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There is only one report describing the emergence of ST131 clone among ESBL-
producing E. coli in South Africa (Peirano et al., 2011).  
 
The objective of this chapter was to characterize ESBL-producing E. coli ST131 
isolates collected from Port Elizabeth hospital complex. 
 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 DNA extraction 
Chromosomal and plasmid DNA was extracted as outlined in section 3.2.1 of Chapter 
3. 
 
4.2.2 ESBL and PMQR gene amplification 
The protocol previously described in Section 3.2.2 of Chapter 3, was used for ESBL 
and PMQR gene amplification of E. coli isolates. 
 
4.2.3 pabB gene (ST131 clone) 
Presence of E. coli sequence type 131 clone was assessed by PCR-based detection of 
the pabB gene which is present in all isolates belonging to the serogroup O25b-ST131 
clonal complex (Table 4.1).  
 
 
Table 4.1: Primers and PCR conditions employed for the amplification of pabB gene (ST131 clone). 
 
Gene Primer Sequence Size (bp) Reference 
pabB O25pabBspe-F 5’-TCCAGCAGGTGCTGGATCGT–3’ 347 Clermont et al. (2009) 
 O25pabBspe-R 5’-GCGAAATTTTTCGCCGTACTGT-3’  
     
PCR conditions: 
(Clermont et al., 2009) 
                                                    Initial denaturation: 4 min at 94ºC 
30 cycles:                5 s at 94ºC 
                               10 s at 65ºC 
Final extension:      5 min at 72oC 
 
4.2.4 Agarose gel electrophoresis (AGE) and Sequencing 
Analysis and sequencing of PCR products were carried out as indicated in sections 
3.2.3 and 3.2.4 of Chapter 3. 
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4.2.5 Investigation of genetic similarity between E. coli ST131 isolates using 
pulsed-field gel electrophoresis (PFGE) 
 
This section of the project was carried out at the Division of Medical Microbiology, 
University of Cape Town. Genetic similarity between E. coli isolates belonging to the 
ST131 clone was investigated using PFGE according to PulseNet standardised E. coli 
PFGE protocol (PulseNet, 2013) but with some modification. E. coli ATCC 35218 was 
used as a positive control.  
 
4.2.5.1 Plug preparation 
Bacterial isolates were grown on MacConkey agar at 37ºC overnight and 3 - 4 isolated 
colonies re-suspended in Cell Suspension Buffer (100 mM Tris, pH 8.0; 100 mM EDTA, 
pH 8.0) and diluted to obtain an optical density of ~1.0 at 610 nm wavelength using a 
BioDropTM Spectrophotometer (BioDrop). A volume of 1 mL of the adjusted bacterial 
cell suspension was transferred into a 2 mL microcentrifuge tube. Four hundred 
microliters of the adjusted cell suspension was removed and 20 µL Proteinase K (20 
mg/mL stock [Fermentas]) was added and mixed gently. This was followed by addition 
of 400 µL of 1% melted Plug Agarose (1 g SeaKem Gold Plug Agarose in 100 mL Tris-
EDTA buffer [10 mM Tris, 1 mM EDTA, pH 8]) to the cell suspension and mixed gently. 
The mixture was dispensed into 2 – 3 slots (per isolate) of the PFGE Plug mould and 
allowed to solidify at room temperature for 10 – 15 min. 
 
4.2.5.2 Cell lysis 
A 1.8 mL aliquot of Cell Lysis Buffer (50 mM Tris, 50 mM EDTA, pH 8; 1% Sarcosyl 
[Sigma]) was transferred into a 2 mL microcentrifuge tube (2 per isolate), followed by 
addition of 10 µl Proteinase K (20 mg/mL) to each microcentrifuge tube (Proteinase K 
final concentration: 0.1 mg/mL). The plugs were transferred into prepared Cell Lysis 
Buffer + Proteinase K (2 per isolate) and incubated at 55ºC for 2 h with agitation at 300 
rpm (Eppendorf Thermomixer CompactTM).  
 
4.2.5.3 Plug washing 
The Cell Lysis Buffer was removed carefully from the microcentrifuge tubes, followed 
by addition of 2 mL ddH2O (pre-heated to 50ºC) into the plugs and incubated at 50ºC 
for 10 – 15 min. The ddH2O was removed and the wash step with pre-heated ddH2O 
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was repeated. Two millilitres of pre-heated (50ºC) TE buffer (10 mM Tris, 1 mM EDTA, 
pH 8) was added into the plugs and incubated at 50ºC for 10 – 15 min. The TE buffer 
was removed and the wash step with pre-heated TE buffer was repeated three more 
times. The last TE buffer wash was decanted and the plugs were stored in sterile TE 
buffer at 4ºC until required for DNA digestion.  
 
4.2.5.4 Chromosomal DNA digestion 
Approximately 2 X 2 mm sections were cut from the plug (containing intact genomic 
DNA) using a sterile scalpel blade and transferred into a 2 mL microcentrifuge tube. 
Each plug slice was digested individually in a 200 µl XbaI digestion reaction (175 µL 
ddH2O, 20 µL 10 X Buffer Yellow (BSA in buffer) and 5 µL of 50 U XbaI [Fermentas]). 
Digestion preparations were incubated at 37oC for 2 h with no agitation.  
 
4.2.5.5 PFGE: Contour-clamped homogeneous electric field electrophoresis 
(CHEF) 
The PFGE unit was filled with TBE buffer (200 mL of 10 X TBE buffer stock into 4 L 
ddH2O) and allowed to chill at 14oC. Subsequently, 1% PFGE SeaKem Gold Agarose 
was prepared in 0.5 X TBE, poured into the prepared gel rig and allowed to solidify at 
room temperature for 30 min. A small volume (5 mL) of melted and cooled (55oC) 1% 
PFGE Agarose was kept for sealing the wells. The digestion mixture was removed from 
the plug slices, followed by washing of the plug slices with 2 mL 0.5 X TBE at room 
temperature for 5 min. Plug slices were loaded into the prepared PFGE Agarose gel 
with the Lambda Ladder PFGE marker (BioLabs Inc.) in every fifth lane. The wells were 
sealed with the remaining PFGE Agarose and allowed to solidify at room temperature 
for 5 min. The PFGE gel was subsequently placed into the PFGE rig pre-cooled to 
14oC while the 24-electrode array (CHEF) was positioned into a correct arrangement. 
Electrophoresis run was accomplished using a pulse time of 6 s – 50 s for 18 h at 200 
V.  
 
After electrophoresis, the gel was stained with 20 µL ethidium bromide in 500 mL 
ddH2O for 30 min with gentle agitation and destained with ddH2O for 30 min. The gel 
image was captured using Chemi Genius BioImaging System (SyngeneTM) and the 
DNA banding/ migration patterns on the gel were analysed using Gel Compar® II 
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version 4.6 (Applied Maths, BVBA, Belgium). Dice co-efficient (UPGMA) was used to 
calculate similarity/ relatedness between PFGE profiles.  
 
Cluster designation was based on isolates showing approximately 80% or greater 
relatedness, which corresponds to the “possibly related (4 – 6 band difference)” criteria 
of Tenover et al. (1995). 
 
4.2.6 Statistical analysis 
Statistical analysis was performed using Pearson chi-square and P-values were 
determined where applicable.  
 
4.3 RESULTS 
 
4.3.1 pabB gene (ST131 clone) 
PCR for the pabB allele was performed in all non-duplicate ESBL-producing E. coli 
isolates (n=21) and carbapenem-resistant E. coli (n=1) to identify ST131 clone (Fig. 
4.1A). This PCR assay identified 57.1% (12/21) of E. coli isolates belonging as to 
ST131 lineage and 42.9% (9/21) were ST131-negative.  
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Figure 4.1: A: ST131 clone identified among E. coli isolates on a 2% agarose gel following pabB gene PCR amplification and electrophoresis. Lane 1: Molecular weight 
marker (100 bp Bioline DNA ladder); Lane 2: Negative control (ddH2O); Lane 3: pabB gene (347 bp). B: PFGE profiles of XbaI-digested genomic DNA of 
ESBL-producing E. coli ST131-positive isolates from Port Elizabeth hospital complex on a 1% PFGE agarose gel. Lanes 1, 6, 11 and 17: Molecular weight 
markers (Lambda ladder PFGE marker [size range: 50 – 1000 kb); Lane 2: E. coli PE1; Lane 3: E. coli PE2; Lane 4: E. coli PE3; Lane 5: E. coli PE4; Lane 7: 
E. coli PE5; Lane 8: E. coli PE6; Lane 9: E. coli PE7; Lane 10: E. coli PE8; Lane 12: E. coli PE9; Lane 13: E. coli PE10; Lane 14: E. coli PE11; Lane 15: E. 
coli PE12; Lane 16: E. coli ATCC 35218 (positive control). 
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4.3.2 PFGE analysis of E. coli ST131-positive isolates (n=12) 
 
PFGE analysis was performed for all E. coli ST131-positive isolates (Figs. 4.1B and 
4.2). The majority of E. coli ST131-positive isolates came from female patients (10/12, 
83.3%) and only 16.7% (2/12) from male patients. E. coli ST131-positive isolates were 
found in patients of all ages (10 months to 88 years old) (Fig. 4.2). PFGE cluster 
designation was based on isolates showing approximately 80% or greater similarity 
which corresponds to the “possibly related (4 – 6 band difference)” criteria of Tenover 
et al. (1995). PFGE identified a closely related group of E. coli ST131-positive isolates 
that was designated as cluster A (n=5) as well as 2 isolates designated cluster B (PE6 
and PE9) that were related to cluster A with 74.6% similarity (Fig. 4.2). The remaining 
isolates were not clonally related (unique) as they showed less than 70% similarity.  
 
Isolates belonging to cluster A (i.e. isolates PE1, PE2, PE3, PE4 and PE10) had >80% 
similar PFGE profiles. Notably, these isolates were collected from different healthcare 
institutions. Isolates PE3 and PE4 showed identical PFGE profiles (100% similarity) 
and were producing CTX-M-15+OXA-1+aac(6’)-lb-cr and recovered from pus 
specimens (Fig. 4.2). Similarly, isolates PE1 and PE2 had identical PFGE profiles 
(100% similarity) exhibiting 97.1% similarity to isolates PE3 and PE4. Isolates PE1 and 
PE2 were recovered from urine specimens and possessed CTX-M-15+aac(6’)-lb-cr. 
The isolate, PE10 recovered from urine showed 80.3% similarity to PE1, PE2, PE3 and 
PE4 and carried CTX-M-15+TEM-1+OXA-1+aac(6)-lb-cr. All the isolates that belonged 
to cluster A exhibited resistance to the following antimicrobial agents: AMP, AMC, 
CXM, CAE, CTX, NAL, CIP and SXT (Table 4.2). However, isolates PE4 and PE10 
were also resistant to AMK and GEN, respectively.  
 
Isolates PE6 and PE9 belonging to cluster B had 81.3% similarity and carried CTX-M-
15+TEM-1+OXA-1+aac(6’)-lb-cr and CTX-M-14+TEM-1+OXA-1+qnrB1+aac(6’)-lb-cr, 
respectively. These two isolates were derived from blood (PE6) and pus (PE9) and 
exhibited resistance to AMP, CXM, CAE, CTX, NAL, CIP and SXT (Table 4.2). 
However, PE6 exhibited further resistance to AMC similar to cluster A isolates. Cluster 
B isolates were collected from same hospital: Dora Nginza.  
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Figure 4.2: Dendrogram of CTX-M-producing E. coli ST131-positive isolates from Port Elizabeth hospital complex generated using the 
band-based DICE similarity coefficient and UPGMA with position tolerance of 1.0% for optimization and 1.0% for band 
comparisons in the Gel Compar® II version 4.6 fingerprinting software (Applied Maths, BVBA, Belgium). Isolates clustered by 
PFGE profiles with ≥80% similarity. Abbreviations: Dor., Dora Nginza hospital; Liv., Livingstone hospital; Pro., Provincial 
hospital; Kwa., KwaDwesi clinic; Mas., Masakhane clinic; ND - No data; M – male; F - Female. 
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The unique (genetically unrelated) E. coli ST131-positive isolates (similarity <80%) 
included isolates PE5, PE7, PE8, PE11 and PE12. Isolate PE12 possessed the 
same resistance determinants (i.e. CTX-M-15+TEM-1+OXA-1+aac(6’)-lb-cr) 
observed in isolates PE6 (cluster B) and PE10 (cluster A). Although genetically 
unrelated (similarity <80%), isolates PE8 and PE7 carried the same type of ESBLs, 
viz., CTX-M-15+TEM-1+OXA-1. Isolates PE5 and PE11 possessed a slightly 
different set of resistance determinants, i.e., CTX-M-3+qnrS1 and CTX-M-9+TEM-
1+OXA-1, respectively. These isolates were recovered from pus (PE5) and blood 
(PE11) specimens collected from Livingstone and Dora Nginza hospitals, 
respectively. This study describes the first occurrence of CTX-M-9 in South Africa. 
The sequence alignment for CTX-M-9 is shown in Fig. 4.3. All E. coli ST131-positive 
isolates, irrespective of PFGE types, were susceptible to the carbapenems (ETP, 
IPM and MEM), TZP, TGC and CST. 
 
Table 4.2: Summary of antibiotic resistance profiles of ESBL-producing E. coli ST131-positive 
isolates (n=12). 
Isolate No. 
Antimicrobial resistance PFGE cluster 
Resistant Intermediate 
PE 1 AMP, CXM, CAE, CTX, NAL, CIP, SXT AMC A 
PE 2 AMP, CXM, CAE, CTX, NAL, CIP, SXT AMC A 
PE 3 AMP, AMC, CXM, CAE, NAL, CIP, SXT CTX A 
PE 4 AMP, AMC, CXM, CAE, CTX, NAL, CIP, SXT AMK A 
PE 5 AMP, CXM, CAE, CTX, SXT  Unique 
PE 6 AMP, CXM, CAE, CTX, NAL, CIP, SXT AMC B 
PE 7 AMP, AMC, CXM, CAE, CTX, CAZ, FEP, GEN, SXT  Unique
PE 8 AMP, CXM, CAE, CTX, NAL, CIP, SXT AMC Unique
PE 9 AMP, CXM, CAE, CTX, NAL, CIP, SXT  B 
PE 10 AMP, CXM, CAE, CTX, GEN, NAL, CIP, SXT AMC A 
PE 11n AMP, CXM, CAE, FOX, CTX, NIT, SXT AMC Unique
PE 12 AMP, AMC, CXM, CAE, FOX, CTX, CAZ, FEP, GEN, 
NAL, CIP, SXT 
NIT Unique
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = cefuroxime axetil; FOX = 
cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; AMK = amikacin; GEN = gentamicin; NAL = nalidixic acid; 
CIP = ciprofloxacin; NIT = nitrofurantoin; SXT = trimethoprim-sulfamethoxazole. (n) indicates isolate from neonatal/ infant 
specimen. 
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Figure 4.3: DNA sequence of CTX-M-9 variant from E. coli ST131-positive isolate PE11 aligned with a GenBank CTX-M-9 
sequence (sequence corresponding to position 53 - 485 of blaCTX-M-9 with accession number: KC859413.1). 
Sequence identity = 99%.  
Clinical isolate: E. coli 
GenBank strain: Acc. No. KC859413.1 
Clinical isolate: E. coli 
GenBank strain: Acc. No. KC859413.1 
Clinical isolate: E. coli 
GenBank strain: Acc. No. KC859413.1 
Clinical isolate: E. coli 
GenBank strain: Acc. No. KC859413.1 
Clinical isolate: E. coli 
GenBank strain: Acc. No. KC859413.1 
Clinical isolate: E. coli 
GenBank strain: Acc. No. KC859413.1 
Clinical isolate: E. coli 
GenBank strain: Acc. No. KC859413.1 
Clinical isolate: E. coli 
GenBank strain: Acc. No. KC859413.1 
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4.3.3 E. coli ST131-negative isolates (n=9) 
 
Although limited by insufficient clinical data, E. coli ST131-negative isolates were 
identified from both male (4/9) and female (2/9) patients (no gender and age data for 
3 isolates) (Table 4.3) and were not prevalent in any particular age group. An 
observation contrary to E. coli ST131-positive isolates is that E. coli ST131-negative 
isolates were predominantly expressing CTX-M-14 (5/9, 55.6%) (Table 4.3). E. coli 
ST131-negative isolates were mainly possessing one ESBL type (5/9, 55.6%) and 
only a few had three (3/9, 33.3%) or two (1/9, 11.1%) ESBL genes. CTX-M-14 
variant was found alone (2/9) and in combination with TEM-1+OXA-1 (1/9), TEM-
1+OXA-1+qnrS1 (1/9) and OXA-1 (1/9). CTX-M-3 was found alone (1/9) and in 
combination with qnrS1 (1/9). CTX-M-15 and CTX-M-1 were very rare with CTX-M-
15 detected alone (1/9) and CTX-M-1 detected in combination with TEM-1+OXA-1 
(1/9). CTX-M-1 sequence alignment is shown in the Appendix (Fig. A.10).  
 
E. coli ST131-negative isolates were mainly recovered from pus (5/9, 55.6%) and 
urine (4/9, 44.4%) specimens. All of these isolates were resistant to AMP, CXM, 
CAE, CTX and SXT (Table 4.3). However, 55.6% (5/9) exhibited resistance to both 
NAL and CIP, 11.1% (1/9) to FEP (PE13), 44.4% (4/9) to AMC and 11.1% (1/9) to 
GEN + NIT + FOX (PE16). All E. coli ST131-negative isolates were susceptible to 
the carbapenems (ETP, IPM and MEM), CAZ, TZP, AMK, TGC and CST.  
 
Of major concern, 1 patient from whom ESBL-producing E. coli ST131-negative 
isolate PE19 was recovered demised. However, it could not be confirmed if mortality 
was associated with ESBL-producing E. coli. 
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Table 4.3: Summary of antibiotic resistance profiles and genetic characterization of ESBL-producing E. coli ST131-negative isolates (n=9). 
 
Isolate 
No. Specimen Gender Age Hospital/clinic 
Antimicrobial resistance PMQR β-lactamases ST131 PCR Resistant Intermediate 
PE 13 Urine Male 36 Livingstone AMP, CXM, CAE, CTX, FEP, NAL, CIP, SXT   CTX-M-1, TEM-1; OXA-1 - 
PE 14 Urine ND ND ND AMP, CXM, CAE, CTX, NAL, CIP, SXT   CTX-M-14, TEM-1; OXA-1 - 
PE 15 Urine Female 10 ND AMP, CXM, CAE, CTX, NAL, CIP, SXT   CTX-M-14 - 
PE 16 Urine ND ND ND AMP, CXM, CAE, CTX, GEN, NAL, CIP, NIT, SXT AMC, FOX qnrS1 CTX-M-3 - 
PE 17 Pus Male 19 Livingstone AMP, CXM, CAE, SXT CTX qnrS1 CTX-M-14, TEM-1; OXA-1 - 
PE 18 Pus Male 64 Provincial AMP, CXM, CAE, CTX, SXT   CTX-M-14 - 
PE 19d Pus Female 59 Livingstone AMP, CXM, CAE, CTX, SXT AMC  CTX-M-14; OXA-1 - 
PE 20 Pus ND ND ND AMP, CXM, CAE, CTX, SXT AMC  CTX-M-3 - 
PE 21* Pus Male 72 ND AMP, CXM, CAE, CTX, NAL, CIP, SXT AMC  CTX-M-15 - 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; AMK = 
amikacin; GEN = gentamicin; NAL = nalidixic acid; CIP = ciprofloxacin; NIT = nitrofurantoin; SXT = trimethoprim-sulfamethoxazole. (*) indicates isolate that was co-colonizing or co-infecting 
one male patient with P. mirabilis isolate CS38 which is characterized in Chapter 3; (-) indicates negative PCR; ND – no data; (d) indicates that the patient demised. 
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4.4 DISCUSSION 
 
ESBL-producing E. coli ST131 with CTX-M enzymes, specifically CTX-M-15, is a 
successful intercontinental MDR clone which poses a serious threat to the public 
healthcare facilities causing significant morbidity and mortality (Clermont et al., 2008; 
Coque et al., 2008b; Lau et al., 2008; Peirano and Pitout, 2010). Of the E. coli 
isolated from Port Elizabeth hospital complex, 57.1% belonged to the ST131 clone. 
A lower prevalence was reported in Cape Town (Peirano et al., 2011) and New York 
City (Tiruvury et al., 2012) where 45% and 39% E. coli isolates belonged to the 
ST131 clone, respectively. E. coli ST131 was identified in patients of all ages and 
predominantly in female patients (83.3%) in contrast to the findings in India where E. 
coli ST131 isolates were predominantly found in male patients (62.5%) (Hussain et 
al., 2012). 
 
The majority of E. coli ST131-positive isolates were recovered from urine (41.7%), 
followed by pus (33.3%) and blood (25%) specimens similar to the study conducted 
by Peirano et al. (2011). Previous studies from Canada, USA and South Africa 
reported CTX-M-14- and CTX-M-15-producing E. coli ST131 isolates as important 
cause of community-acquired UTIs and bloodstream infections (Pitout et al., 2009; 
Peirano et al., 2010b; Peirano et al., 2011) which might also be the case in this 
study. However, there is little data on the emergence and prevalence of CTX-M-15-
producing E. coli ST131 in Africa with a few reports having been published in Tunisia 
(Dahmen et al., 2010; Mnif et al., 2013), Central African Republic (Clermont et al., 
2008), South Africa (Peirano et al., 2011), Nigeria (Aibinu et al., 2012), Tanzania 
(Mshana et al., 2011) and Kenya (Albrechtova et al., 2012). 
 
There was a clear distinction between the CTX-M variants and PMQR genes 
possessed by E. coli ST131-positive and ST131-negative isolates. CTX-M-15 variant 
and aac(6’)-lb-cr were frequently detected in E. coli ST131 isolates while CTX-M-14 
variant was mainly detected in E. coli ST131-negative isolates (P < 0.05) (Fig. 4.2 
and Table 4.3). None of the E. coli ST131-negative isolates produced aac(6’)-lb-cr in 
this study while in Cape Town only two of twelve (16.7%) E. coli ST131-negative 
isolates were positive for aac(6’)-lb-cr (Peirano et al., 2011). In accordance with 
findings from Peirano et al. (2011) and other studies worldwide (Peirano et al., 
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2010a; Peirano et al., 2010b; Aibinu et al., 2012; Rakotonirina et al., 2013) most of 
the E. coli ST131-positive isolates that possess CTX-M-15 also carried TEM-1 and 
OXA-1 β-lactamases with the majority positive for aac(6’)-lb-cr. Co-existence of 
multiple resistance determinants is due to the fact that the plasmids carrying CTX-M 
genes are usually large (64 – 160 kb) and often carries genes encoding for TEM-1, 
OXA-1 and Aac(6’)-lb-cr (Boyd et al., 2004; Coque et al., 2008b; Nicolas-Chanoine 
et al., 2008; Pitout et al., 2009). 
 
Interestingly, some E. coli ST131-positive isolates did not produce CTX-M-15 
(isolates PE5, PE9 and PE11) but were producing other CTX-M variants. Isolate PE5 
produced CTX-M-3+qnrS1 whereas isolates PE9 and PE11 produced CTX-M-
14+TEM-1+OXA-1+qnrB1+aac(6’)-lb-cr and CTX-M-9+TEM-1+OXA-1, respectively. 
Variation in antibiotic resistance genes was expected within E. coli ST131 since 
these genes are normally carried on plasmids which have been characterized and 
shown to vary within and between different E. coli sequence type lineages (Karisik et 
al., 2006; Suzuki et al., 2009). Furthermore, unique E. coli ST131-positive isolate 
PE12 possessed the same resistance determinants as isolates belonging to cluster 
A (PE10) and B (PE6), thus suggesting possession of the same plasmid type. 
 
All E. coli ST131-positive isolates expressing aac(6’)-lb-cr were resistant to the 
quinolones (NAL and CIP) while qnrS1-positive isolate PE5 was susceptible to the 
quinolones (similar phenomenon has been observed and discussed in detail in 
Chapter 3). ESBL and non-ESBL-producing E. coli ST131 isolates have been 
frequently reported to exhibit fluoroquinolone resistance which may serve as a 
marker for ST131-positive E. coli (Cagnacci et al., 2008; Jones et al., 2008; Johnson 
et al., 2010a; Uchida et al., 2010). This is in agreement with our findings where 75% 
of E. coli ST131-positive isolates exhibited fluoroquinolone resistance while only 
55.6% of E. coli ST131-negative isolates exhibited fluoroquinolone resistance (P < 
0.05).  
 
This study describes the first occurrence of CTX-M-9, qnrB1+aac(6’)-lb-cr and CTX-
M-3+qnrS1 among E. coli ST131-positive isolates in South Africa. qnrB1+aac(6’)-lb-
cr was reported in CTX-M-15-producing E. coli ST131-positive isolates in Nigeria 
(Aibinu et al., 2012). CTX-M-9 has been described in E. coli from Brazil (Queiroz et 
86 
al., 2012) and Spain (Briales et al., 2012). CTX-M-1-producing, ST131-negative E. 
coli was identified in this study. However, CTX-M-1 is rarely reported in South Africa 
(Mocktar et al., 2009) but has been described in Germany (Valenza et al., 2013), 
Spain (Dahbi et al., 2013) and Italy (Brigante et al., 2005; Gagliotti et al., 2009).  
 
The CIP susceptibility rate of 0% observed for E. coli urinary isolates (including 
ST131-positive and ST131-negative) in this study is inconsistent with the reported 
CIP susceptibility range of 70 – 79% for E. coli urinary isolates from both private and 
public sector hospitals in Port Elizabeth over a five-year period, 2007 – 2011 
(Bamford et al., 2012). Low CIP susceptibility rates among E. coli ST131-positive 
isolates have also been reported in Cape Town (35.3%) (Peirano et al., 2011) and 
India (18.7%) (Hussain et al., 2012). Reduced CIP susceptibility poses a serious 
threat in the local medical community since fluoroquinolones are first-line drugs 
recommended internationally (Hooton et al., 2005) and in the local Essential Drug 
List (National Essential Drug List Committee, 2012) and are widely used in public 
and private sectors for UTIs (Bosch et al., 2011; Lewis et al., 2013).  
 
Our findings support carbapenem monotherapy or combination with AMK, which has 
been successfully used to treat infections caused by CTX-M-producing isolates 
(Ender et al., 2009; Vigil et al., 2010). Consistent with other studies, TGC was very 
effective (100% susceptible) against E. coli isolates including both ST131-positive 
and ST131-negative isolates (Morosini et al., 2006; Nix and Matthias, 2010). This 
study further supports the recommendation that CTX, AMC and SXT can only be 
effective against non-ESBL-producers since all the ESBL-producing E. coli isolates 
were resistant to these agents (Rodriguez-Bano et al., 2008; Johnson et al., 2009; 
Lee et al., 2010b; Rogers et al., 2011). Recent findings by Bamford et al. (2012) 
suggested that empiric therapy for UTIs due to E. coli may include fluoroquinolones, 
AMC and cephalosporins in many local settings, however, our findings do not 
support this.  
 
In this study, multiple PFGE profiles of E. coli ST131-positive were observed 
including clusters A and B as well as unique strains indicating genetic diversification 
within ST131 lineage similar to other studies in UK (Lau et al., 2008), Japan (Suzuki 
et al., 2009), Chicago (Peirano et al., 2010a), South Africa (Peirano et al., 2011) and 
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recently Tunisia (Mnif et al., 2013). Similarity of E. coli ST131 in our locale was very 
low (49.5%; Fig. 4.2) compared to E. coli ST131 similarities reported in Cape Town 
(65%), United Kingdom (73%), Tunisia (61%), Japan (70%) and Chicago (67%) (Lau 
et al., 2008; Suzuki et al., 2009; Peirano et al., 2010a; Peirano et al., 2011; Mnif et 
al., 2013). Genomic diversification within E. coli ST131 clone reflects the role played 
by genetic events (including insertions, deletions, DNA rearrangements and 
substitutions including single base transitions and transversions) which have a 
potential influence on macro-restriction fragment size and PFGE profile (Lau et al., 
2008; Goering, 2010). Since PFGE is mainly based on the separation of DNA 
molecules due to size-dependent migration in the electric field, any change in 
molecular size will affect PFGE profile (Goering, 2010).  
 
There are various possible reservoirs of E. coli ST131 including contaminated food 
or water sources, companion and non-companion animals and returning travellers 
from areas with high prevalence of ST131 clone (implicated regions including Indian 
subcontinent and the Middle East) possibly explaining the occurrence of genetically 
heterogeneous strains within ST131 lineage in various regions (Rogers et al., 2011). 
There is evidence of transmission of ST131 clone between humans. A study from 
Pennsylvania, USA, has shown direct transmission of an ST131 clone between a 
father and daughter leading to septic shock and emphysematous pyelonephritis 
(Ender et al., 2009). Another study from Minnesota, USA, illustrated within-
household sharing of a fluoroquinolone-resistant ST131 between a young child and 
her mother leading to paediatric osteoarticular infection (Johnson et al., 2010b). 
Interestingly, cluster A isolates were collected from different healthcare institutions, 
thus confirming the clonal nature (i.e. conserved genomic structure) of ST131 
strains. Nonetheless, this study illustrates the emergence of genetically diverse E. 
coli ST131-positive isolates with MDR phenotypes and predominantly producing 
CTX-M-15 enzyme among patients in Port Elizabeth hospital complex.  
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CHAPTER FIVE 
 
DETECTION OF RESISTANCE DETERMINANTS: CARBAPENEM-
RESISTANT ISOLATES 
 
5.1 INTRODUCTION 
Carbapenems are the most potent β-lactam drugs commonly used as last line of 
defense to treat severe infections caused by MDR Gram-negative bacteria including 
members of the Enterobacteriaceae, A. baumannii and P. aeruginosa (El Gamal and 
Oh, 2010; Coetzee and Brink, 2011; Kanj and Kanafani, 2011; Patel and Bonomo, 
2013). Carbapenem-resistant bacteria have been implicated in severe infections 
including bacteremia, meningitis and pneumonia often associated with high mortality 
rates in critically ill patients (van Duin et al., 2013). The rapid rise in carbapenem 
resistance is associated with high usage of carbapenem antibiotics (i.e. imipenem 
[IPM], meropenem [MEM], doripenem [DOR] and ertapenem [ETP]) (Bush, 2013a).  
 
Carbapenemases have emerged globally and are the primary cause of carbapenem 
resistance in Gram-negative pathogens coupled with up-regulation of efflux pump 
genes and alteration of porin expression in combination with over-production of an 
AmpC or ESBL type enzyme (Lu et al., 2009; Lee et al., 2010a; Patel and Bonomo, 
2013). Most carbapenemases can hydrolyze all the β-lactam drugs including 
penicillins, cephalosporins, monobactams and carbapenems (Queenan and Bush, 
2007; Bush, 2013a; Bush, 2013b; Nordmann, 2013). Carbapenemases belong to two 
major molecular families namely serine and metallo-carbapenemases distinguished 
by the hydrolytic mechanism at the active site (Queenan and Bush, 2007). 
Carbapenemases belong to the following Ambler classification groups: A, B and D 
(Nordmann, 2013).  
 
Class A representatives include KPC, SME, IMI, NMC and GES common in 
Enterobateriaceae and rare in P. aeruginosa and A. baumannii (Perovic, 2013). 
Previously described class A carbapenemases in South Africa include KPC-2 in K. 
pneumoniae and E. cloacae from Johannesburg (Brink et al., 2012a) and GES in P. 
aeruginosa (Pretoria), S. marcescens (Port Elizabeth), K. pneumoniae (Cape Town), 
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K. oxytoca (Bloemfontein) and E. cloacae (Witbank) (Labuschagne et al., 2008; Brink 
et al., 2012b). Class B representatives include NDM, IMP, VIM, GIM, and SPM 
common in P. aeruginosa, Enterobacteriaceae and A. baumannii (Perovic, 2013). 
Previously described class B carbapenemases in South Africa include NDM-1 in K. 
pneumoniae and E. cloacae from Johannesburg (Brink et al., 2012a) and Durban 
(Govind et al., 2013), respectively; VIM-2 in P. aeruginosa from Cape Town 
(Jacobson et al., 2012) and VIM in A. baumannii from Pretoria (Kock et al., 2013).  
 
Class D representatives include OXA-48, OXA-48 variants, OXA-23, OXA-24 and 
OXA-58 common in A. baumannii and also in Enterobacteriaceae (Perovic, 2013). 
Previously described class D carbapenemases in South Africa include OXA-48 
predominantly in K. pneumoniae and less frequent in S. marcescens from 
Johannesburg, Cape Town and Port Elizabeth (Brink et al., 2013), OXA-181 in K. 
pneumoniae from Cape Town and Johannesburg (Brink et al., 2013), OXA-23, OXA-
51 and OXA-58 in A. baumannii from Pretoria (Kock et al., 2013). The insertion 
sequence ISAba1 has been shown to play a significant role in carbapenem 
resistance in A. baumannii by acting as a strong promoter when located upstream of 
blaOXA genes thereby increasing gene expression which results in increased 
carbapenemase activity of OXA carbapenemases (Turton et al., 2006; Mak et al., 
2009). However, Kock et al. (2013) did not investigate the presence of ISAba1 in 
OXA-23-, OXA-51- and OXA-58-producing A. baumannii isolates.  
 
Loss/ modification of the following porins is usually associated with carbapenem 
resistance: OmpK35 and OmpK36 in K. pneumoniae (Shin et al., 2012), OmpF and 
OmpC in E. coli and Enterobacter spp. (Lartigue et al., 2007; Chia et al., 2009); 
CarO in A. baumannii (Bonomo and Szabo, 2006); and OprD in P. aeruginosa 
(Meletis et al., 2012). In South Africa, simultaneous loss of OmpK35 and OmpK36 in 
conjunction with CTX-M group 1 production in K. pneumoniae isolates was reported 
to confer ETP resistance and reduced susceptibility to MEM and IPM (Elliot et al., 
2006). Carbapenem resistance associated with efflux pump overexpression is often 
seen in P. aeruginosa and A. baumannii. Efflux pumps normally involved in 
carbapenem resistance in P. aeruginosa include MexAB-OprM, MexCD-OprJ and 
MexXY-OprM (Poole, 2004; Vettoretti et al., 2009; Tomas et al., 2010). AdeABC 
efflux pump is associated with carbapenem resistance in A. baumannii (Lee et al., 
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2010a). There is no report on efflux pumps or porin loss/ modification contributing to 
carbapenem resistance observed in South African P. aeruginosa or A. baumannii 
clinical isolates.  
 
This chapter investigated the resistance determinants of carbapenem-resistant 
Enterobacteriaceae, A. baumannii and P. aeruginosa isolates. 
 
 
5.2 MATERIALS AND METHODS 
5.2.1 DNA extraction 
Chromosomal and plasmid DNA was extracted as outlined in section 3.2.1 of 
Chapter 3. 
 
5.2.2 ESBL and PMQR gene amplification 
The protocol previously described in Section 3.2.2 of Chapter 3, was used for ESBL 
and PMQR gene amplification of E. coli isolates. 
 
5.2.3 Detection of metallo-β-lactamases and serine carbapenemases  
PCR screening for carbapenemase genes was performed using plasmid and 
chromosomal DNA as a template with the primers and PCR conditions shown in 
Table 5.1. 
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Table 5.1:   
 
Primers and PCR conditions employed for the amplification of genes encoding common  
metallo-β-lactamases and non-metallo-β-lactamases. 
Gene Primer Sequence Size (bp) 
GenBank 
Reference Reference 
Metallo-β-lactamase 
genes 
    
blaNDM-1 NDM-F 5’-GGTTTGGCGATCTGGTTTTC-3’ 
 
621 FN396876 Nordmann et al. (2011) 
 NDM-R 5’-CGGAATGGCTCATCACGATC-3’ 
(10 min at 94°C; 36 cycles of 30 s at 94°C, 40 
s at 52°C, and 50 s at 72°C and 5 min at 
72°C for the final extension) 
   
      
blaVIM VIM-F 5’-GATGGTGTTTGGTCGCATA-3’ 390 AF191564  Ellington et al. (2007) 
 VIM-R 5’-CGAATGCGCAGCACCAG-3’    
      
blaIMP IMP-F 5’-GGAATAGAGTGGCTTAAYTCTC-3’ 188 AB010417  Ellington et al. (2007) 
 IMP-R 5’-CCAAACYACTASGTTATCT-3’    
      
Serine 
carbapenemase 
genes 
    
blaKPC KPC-F 5’-ATGTCACTGTATCGCCGTCT-3'  
 
882 
 
AF297554 Pillai et al. (2009) 
 KPC-R 5’-TTACTGCCCGTTGACGCCC-3’ 
(5 min at 95°C followed by 35 cycles at 95°C 
for 1 min, at 58°C for 30 s and at 72°C for 90 
s; final extension at 72°C for 10 min) 
   
      
blaBIC BIC-F 5’-TATGCAGCTCCTTTAAGGGC-3’ 537 GQ260093 Poirel et al. (2011b) 
 BIC-R 5’-TCATTGGCGGTGCCGTACAC-3’    
      
blaNMC-A NMC1-F 5’-GCATTGATATACCTTTAGCAGAGA-3’ 2 158 Z21956 Radice et al. (2004) 
 NMC4-R 5’-CGGTGATAAAATCACACTGAGCATA-3’ 
(4 min at 95°C: followed by 35 cycles at 94°C 
for 1 min, at 50°C for 1 min and at 72°C for 1 
min; final extension at 72°C for 5 min) 
   
      
blaSME IRS5-F 5’-AGATAGTAAATTTTATAG-3’ 1 138 Z28968 Queenan et al. (2000) 
 IRS6-R 5’-CTCTAACGCTAATAG-3’ 
(10 min at 95°C: followed by 30 cycles at 
94°C for 30 s, at 50°C for 30 s and at 72°C for 
1 min; final extension at 72°C for 5 min) 
   
      
blaIMI IMIA-F 5’-ATAGCCATCCTTGTTTAGCTC-3’ 818 DQ173429.1 Aubron et al. (2005) 
 IMIB-R 5’-TCTGCGATTACTTTATCCTC-3’ 
(4 min at 95°C: followed by 35 cycles at 94°C 
for 1 min, at 50°C for 1 min and at 72°C for 1 
min; final extension at 72°C for 5 min) 
   
      
blaGES GESC-F 5’-GTTTTGCAATGTGCTCAACG-3’ 371 AF326355 Weldhagen and 
Prinsloo (2004) 
 GESD-R 5’-TGCCATAGCAATAGGCGTAG-3’ 
(2 min at 95°C: followed by 35 cycles at 95°C 
for 30 s, at 50°C for 1 min and at 72°C for 1 
min; final extension at 72°C for 5 min) 
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Table 5.1 Continued….  
Gene Primer Sequence Size (bp) 
GenBank 
Reference Reference 
blaOXA-23-like Oxa-23-like-F 5’-GATCGGATTGGAGAACCAGA-3’ 474 AJ132105 Woodford et al. (2006) 
 Oxa-23-like-R 5’-ATTTCTGACCGCATTTCCAT-3’ 
 
   
      
blaOXA-24-like Oxa-24-like-F 5’-GGTTAGTTGGCCCCCTTAAA-3’ 246 JQ409996.1  
 
Woodford et al. (2006) 
 Oxa-24-like-R 5’-AGTTGAGCGAAAAGGGGATT-3’    
      
blaOXA-48 OXA48-F 5’-GCGTGGTTAAGGATGAACAC-3’ 438 AY236073 Poirel et al. (2011b) 
 OXA48-R 5’-CATCAAGTTCAACCCAACCG-3’ 
 
   
      
blaOXA-51-like Oxa-51-like-F 5’-TAATGCTTTGATCGGCCTTG-3’  
 
353 AJ309734 Woodford et al. (2006) 
 Oxa-51-like-R 5’-TGGATTGCACTTCATCTTGG-3’ 
 
   
      
blaOXA-58-like Oxa-58-like-F 5’-AAGTATTGGGGCTTGTGCTG-3’ 
 
575 JQ409994.1 
 
Woodford et al. (2006) 
 Oxa-58-like-R 5’-CCCCTCTGCGCTCTACATAC-3’    
PCR conditions: blaVIM, blaIMP, blaBIC and blaOXA-48 
 
[Ellington et al. (2007) and Poirel et al. (2011b)] 
 
Initial denaturation:10 min at 94ºC 
36 cycles:               30 s  at 94ºC 
                               40 s  at 52ºC 
                               50 s  at 72ºC 
Final extension:      5 min at 72oC 
PCR conditions: blaOXA-23,-24, -51, -58 
(Woodford et al., 2006) 
 
Initial denaturation: 5 min at 94ºC 
30 cycles:      25 s at 94ºC 
       40 s at 52ºC 
       50 s at 72ºC 
Final extension:     6 min at 72ºC 
 
 
5.2.4 Detection of insertion sequence ISAba1 upstream blaOXA genes in OXA-
23-/-24-/-51-/-58-producing isolates 
PCR mapping was carried out to investigate the presence of an insertion sequence 
ISAba1 upstream blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 genes. The following 
specific primers and PCR conditions were employed for the detection of an insertion 
sequence ISAba1 upstream blaOXA genes shown in Table 5.2. 
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Table 5.2:   Primers and PCR conditions employed for the detection of an insertion sequence ISAba1 
upstream blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 genes. 
Gene  
 
Primer  Sequence  Size 
(bp) 
GenBank 
Reference 
Reference 
ISAba1 ISAba1-F* 5’-CACGAATGCAGAAGTTG-3’  
 
500 AY823412 
(EF015500) 
Segal et al. 2005) 
 ISAba1-R 5’-CGACGAATACTATGACAC-3’ 
(Amplification conditions: Initial 
denaturation at 95 oC for 5 min; 35 
cycles at 95 oC for 45 s, 56 oC for 45 
s and 72 oC for 3 min. A final 
extension step  at 72 oC for 5 min) 
   
      
ISAba1-blaOXA-23-like ISAba1-F* 5’-CACGAATGCAGAAGTTG-3’  
 
1150 AJ132105 Segal et al. 2005) 
and Woodford et 
al. (2006) 
 Oxa-23-like-R 5’-ATTTCTGACCGCATTTCCAT-3’ 
 
   
      
ISAba1-blaOXA-24-like ISAba1-F* 5’-CACGAATGCAGAAGTTG-3’  
 
~795 JQ409996.
1  
 
Segal et al. 2005) 
and Woodford et 
al. (2006) 
 Oxa-24-like-R 5’-AGTTGAGCGAAAAGGGGATT-3’    
      
ISAba1-blaOXA-51-like ISAba1-F* 5’-CACGAATGCAGAAGTTG-3’  
 
~902 AJ309734 Segal et al. 2005) 
and Woodford et 
al. (2006) 
 Oxa-51-like-R 5’-TGGATTGCACTTCATCTTGG-3’ 
 
   
      
ISAba1-blaOXA-58-like ISAba1-F* 5’-CACGAATGCAGAAGTTG-3’  
 
~1148 JQ409994.
1 
 
Segal et al. 2005) 
and Woodford et 
al. (2006) 
 Oxa-58-like-R 5’-CCCCTCTGCGCTCTACATAC-3’    
      
PCR conditions: ISAba1-blaOXA-23,-24, -51, -58 
(Woodford et al., 2006) 
 
Initial denaturation: 5 min at 94ºC 
30 cycles:      25 s at 94ºC 
       40 s at 52ºC 
       50 s at 72ºC 
Final extension: 6 min at 72ºC 
 
 
5.2.5 Agarose gel electrophoresis (AGE) and Sequencing 
Analysis and sequencing of PCR products were carried out as indicated in sections 
3.2.3 and 3.2.4 of Chapter 3. 
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5.2.6 Analysis of porins/ outer membrane proteins (OMPs) 
 
5.2.6.1 Extraction of porins/ OMPs 
Porins/ OMPs were extracted using N-lauroylsarcosine (Sarcosyl) as described 
previously (Hobb et al., 2009) but with modification. Carbapenem-susceptible 
isolates were used as positive controls. Bacterial cells were grown overnight in 100 
mL MH broth with agitation at 200 rpm (Labcon shaker) at 37ºC and the overnight 
culture was transferred into a 10 mL Falcon tube and centrifuged at 5000 rpm for 10 
min at 4ºC. The resultant pellet containing bacterial cells was re-suspended in 7 mL 
HEPES (4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid) (10 mM, pH 7.4) 
(Sigma), and subjected to rigorous ‘freeze and thaw’ over 3 consecutive days (frozen 
at -20oC for 4 h and thawed at 37oC for 1 h twice a day). On the 3rd day, the bacterial 
cells were thawed and were treated with 5 µL lysozyme (10 mg/mL [Roche]) and 
incubated at 37ºC for 30 min with agitation. This was followed by lysis of bacterial 
cells using a Sonicator (Bandelin Sonoplus) (conditions: 4 cycles of sonication at 38 
W for 45 s). Lysed cell preparation was centrifuged at 5000 rpm for 10 min at 4ºC to 
remove cell debris and unlysed cells. The resultant supernatant was transferred to 
the ultracentrifuge tubes and the volume was adjusted to 10 mL with HEPES (10 
mM, pH 7.4) to prevent the centrifuge tubes from crinkling. 
 
The bacterial membranes were collected from the supernatant by ultracentrifugation 
at 100 000 xg for 1 h at 4oC (Beckman, Ti70.1 rotor). The resultant pellet was re-
suspended in 2 mL HEPES (10 mM, pH 7.4) and washed in a total volume of 10 mL 
HEPES (10 mM, pH 7.4) and ultracentrifuged again using the conditions described 
above. The resultant pellet was re-suspended in 1 mL of 30% N-lauroylsarcosine 
sodium salt (Sigma) and incubated at 37ºC for 30 min with agitation to solubilise the 
inner and outer membranes. The volume of the N-lauroylsarcosine-treated 
membranes was adjusted to 10 mL with HEPES (10 mM, pH 7.4) and were spun at 
100 000 xg for 1 h at 4ºC. The resultant pellet was washed with 10 mL HEPES (10 
mM, pH 7.4) and ultracentrifuged using the conditions described above. The 
resultant pellet (containing N-lauroylsarcosine-insoluble proteins: porins/ OMPs) was 
re-suspended in 500 µL HEPES (10 mM, pH 7.4) and stored at -20oC until required 
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for further analysis. Extracted proteins were quantified using the NanoDropTM 
Spectrophotometer (Thermo Scientific) at 280 nm. 
 
5.2.6.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
(SDS-PAGE)  
SDS-PAGE was carried out to investigate the loss of porins/ OMPs in carbapenem-
resistant isolates. Extracted porins were analysed using a 12% resolving gel (3.4 mL 
ddH2O; 4 mL of 30% degassed acrylamide/bis [Bio-Rad]; 2.5 mL resolving gel buffer 
(1.5 M Tris-HCl, pH 8.8) [Bio-Rad]; 100 µl of 10% w/v SDS [Bio-Rad]; 50 µl of 10% 
ammonium persulphate (0.1 g in 1 mL ddH2O) [Bio-Rad]; and 5 µl TEMED [Bio-
Rad]); and a 4% stacking gel (6.1 mL ddH2O; 1.3 mL of 30% degassed 
acrylamide/bis [Bio-Rad]; 2.5 mL stacking gel buffer (0.5 M Tris-HCl, pH 6.8) [Bio-
Rad]; 100 µl of 10% w/v SDS [Bio-Rad]; 50 µl of 10% ammonium persulphate (0.1 g 
in 1 mL ddH2O) [Bio-Rad]; and 5 µl TEMED [Bio-Rad]).  
 
Protein samples were treated with Laemmli sample buffer (ratio 1:1) (Bio-Rad) and 
denatured at 96oC for 5 min. Ten microliters of the protein sample (~30 µg) and 10 
µL of the HyperPAGE prestained protein marker (10 kDa to 190 kDa [Bioline]) were 
loaded on a standard polyacrylamide gel. The proteins were electrophoresed on a 
Mini-PROTEAN 2 apparatus (Bio-Rad) using a 1X Tris-glycine-SDS electrode buffer 
(25 mM Tris, 192 mM glycine and 0.1% w/v SDS, pH 8.3 [Bio-Rad]) at 150 V, 64 mA 
for ~15 min until the tracking dye reached the resolving gel and then the voltage was 
increased to 150 V for 1 h. The gels were stained with Coomassie Brilliant blue (Bio-
Rad) for 1 h and destained with a Destaining solution (methanol:glacial acetic 
acid:ddH2O at a ratio 40:10:50 [Bio-Rad]) for visual analysis. The porin profiles were 
viewed using an Alpha ImagerTM 3400 gel system (Alpha Innotech). 
 
The following porins associated with carbapenem resistance were investigated: 
CarO (25- to 29 kDa) in A. baumannii (Lee et al., 2011); OmpC (36 kDa) and OmpF 
(35 kDa) in E. coli, E. asburiae and E. cloacae (Doumith et al., 2009; Bekhit et al., 
2011; Yang et al., 2012); OprD (~46 kDa) in P. aeruginosa (Quale et al., 2006); 
OmpK35 (35 kDa) and OmpK36 (36 kDa) in K. pneumoniae (Poirel et al., 2004). 
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5.3 RESULTS 
Carbapenemases identified include: OXA-23, OXA-51, OXA-58 and IMI-2 (Figs. 5.1 
and 5.2A). Isolates possessing OXA-23, OXA-51 and OXA-58 were further screened 
for the presence of the insertion sequence ISAba1 (Fig. 5.1-C). This study 
documents the first occurrence of IMI-2 and sequence alignment for this 
carbapenemase is shown in Fig. 5.2-B. Sequence alignments for other genes are 
attached in the Appendix section (Figs. A.11 – A.15). None of the class B metallo-β-
lactamases were identified in this study.  
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Figure 5.1: A: OXA-23 and OXA-51 genes identified among carbapenem-resistant isolates on a 2% agarose gel following PCR amplification and 
electrophoresis. Lane 1: Molecular weight marker (100 bp Bioline DNA ladder); Lane 2: blaOXA-23 (474 bp); Lane 3: blaOXA-51 (353 bp); Lane 4: 
Negative control (ddH2O). B: OXA-58 gene identified in A. baumannii isolate (CR13) on a 2% agarose gel following PCR amplification and 
electrophoresis. Lane 1: Molecular weight marker (100 bp Bioline DNA ladder); Lane 2: Negative control (ddH2O); Lane 3: blaOXA-58 (575 bp). C: 
ISAba1 upstream of blaOXA-23 gene identified among carbapenem-resistant isolates on a 2% agarose gel following PCR amplification and 
electrophoresis. Lane 1: Molecular weight marker (100 bp Bioline DNA ladder); Lane 2: ISAba1 (500 bp); Lane 3: ISAba1-blaOXA-23 (1150 bp); 
Lane 4: Negative control (ddH2O). 
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Figure 5.2: A: IMI-2 carbapenemase gene identified in an E. asburiae isolate (CR38) on a 2% agarose gel following PCR amplification and electrophoresis. Lane 1: 
Molecular weight marker (100 bp Bioline DNA ladder); Lane 2: Negative control (ddH2O); Lane 3: blaIMI-2 (818 bp). B: DNA sequence of IMI-2 variant (blaIMI-2) from 
Enterobacter asburiae aligned with a GenBank IMI-2 sequence (sequence corresponding to position 2957 - 3724 of blaIMI-2 with accession number: JN412066.1). 
Sequence identity = 99%. 
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5.3.1 A. baumannii (n=14) 
The majority of A. baumannii isolates were recovered from pus (7/14, 50%), followed 
by urine (3/14, 21.4%), sputum (3/14, 21.4%) and blood (1/14, 7.2%) specimens. As 
was indicated in Chapter 2 (Section 2.3.4), all A. baumannii isolates exhibited MDR 
phenotypes. However, 100% susceptibility to CST was observed (antimicrobial 
susceptibility/ resistance profiles are indicated in Chapter 2 – Table 2.2 and in the 
Appendix – Table A.9). Notably, all A. baumannii isolates (100%) were resistant to 
IPM (MIC range: 16 – 64 mg/L) and MEM (MIC range: 32 – 64 mg/L) but only 9 of 14 
(64.3%) were resistant to ETP (MIC [resistance] range: 3 - >32 mg/L) (Table 5.3).  
 
All A. baumannii isolates possessed both OXA-23 and OXA-51 while only one isolate 
(CR13) had OXA-58 (Table 5.3). All A. baumannii isolates possessed ISAba1 and 
the majority (71.4%, 10/14) harboured ISAba1 upstream of the blaOXA-23 gene. When 
ISAba1 is located upstream of the blaOXA-23 or blaOXA-51 gene, it acts as a strong 
promoter and leads to gene overexpression resulting in an increase in 
carbapenemase activity of the corresponding gene usually leading to MEM and IPM 
resistance (Heritier et al., 2005). Four isolates (CR11, CR12, CR13 and CR14) that 
had ISAba1 not located upstream of blaOXA-23/-51-/-58 genes were all resistant to IPM 
and MEM while only three exhibited resistance to ETP. In this study, ISAba1 was not 
identified upstream of blaOXA-51 and blaOXA-58 genes. Furthermore, none of the 
isolates were positive for OXA-24.  
 
ESBLs and PMQRs were also investigated in these isolates (Table 5.3). OXA-
23+OXA-51-producing A. baumannii isolates also carried TEM-1+OXA-1+qnrB1 
(2/13), TEM-1+OXA-1+aac(6’)-lb-cr (2/13), TEM-1+OXA-1+qnrB1+aac(6’)-lb-cr 
(1/13), TEM-1+OXA-1 (2/13), TEM-1+SHV-1+OXA-1+qnrB1 (1/13), TEM-1+SHV-
1+OXA-1+aac(6’)-lb-cr (1/13), TEM-1+SHV-1+OXA-1 (1/13), SHV-1+OXA-1+qnrB1 
(1/13), CTX-M-15+TEM-1+SHV-1+OXA-1+aac(6’)-lb-cr (1/13), and CTX-M-15+TEM-
1+OXA-1 (1/13). OXA-23+OXA-51+OXA-58-carrying isolate CR13 also carried OXA-
1. 
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Table 5.3: Molecular characteristics and carbapenem resistance profiles of A. baumannii isolates (n=14). 
Isolate 
No. Specimen 
MIC (mg/L) 
Carbapenemases ISAba1 
ISAba1-
upstrea
m OXA-
23 
ISAba1-
upstream 
OXA-51 
ISAba1-
upstream 
OXA-58 
Other β-lactamases PMQR genes Porins (+/-) 
ETP IPM MEM 
CR1 Urine ˃32 (R) 64 (R) 64 (R) OXA-23; OXA-51 + + - - TEM-1; SHV-1; OXA-1 qnrB1 + 
CR2n Urine ˃32 (R) 64 (R) 64 (R) OXA-23; OXA-51 + + - - TEM-1; SHV-1; OXA-1 - + 
CR3* Pus 0.094 (S) 64 (R) 64 (R) OXA-23; OXA-51 + + - - SHV-1; OXA-1 qnrB1 + 
CR4n Pus ˃32 (R) 64 (R) 64 (R) OXA-23; OXA-51 + + - - CTX-M-15; TEM-1; SHV-1; OXA-1 aac(6')-lb-cr + 
CR5n Pus ˃32 (R) 64 (R) 64 (R) OXA-23; OXA-51 + + - - TEM-1; OXA-1 qnrB1 + 
CR6 Sputum ˃32 (R) 32 (R) 32 (R) OXA-23; OXA-51 + + - - TEM-1; OXA-1 qnrB1; aac(6')-lb-cr + 
CR7 Urine 1 (S) 64 (R) 64 (R) OXA-23; OXA-51 + + - - TEM-1; OXA-1 - + 
CR8n Blood  ˃32 (R) 64 (R) 64 (R) OXA-23; OXA-51 + + - - TEM-1; OXA-1 aac(6')-lb-cr + 
CR9n Sputum 0.38 (S) 64 (R) 64 (R) OXA-23; OXA-51 + + - - TEM-1; SHV-1; OXA-1 aac(6')-lb-cr + 
CR10 Pus 0.064 (S) 64 (R) 64 (R) OXA-23; OXA-51 + + - - TEM-1; OXA-1 - + 
CR11* Pus 0.5 (S) 32 (R) 64 (R) OXA-23; OXA-51 + - - - TEM-1; OXA-1 qnrB1 + 
CR12n Pus ˃32 (R) 32 (R) 32 (R) OXA-23; OXA-51 + - - - TEM-1; OXA-1 aac(6')-lb-cr + 
CR13 Sputum  ˃16 (R) 32 (R) 32 (R) OXA-23; OXA-51; OXA-58 + - - - OXA-1 - + 
CR14 Pus 3 (R) 16 (R) 32 (R) OXA-23; OXA-51 + - - - CTX-M-15; TEM-1; OXA-1 - + 
Ab. indicates A. baumannii; (-) indicates absence; (+) indicates presence; (*) indicates isolates co-colonizing/ co-infecting male patients with CR18 (P. aeruginosa) and CR15 (P. aeruginosa), 
respectively; (n) indicates isolates from neonatal/ infant specimens. 
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SDS-PAGE revealed that the 25 to 29 kDa heat-modifiable porin CarO was present 
in all carbapenem-resistant A. baumannii isolates (Fig. 5.3). However, due to time 
constraints these were not investigated further for possible down-regulation of porin 
synthesis either at transcriptional or translational level. 
 
 
 
 
           
 
Figure 5.3: SDS-PAGE showing outer membrane protein (OMP) profile of carbapenem-resistant A. baumannii 
isolate CR1. Lane 1: HyperPAGE prestained protein marker (size range: 10 kDa to 190 kDa [Bioline]); 
Lane 2: Representative carbapenem-resistant A. baumannii isolate CR1 with a 25 – 29 heat-
modifiable CarO porin. Note: carbapenem-susceptible A. baumannii (positive control) was lacking in 
this study, hence a positive control does not appear in this image. 
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5.3.2 P. aeruginosa (n=9) 
P. aeruginosa isolates were mainly detected from pus (5/9, 55.6%) and sputa (4/9, 
44.4%). All P. aeruginosa isolates exhibited MDR phenotypes with reduced 
resistance noted for CAZ (11.1%), CIP (44.4%) and AMK (44.4%) as indicated in 
Chapter 2 - Table 2.2. All P. aeruginosa isolates (100%) were resistant to MEM (MIC 
range: 16 - 64 mg/L), 88.9% (8/9) resistant to IPM (MIC [resistance] range: 16 – 64 
mg/L) and 55.6% (5/9) resistant to ETP (MIC [resistance] range: 2 – >32 mg/L) 
(Table 5.4).  
Mechanisms associated with carbapenem resistance in P. aeruginosa isolates 
remain unknown. However, two isolates possessed both OXA-23 and OXA-51 
(isolate CR15 and CR16) with ISAba1 located upstream of blaOXA-23 which may have 
been responsible for the observed carbapenem resistance (Table 5.4). Four isolates 
possessed OXA-51 alone with two having ISAba1 (isolates CR17 and CR18) but not 
located upstream of the OXA-51 gene. Three P. aeruginosa isolates did not possess 
any carbapenemase genes but were carrying the following ESBLs: OXA-1 (isolates 
CR21 and CR23) and TEM-1 (CR22). P. aeruginosa isolates carrying OXA-23+OXA-
51 also carried TEM-1+SHV-1+OXA-1+qnrB1 (isolate CR15) and TEM-1 (isolate 
CR16). Moreover, two OXA-51-positive isolates co-possessed SHV-11+OXA-1 
(isolate CR17) and OXA-1 (isolate CR18). The most common carbapenemases in P. 
aeruginosa including class B metallo-β-lactamases were not detected in this study. 
SDS-PAGE revealed that the porin OprD (~46 kDa) was present in all carbapenem-
resistant P. aeruginosa isolates (Fig. 5.4).  
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Table 5.4: Molecular characteristics and carbapenem resistance profiles of P. aeruginosa isolates (n=9). 
Isolate 
No. Species Specimen 
MIC (mg/L) Carbapenemases
ISAba1 
ISAba1-
upstream 
OXA-23 
ISAba1-
upstream 
OXA-51 
Other β-lactamases PMQR genes Porins (+/-) ETP IPM MEM  
CR15* P. aeruginosa Pus 2 (R) 64 (R) 64 (R) OXA-23; OXA-51 + + - TEM-1; SHV-1; OXA-1 qnrB1 + 
CR16 P. aeruginosa  Sputum ˃32 (R) 64 (R) 64 (R) OXA-23; OXA-51 + + - TEM-1 - + 
CR17 P. aeruginosa  Sputum 0.5 (S) 1 (S) 16 (R) OXA-51 + - - SHV-11; OXA-1 qnrB1; aac(6')-lb-cr + 
CR18* P. aeruginosa  Pus 0.19 (S) 16 (R) 32 (R) OXA-51 + - - OXA-1 - + 
CR19 P. aeruginosa  Pus ˃32 (R) 16 (R) 32 (R) OXA-51 - - - - - + 
CR20 P. aeruginosa  Sputum ˃32 (R) 16 (R) 32 (R) OXA-51 - - - - aac(6')-lb-cr  + 
CR21 P. aeruginosa  Sputum 0.19 (S) 16 (R) 16 (R) - - - - OXA-1 - + 
CR22 P. aeruginosa  Pus 0.064 (S) 16 (R) 16 (R) - - - - TEM-1 - + 
CR23 P. aeruginosa  Pus 2 (R) 32 (R) 16 (R) - - - - OXA-1 - + 
(-) indicates absence; (+) indicates presence; (*) indicates isolates co-colonizing/ co-infecting male patients with CR3 (A. baumannii) and CR11 (A. baumannii), respectively. 
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Figure 5.4: SDS-PAGE showing outer membrane protein (OMP) profiles of carbapenem-resistant and –
susceptible P. aeruginosa isolates. Lane 1: HyperPAGE prestained protein marker (size range: 10 
kDa to 190 kDa [Bioline]). Lane 2: Carbapenem-susceptible P. aeruginosa isolate with a ~46 kDa 
OprD porin present; Lane 3 – 4: Representatives: carbapenem-resistant P. aeruginosa isolates CR15 
and CR16 with a ~46 kDa OprD porin present.  
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5.3.3 Enterobacteriaceae (n=16) 
All carbapenem-resistant Enterobacteriaceae isolates exhibited MDR phenotypes 
with reduced resistance observed for TGC (43.8%) as indicated in Chapter 2 - 
Section 2.3.4 - Table 2.1 and in the Appendix – Tables A.10, A.12 – A14. These 
isolates exhibited 100% susceptibility to AMK and CST. Moreover, 100% resistance 
rate was observed for all carbapenems ETP, IPM and MEM, however, one isolate 
(CR37) exhibited intermediate resistance to ETP (MIC = 1 mg/L) (Table 5.5). 
Mechanisms associated with carbapenem resistance observed in 
Enterobacteriaceae isolates remain unknown except for three isolates (CR24, CR38 
and CR39). 
 
The majority of K. pneumoniae isolates (n=10) were recovered from pus (4/10, 40%) 
and sputum (4/10, 40%) specimens, followed by blood (1/10, 10%) and urine (1/10, 
10%) specimens. Two K. pneumoniae isolates, CR24 and CR25, were producing 
both OXA-23 and OXA-51 but lacked ISAba1 upstream of blaOXA-23 and blaOXA-51. 
These isolates co-expressed CTX-M-15+TEM-1+SHV-1+OXA-1 (Table 5.5). Isolate 
CR24 lost two major porins OmpK35 and OmpK36 (Fig. 5.5, Lane 3) associated with 
the observed carbapenem resistance with an MIC of 16 mg/L recorded for each 
carbapenem (ETP, IPM and MEM). The major outer membrane protein, OmpA 
homologue, which is not a porin was present in both carbapenem-resistant and –
susceptible isolates as shown in Fig. 5.5. Other carbapenem-resistant K. 
pneumoniae isolates (CR26 – CR33) were negative for all carbapenemase genes 
and surprisingly the major porins (OmpK35 and OmpK36) were present (Fig. 5.6, 
Lane 2) while an ESBL-producing carbapenem-susceptible K. pneumoniae isolate 
(used as a positive control) was not expressing one major porin OmpK35 (Fig. 5.5, 
Lane 2). Overall, 70% (7/10) of K. pneumoniae isolates carried CTX-M-15+TEM-
1+SHV-1+OXA-1, 20% (2/10) CTX-M-15+TEM-1+OXA-1 and 10% (1/10) CTX-M-
15+SHV-1+aac(6’)-lb-cr (Table 5.5). 
 
Enterobacter cloacae isolates (n=4) were recovered from urine (2/4, 50%), pus (1/4, 
25%) and sputum (1/4, 25%) specimens. None of the E. cloacae isolates possessed 
any of the carbapenemase genes or lost porins but were positive for CTX-M-
15+TEM-1+OXA-1 (1/4), CTX-M-15+TEM-1+OXA-1+qnrB1 (1/4), TEM-1+SHV-
1+OXA-1+qnrB2 (1/4) and TEM-1+OXA-1(1/4) (Table 5.5).  
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Enterobacter asburiae blood isolate CR38 was positive for IMI-2 which is a very rare 
carbapenemase and also carried qnrB2 (sequence alignment shown in the Appendix 
– Fig. A.16). This isolate was resistant to the three carbapenems ETP (MIC = 4 
mg/L), IPM (MIC = 8 mg/L) and MEM (MIC = 32 mg/L) (Table 5.5).  
 
Escherichia coli pus isolate CR39 (ST131-negative) lost two major porins OmpC and 
OmpF but produced TEM-1+SHV-1+OXA-1 (Table 5.5; Fig. 5.5, Lane 5). This isolate 
was resistant to ETP (MIC = 12 mg/L), IPM (MIC = 4 mg/L) and MEM (MIC = 32 
mg/L). Carbapenem-susceptible E. coli expressed OmpF (Fig. 5.5, Lane 4) and 
OmpA homologue which was missing in carbapenem-resistant E. coli.  
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Table 5.5: Molecular characteristics and carbapenem resistance profiles of Enterobacteriaceae isolates (n=16). 
Isolate 
No. Species Specimen 
MIC (mg/L)
Carbapenemases ISAba1 
ISAba1-
upstream 
OXA-23 
ISAba1-
upstream 
OXA-51 
Other β-lactamases PMQR genes 
Porins 
(+/-) ETP IPM MEM 
CR24 K. pneumoniae Sputum 16 (R) 16 (R) 16 (R) OXA-23; OXA-51 + - - CTX-M-15; TEM-1; SHV-1; OXA-1 - - 
CR25d K. pneumoniae  Pus ˃32 (R) 16 (R) 32 (R) OXA-23; OXA-51 + - - CTX-M-15; TEM-1; SHV-1; OXA-1 - + 
CR26 K. pneumoniae  Pus 2 (R) 16 (R) 32 (R) - - - - CTX-M-15; TEM-1; SHV-1; OXA-1 - + 
CR27 K. pneumoniae  Pus 4 (R) 32 (R) 32 (R) - - - - CTX-M-15; TEM-1; SHV-1; OXA-1 - + 
CR28 K. pneumoniae  Sputum 32 (R) 16 (R) 32 (R) - - - - CTX-M-15; TEM-1; SHV-1; OXA-1 qnrB2 + 
CR29 K. pneumoniae  Sputum 16 (R) 32 (R) 32 (R) - - - - CTX-M-15; TEM-1; SHV-1; OXA-1 - + 
CR30 K. pneumoniae  Urine 3 (R) 16 (R) 32 (R) - - - - CTX-M-15; TEM-1; SHV-1; OXA-1 - + 
CR31 K. pneumoniae  Sputum 16 (R) 16 (R) 32 (R) - - - - CTX-M-15; TEM-1; OXA-1 - + 
CR32 K. pneumoniae  Blood 4 (R) 8 (R) 32 (R) - - - - CTX-M-15; SHV-1 aac(6')-lb-cr + 
CR33 K. pneumoniae Pus 4 (R) 16 (R) 32 (R) - - - - CTX-M-15; TEM-1; OXA-1 - + 
CR34 E. cloacae Pus 4 (R) 16 (R) 32 (R) - - - - CTX-M-15; TEM-1; OXA-1 - + 
CR35 E. cloacae Urine 4 (R) 32 (R) 16 (R) - - - - TEM-1; SHV-1; OXA-1 qnrB2 + 
CR36d E. cloacae Urine 4 (R) 16 (R) 32 (R) - - - - TEM-1; OXA-1 - + 
CR37 E. cloacae Sputum 1 (I) 16 (R) 32 (R) - - - - CTX-M-15; TEM-1; OXA-1 qnrB1 + 
CR38 E. asburiae Blood 4 (R) 8 (R) 32 (R) IMI-2 - - - - qnrB2 + 
CR39b E. coli Pus 12 (R) 4 (R) 32 (R) - - - - TEM-1; SHV-1; OXA-1 - - 
 (-) indicates absence; (+) indicates presence; (d) indicates that the patients demised; (b) indicates that E. coli CR39 is ST131-negative. 
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Figure 5.5: SDS-PAGE showing outer membrane protein (OMP) profiles of carbapenem-resistant and –
susceptible Enterobacteriaceae isolates. Lane 1: HyperPAGE prestained protein marker (size range: 
10 kDa to 190 kDa [Bioline]); Lane 2: ESBL-producing carbapenem-susceptible K. pneumoniae isolate 
CS1 (positive control); Lane 3: Carbapenem-resistant K. pneumoniae isolate CR24 lacking OmpK35 
and OmpK36; Lane 4: ESBL-producing carbapenem-susceptible E. coli isolate PE1; Lane 5: 
Carbapenem-resistant E. coli isolate CR39 lacking OmpC and OmpF.  
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Figure 5.6: SDS-PAGE showing outer membrane protein (OMP) profile of a carbapenem-resistant K. pneumoniae 
isolate CR27. Lane 1: HyperPAGE prestained protein marker (size range: 10 kDa to 190 kDa 
[Bioline]). Lane 2: Representative carbapenem-resistant K. pneumoniae isolate CR27 with the major 
porins (OmpK35/OmpK36) present.  
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5.4 DISCUSSION 
The emergence of carbapenem-resistant Gram-negative pathogens in Port Elizabeth 
hospital complex is disturbing since carbapenems are used as drugs of last resort for 
severe infections due to MDR Gram-negative pathogens (Brink et al., 2012b; 
Marchaim et al., 2012). Carbapenem resistance determinants identified in this study 
include blaOXA-23 linked with an upstream ISAba1 (found in 10 A. baumannii and 2 P. 
aeruginosa isolates), IMI-2 carbapenemase in an E. asburiae isolate and porin loss 
in 1 K. pneumoniae and 1 E. coli isolate. Carbapenem resistance determinants 
remained unknown for 24 isolates including 9 K. pneumoniae, 7 P. aeruginosa, 4 A. 
baumannii and 4 E. cloacae isolates. Other possible determinants that may have 
been responsible for the observed carbapenem resistance include porin down-
regulation or mutated porins (e.g. OmpK36 variant) (Garcia-Fernandez et al., 2010; 
Nordmann et al., 2012), efflux pump overexpression and AmpC over-production 
(Poole, 2011).  
 
The map shown in Fig. 5.7 illustrates the different classes of carbapenemases that 
have been described in South Africa thus far. Brink et al. (2013) recently reported the 
first occurrence of OXA-48 in K. pneumoniae and S. marcescens isolates from Port 
Elizabeth while Perovic (2013) reported the emergence of IMP-producing 
Enterobacteriaceae isolates and Brink et al. (2012b) reporting the first occurrence of 
GES in S. marcescens from Port Elizabeth. This study reports on the emergence of 
OXA-23, OXA-51, OXA-58 and IMI-2 among carbapenem-resistant 
Enterobacteriaceae, P. aeruginosa and A. baumannii in Port Elizabeth. OXA-23, 
OXA-51 and OXA-58 have been identified previously in A. baumannii isolates from 
Pretoria (Kock et al., 2013). However, this study describes the first occurrence of 
IMI-2 and OXA-23 linked with an upstream ISAba1 in South Africa.  
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Figure 5.7: Emergence and distribution of carbapenemases in South Africa. Map adapted from Brink et al (2012b). 
Data extracted from Labuschagne et al. (2008), Brink et al. (2012a), Brink et al. (2012b), Jacobson et al. 
(2012), Brink et al. (2013), Govind et al. (2013), Kock et al. (2013) and Perovic (2013). 
The patient harbouring IMI-2-producing E. asburiae was admitted into the hospital 
ICU after a car accident which resulted in quadriplegia. After 3 days in ICU and 
tracheostomy, the patient was diagnosed with ventilator-associated pneumonia 
(VAP). In addition, the patient had severe sacral bedsores. An infection control alert 
was made to the infection control sister at the hospital. Empiric treatment with 
carbapenems (meropenem+ampicillin and ertapenem+ampicillin) was initiated prior 
to initial culture but failed. All the blood cultures were positive for carbapenem-
resistant E. asburiae, thus explaining carbapenem therapy failure. In this case, IMI-2 
carbapenemase was the mechanism responsible for the observed carbapenem 
resistance since this isolate did not produce any ESBLs and the major porins were 
present. The IMI-2 variant has been identified in imipenem-resistant E. asburiae 
isolated from rivers in the United States (Aubron et al., 2005) and in a carbapenem-
resistant E. cloacae clinical isolate from China (Yu et al., 2006). This indicates 
possible exchange of genetic material between environmental and clinical isolates. 
Interestingly, blaIMI-2 gene was identified on the chromosomal DNA in this study not 
on plasmid DNA while in United States (Aubron et al., 2005) and China (Yu et al., 
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2006) blaIMI-2 was located on a plasmid and flanked by transposable elements. The 
genetic environment of blaIMI-2 gene identified in this study requires further analysis 
to characterize mobile genetic elements responsible for mobilization of this gene in 
our locale.  
 
As a result of carbapenem therapy failure, definitive treatment with a fluoroquinolone 
(ciprofloxacin) was initiated and was effective since the E. asburiae isolate (CR38) 
exhibited susceptibility to ciprofloxacin (CIP MIC ≤0.25 mg/L) (Appendix - Table 
A.13), albeit positive for qnrB2. In contrast, a qnrB2-producing K. pneumoniae 
(isolate CR28) and E. cloacae (isolate CR35) identified in this study were resistant to 
the quinolones (NAL and CIP). Therefore, the E. asburiae isolate possibly had 
insufficient quinolone resistance mutations rendering this isolate susceptible to 
quinolones even in the presence of a PMQR determinant. A similar phenomenon 
was described in detail in Chapter 3 whereby qnrS1-positive isolates were 
susceptible to the quinolones.  
 
Nonetheless, the patient recovered and was discharged and referred to a spinal 
clinic for rehabilitation but could not be contacted to monitor his condition. Possible 
risk factors that may have facilitated selection and acquisition of a carbapenem-
resistant E. asburiae isolate in this case include: (i) carbapenem therapy before initial 
culture, (ii) ICU stay – an area known for high antibiotic usage – thus increased risk 
of acquiring highly resistant pathogens and (iii) invasive mechanical ventilation 
(tracheostomy). This case report highlights the need for rapid detection of resistance 
determinants to optimize treatment options and improve clinical outcomes, 
appropriate antibiotic stewardship and adherence to infection control measures 
especially in ICU to limit or prevent further emergence and regional dissemination of 
such pathogens as IMI-2-producing E. asburiae.  
 
The presence of OXA-51 in all A. baumannii isolates was not surprising since this 
enzyme is intrinsic in this pathogen and is often used as a marker for A. baumannii 
isolates (Turton et al., 2006; Peleg et al., 2008; Kempf and Rolain, 2012). On the 
other hand, OXA-23 and OXA-58 are acquired carbapenem-hydrolyzing class D 
carbapenemases (CHDLs), found almost exclusively in A. baumannii and located 
113 
either on plasmids or chromosomes (Poirel and Nordmann, 2006). In this study, 
these CHDLs were identified on chromosomal DNA.  
 
Carbapenem resistance in 71.4% (10/14) of A. baumannii isolates was associated 
with OXA-23 gene expression due to the presence of ISAba1 upstream of blaOXA-23 
(Table 5.3). OXA-51 and OXA-58 genes were not preceded by ISAba1 implying that 
these enzymes did not contribute to the observed carbapenem resistance. Loss of 
CarO was not detected in any of the A. baumannii isolates in this study. The possible 
role of efflux pumps or AmpC hyper-expression in the observed carbapenem 
resistance was not investigated.  
 
OXA-23+OXA-51 was the most common CHDL combination (13/14, 92.9%) 
consistent with the findings from Pretoria [OXA-23+OXA-51 prevalence = 58%] 
(Kock et al., 2013). Only one A. baumannii isolate (CR13) produced OXA-58 in 
combination with OXA-23+OXA-51 while in Pretoria OXA-58 enzyme was detected 
alone (1%) and in combination with OXA-23 (2%). OXA-23 was identified in all A. 
baumannii isolates with a prevalence of 100% consistent with the findings from two 
different Chinese hospitals where the prevalence of OXA-23 in imipenem-resistant A. 
baumannii isolates was reported to be 94% and 97% (Wang et al., 2002; Zhou et al., 
2007). The prevalence of OXA-23 in Pretoria (59%) was relatively lower (Kock et al., 
2013). OXA-58 was uncommon in this study with a prevalence of 7.1%, consistent 
with the findings from previous studies in Pretoria [3%] (Kock et al., 2013), Asia-
Pacific nations [12%] (Mendes et al., 2009) and Iran [15%] (Feizabadi et al., 2008). 
 
All A. baumannii isolates were either expressing one or more ESBL genes (including 
CTX-M-15, TEM-1, OXA-1 and SHV-1) and some also possessed qnrB1 or aac(6’)-
lb-cr genes. This is a first study describing the occurrence of CTX-M-15 and PMQR 
genes in A. baumannii isolates in South Africa.  
 
Class B carbapenemases (i.e. VIM and IMP) are frequently detected in P. 
aeruginosa (Bush, 2013a). In contrast, none of the P. aeruginosa isolates were 
positive for any of the class B or class A carbapenemases in this study. VIM-2 
producing P. aeruginosa isolates were reported in Cape Town (Jacobson et al., 
2012). However, carbapenem resistance in two P. aeruginosa isolates (CR15 and 
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CR16) was associated with the expression of blaOXA-23 gene linked with an upstream 
ISAba1 (Table 5.4). Porin loss was not detected in these isolates. Interestingly, OXA-
23- and OXA-51-producing P. aeruginosa isolate CR15 and OXA-51-producing P. 
aeruginosa isolate CR18 were recovered from male patients co-colonized/ co-
infected with OXA-23- and OXA-51-producing A. baumannii isolates CR3 and CR11, 
respectively. Since OXA-51 is intrinsic in A. baumannii and the acquired OXA-23 is 
almost exclusively found in this pathogen (Mak et al., 2009), it is likely that the P. 
aeruginosa isolates acquired these enzymes from A. baumannii. This highlights 
inter-species transfer of carbapenemase genes among nosocomial pathogens in our 
locale. Co-colonization/ co-infection with two different MDR pathogens (P. 
aeruginosa and A. baumannii in this case) is of great concern as this phenomenon is 
reported to be associated with elevated antimicrobial resistance (limiting therapeutic 
options and leading to therapeutic failure) and increased mortality (Marchaim et al., 
2012). Noticeably, two P. aeruginosa isolates (CR19 and CR20) possessed OXA-51 
in the absence of ISAba1, thus indicating that a different insertion sequence or an 
integron was responsible for blaOXA-51 mobilization.  
 
This is a first study describing the occurrence of OXA-23 and OXA-51 in 
carbapenem-resistant P. aeruginosa isolates in South Africa. There are only two 
published studies describing the occurrence of CHDLs in carbapenem-resistant P. 
aeruginosa. The first study described the emergence of OXA-40 carbapenemase in 
imipenem-resistant P. aeruginosa in Spain (Sevillano et al., 2009). OXA-40 was 
carried on a plasmid also found in A. baumannii isolate recovered in the same 
hospital (Sevillano et al., 2009). The second study described the emergence of a 
novel CHDL, OXA-198, in carbapenem-resistant P. aeruginosa isolate in Belgium 
(Garch et al., 2011). In carbapenemase-negative P. aeruginosa the most common 
intrinsic carbapenem resistance mechanisms include loss/ modification of porin 
OprD and overexpression of efflux pumps or endogenous AmpC enzyme (Poole, 
2004; Wolter et al., 2004; Quale et al., 2006; Poole, 2011). However, none of the 
carbapenemase-negative P. aeruginosa isolates had porin loss in this study 
suggesting that the observed carbapenem resistance is possibly associated with 
efflux pump over-expression or AmpC hyper-production which should be 
investigated further in future studies.  
 
115 
It has been reported that ESBLs are less common in P. aeruginosa (Poole, 2011) 
with no report of CTX-M-producing P. aeruginosa thus far which is in agreement with 
the findings of this study. Only TEM-1, OXA-1, SHV-1 and SHV-11 β-lactamases 
were identified from P. aeruginosa isolates in this study. It has also been reported 
that PMQR genes are less frequent in Pseudomonas spp. (Cattoir and Nordmann, 
2009). In this study, 33.3% (3/9) of P. aeruginosa isolates were positive for qnrB1 in 
combination with TEM-1+SHV-1+OXA-1, qnrB1+aac(6’)-lb-cr in combination with 
SHV-11+OXA-1 and aac(6’)-lb-cr alone.  
 
K. pneumoniae isolate CR24 resistant to the carbapenems lost both OmpK35 and 
OmpK36 porins and possessed four ESBL genes (CTX-M-15+TEM-1+SHV-1+OXA-
1) (Table 5.5). Simultaneous loss of OmpK35 and OmpK36 coupled with CTX-M 
production was reported to confer ETP resistance in K. pneumoniae isolates during 
ETP therapy in Johannesburg (Elliot et al., 2006). Similar findings have been 
reported in other regions including the United Kingdom (Doumith et al., 2009), United 
States (Szabo et al., 2006) and Taiwan (Yang et al., 2012). Therefore, loss of 
OmpK35+OmpK36 in combination with ESBL production was responsible for the 
observed carbapenem resistance in K. pneumoniae isolate CR24. Loss/ reduced 
expression of porins may be due to point mutations or disruption of the coding 
sequence by insertion sequences (Lartigue et al., 2007; Doumith et al., 2009; Little et 
al., 2012) and alterations in the promoter sequence (Doumith et al., 2009). The 
possibility of efflux pump or AmpC over-expression in isolate CR24 cannot be 
excluded, and requires further investigation.  
 
Tsai et al. (2013) discouraged the use of ETP in treatment of infections due ESBL-
producing K. pneumoniae with porin loss but recommended the use of other 
carbapenems (IPM and MEM) which appear less affected by ESBLs and porin loss. 
However, our findings do not support this since the K. pneumoniae isolate with porin 
loss was resistant to all carbapenems (ETP, IPM and MEM) with an MIC of 16 mg/L 
for each carbapenem drug. 
 
It is worth-mentioning that the carbapenem-susceptible K. pneumoniae isolate that 
was used as a positive control in SDS-PAGE was an ESBL-producing isolate hence 
it lacked the porin OmpK35 (Fig. 5.5, Lane 2). Most ESBL-producing K. pneumoniae 
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isolates (both carbapenem-resistant and –susceptible) are known to express 
predominantly OmpK36 and express reduced amounts of OmpK35 (Crowley et al., 
2002; Hernandez-Alles et al., 1999; Elliot et al., 2006). The carbapenem-resistant 
ESBL-producing K. pneumoniae isolates in this study did not lose their major porins 
which is unusual; therefore, further investigation is required. 
 
Interestingly, K. pneumoniae isolates CR24 and CR25 were positive for 
chromosomally located OXA-23 and OXA-51 enzymes which are predominantly 
found in A. baumannii (Poirel and Nordmann, 2006; Mugnier et al., 2010; Poirel et 
al., 2010). ISAba1 was detected in these isolates but was not located upstream of 
blaOXA-23 and blaOXA-51 genes, thus indicating that ISAba1 did not act as a promoter 
but rather played a role in the mobilization of these genes from the source (possibly 
A. baumannii) to K. pneumoniae isolates. A similar process described for acquisition 
of OXA-23 in P. mirabilis (Bonnet et al., 2002) may have taken place in these 
isolates. It is suggested that P. mirabilis acquired a plasmid harboring OXA-23 but 
the OXA-23-encoding plasmid could not be maintained in P. mirabilis possibly due to 
incompatibility or instability. Therefore, the blaOXA-23 gene must have been inserted 
into the chromosome by genetic events such as recombination, transposition or co-
integration in order to be maintained in P. mirabilis (Bonnet et al., 2002), which may 
also be the case in this study.  
 
This study describes the first occurrence of OXA-23 and OXA-51 in carbapenem-
resistant K. pneumoniae carrying plasmid-borne CTX-M-15+TEM-1+SHV-1+OXA-1 
in South Africa. OXA-51-carrying K. pneumoniae isolate was recently described for 
the first time in Turkey and it was suggested that this isolate acquired the blaOXA-51 
gene from OXA-51-producing A. baumannii isolate co-infecting the same patient 
(Budak et al., 2013). CHDLs previously described in K. pneumoniae in South Africa 
include OXA-48 and OXA-181 (Brink et al., 2013). The patient colonized/ infected 
with OXA-23+OXA-51-carrying K. pneumoniae (isolate CR25) demised and the 
cause of death could not be confirmed due to lack of data. In Cape Town and 
Johannesburg, 5 of 6 patients infected with carbapenem-resistant OXA-48 and OXA-
181-producing K. pneumoniae isolates demised (Brink et al., 2013). The increasing 
reports of mortality associated with infections due to carbapenem-resistant 
pathogens in South Africa is of concern.  
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E. coli isolate CR39 lost two major porins (OmpC and OmpF) and the OmpA 
homologue but was positive for TEM-1+SHV-1+OXA-1. Similar to K. pneumoniae 
isolate CR24, combination of porin loss and ESBL production was responsible for 
the observed carbapenem resistance in E. coli isolate as described previously 
(Lartigue et al., 2007; Oteo et al., 2008; Goessens et al., 2013). There seems to be 
contrasting reports concerning migration of OmpC and OmpF on SDS-PAGE. A 
study by Doumith et al. (2009) showed OmpC (36 kDa) to migrate slower than OmpF 
(35 kDa) while Lartigue et al. (2007) showed OmpF to migrate slower than OmpC. 
Doumith et al. (2009) findings correlate with the molecular weight of the porin 
proteins hence their analysis for E. coli OMP profiles on SDS-PAGE was applied in 
this study. This highlights the need to confirm the identity of porins observed on 
SDS-PAGE using highly specific methods such as Western blot, PCR and 
sequencing.  
 
Carbapenem resistance mechanisms in ESBL-producing E. cloacae isolates in this 
study remain unknown. These isolates were negative for all carbapenemases 
investigated and did not lose porins. Locally, KPC-2- and NDM-1-producing 
carbapenem-resistant E. cloacae were reported in Johannesburg and Durban, 
respectively (Brink et al., 2012a; Govind et al., 2013). Possible mechanisms 
mediating the observed carbapenem resistance in E. cloacae isolates include 
combination of porin down-regulation, ESBL and AmpC β-lactamase over-production 
and efflux pump over-expression (Szabo et al., 2006; Yang et al., 2012).  
 
Our findings have shown OXA-23 linked with an upstream ISAba1 as the most 
common mechanism mediating carbapenem resistance particularly in A. baumannii 
in our locale. There was no porin loss in most isolates while carbapenem resistance 
determinants remained unknown for 24 of 39 isolates, hence further studies are 
required to investigate possible determinants responsible for the observed 
carbapenem resistance phenotype in these isolates.  
118 
CHAPTER SIX 
 
CONCLUSIONS 
 
6.1 THE RESEARCH IN PERSPECTIVE 
 
The emergence and dissemination of MDR ESBL-producing and carbapenem-
resistant Enterobacteriaceae, A. baumannii and P. aeruginosa in Port Elizabeth 
hospital complex is of great concern. Moreover, a great deal of attention should be 
given to neonatal units in terms of continuous surveillance, judicious use of 
antibiotics, cohorting of colonized and non-colonized patients and practice of good 
hand hygiene to ensure minimal emergence and transmission of MDR ESBL-
producing Enterobacteriaceae and highly resistant A. baumannii in paediatric 
patients.  
 
A major threat posed by MDR ESBL- and carbapenamse-producing bacteria in this 
study is the limitation of therapeutic options. According to the outcomes of this study, 
viable treatment options for isolates with confirmed carbapenem susceptibility would 
include combination or monotherapy of FOX, TGC, AMK, CST and the 
carbapenems. For carbapenem-resistant bacteria, treatment options are limited to 
CST and AMK according to our findings. Of concern, if susceptibility to these agents 
remains stable, the clinicians may be compelled to prescribe these antibiotics more 
frequently, thus increasing probability of selection and emergence of resistant 
strains.  
 
Co-ordinated action and teamwork between our health care professionals (clinicians, 
physicians and nurses) and patients would ensure efficient infection control and 
prevention. Improved and more efficient method of capturing and storing patient 
medical records in our healthcare system is necessary as clinical data would provide 
directives for interventions. Due to lack of cooperation within our healthcare system, 
a conclusion could not be drawn concerning the impact of the observed resistance 
rates on the clinical outcomes of the patients. 
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Although our study was limited by the small sample size, the following findings have 
been highlighted: (1) high prevalence of CTX-M-15-producing K. pneumoniae, (2) 
increased multidrug resistance among ESBL-producing Gram-negative bacteria, (3) 
association of PMQR genes (qnrB1 and aac(6’)-lb-cr) with quinolone-resistant 
isolates, (4) predominance of MDR ESBL-producing K. pneumoniae and 
carbapenem-resistant A. baumannii isolates in neonatal/ infant clinical specimens, 
(5) emergence of genetically diverse ESBL-producing E. coli ST131 isolates, (6) 
emergence of carbapenem-resistant Enterobacteriaceae, A. baumannii and P. 
aeruginosa isolates, (7) high prevalence of OXA-23-producing carbapenem–resistant 
A. baumannii, (8) first description of IMI-2 serine carbapenemase in carbapemen-
resistant E. asburiae isolate in Africa and (9) low prevalence of porin loss among 
carbapenem-resistant bacteria. Furthermore, aac(6’)-lb-cr, qnrS and qnrB PMQRs 
were common compared to qnrA, qnrC, qnrD and qepA while aac(6′)-lb-cr variant 
was frequently associated with CTX-M-15-possessing isolates and qnrS1 genes 
were prevalent among quinolone-susceptible CTX-M-22- and CTX-M-3-producing 
isolates. 
 
Carbapenem resistance determinants identified in this study included (1) expression 
of OXA-23 preceded by ISAba1 in A. baumannii and P. aeruginosa isolates, (2) 
expression of IMI-2 carbapenemase in an E. asburiae isolate, and (3) combination of 
porin loss and ESBL production in K. pneumoniae and E. coli isolate. Since A. 
baumannii isolates were not typed, it is likely that the high prevalence of OXA-23 and 
OXA-51 genes may be as a result of dissemination of a single clone, thus 
emphasizing the need for stringent infection control to prevent further regional 
dissemination of this highly resistant pathogen. 
 
This study is the first in South Africa to describe the occurrence of CTX-M-9, CTX-M-
22, SHV-11, qnrB13, co-expression of qnrB1+aac(6’)-lb-cr, OXA-23, OXA-51 and 
IMI-2 among Enterobacteriaceae isolates; CTX-M-15, qnrB1 and aac(6’)-lb-cr in A. 
baumannii isolates; and OXA-23, OXA-51, qnrB1 and aac(6’)-lb-cr in P. aeruginosa 
isolates. Furthermore, this is a first study highlighting the emergence of MDR ESBL-
producing Enterobacteriaceae and carbapenem-resistant A. baumannii isolates 
recovered from neonatal/ infant specimens in Port Elizabeth.  
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In essence, this study highlights the need for longitudinal surveillance of these 
pathogens and their susceptibility patterns to guide recommendations for empiric 
treatment (both in hospital and outpatient/ primary healthcare settings) and 
implementation of effective infection control strategies to prevent further 
dissemination. Lastly, PMQR genes need to be taken into account in resistance 
screening by all clinical microbiology laboratories in South Africa to further optimize 
therapy and prevent selection of highly resistant strains. 
 
 
6.2   POTENTIAL FOR FUTURE DEVELOPMENT OF THE WORK 
 
There are various aspects that could not be investigated in this study due to time 
constraints. In order to gain insight on the emergence of multidrug resistance among 
clinical isolates in our locale, all antibiotic resistance determinants and relevant 
clinical data must be included.  
 
In an attempt to fully understand the epidemiology of molecular resistance 
mechanisms there are certain aspects that need further investigation and these 
include: 1) analysis of plasmids carrying CTX-M-15 (either by plasmid replicon typing 
or conjugation experiments) or genotyping of the isolates producing CTX-M-15 
variant using PFGE or multi-locus sequence typing to determine whether the high 
prevalence CTX-M-15 is associated with a particular clone or is simply disseminated 
by mobile genetic elements; 2) PCR screening for AmpC cephalosporinases and to 
establish their prevalence and contribution to the observed multidrug resistance; 3) 
investigation of quinolone resistance-mediating mutations in the DNA gyrase and 
topoisomerase IV enzymes and correlation of the rate of these mutations with the 
absence or presence of PMQR genes as well as the level of quinolone resistance; 4) 
investigation of aminoglycoside resistance determinants including genes encoding 
16S rRNA methylases and plasmid-borne armA methylase; 5) investigation of 
genetic relatedness among bacterial species included in this study; and 6) 
investigation and assessment of the risk factors associated with transmission of 
MDR ESBL-producing Enterobacteriaceae and carbapenem-resistant A. baumannii 
in paediatric units and identify potential reservoirs in order to curtail or prevent further 
emergence and dissemination of these pathogens. 
121 
Furthermore, typing of E. coli ST131-negative isolates is essential and would allow 
comparison with E. coli ST131 isolates. Use of MLST is encouraged as it would 
facilitate identification and confirmation of E. coli sequence types circulating in our 
vicinity. Phylogenetic grouping and serotyping of E. coli ST131 isolates would be 
informative and should provide deeper understanding of the virulence of this clone.  
 
For accurate analysis and investigation of possible epidemiological link between E. 
coli ST131 isolates within our data set (albeit not associated with an outbreak), an 
additional clinical data is required such as location of the patients, whether the 
patients were hospitalized or not, and the type of infection presented in a health care 
institution prior isolation of E. coli ST131 isolate. This data may help in 
epidemiological evaluation of future outbreaks associated with E. coli ST131 in our 
locale. More studies are required from all South African public sector hospitals to 
assess the prevalence of E. coli ST131.  
 
PCR screening and sequencing of porin genes is required to confirm the presence or 
absence of porins and to investigate the basis of porin loss (including insertional 
inactivation or mutations that may have changed porin’s substrate specificity). SDS-
PAGE indicates the presence of the expressed porins but does not efficiently 
indicate expression levels of porin genes hence more efficient molecular techniques 
such as real-time PCR would be useful to determine the expression levels of porin 
genes as well as efflux pumps in carbapenem-resistant isolates. Another aspect that 
needs to be given some attention is the effect of broth osmolality on porin expression 
in carbapenem-resistant bacteria as this may affect the results observed on SDS-
PAGE.  
 
In an attempt to prevent further emergence and dissemination of MDR Gram-
negative pathogens, investigation of potential reservoirs and possible transmission 
pathways of these pathogens is necessary. Moreover, large-scale study with a 
balanced distribution of bacterial species is essential to obtain an accurate 
prevalence of the resistance determinants described in this study. 
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APPENDIX 
 
A.1 Antimicrobial susceptibility profiles 
 
Carbapenem-susceptible isolates 
A.1.1 K. pneumoniae 
Of the 25 K. pneumoniae isolates, 25 (100%) exhibited resistance to AMP, CXM and 
CAE, 7 (28%) to AMC, 5 (20%) to TZP and FEP, 23 (92%) to CTX, 14 (56%) to CAZ, 
18 (72%) to GEN, 11 (44%) to NAL, 9 (36%) to CIP, 1 (4%) to TGC, 13 (52%) to NIT, 
and 16 (64%) to SXT (Table A.1). Of the 25 K. pneumoniae isolates, 7 (28%) were 
classified with intermediate resistance to AMC, 4 (16%) to TZP and CIP, 1 (4%) to 
FOX and TGC, 2 (8%) to CTX, 3 (12%) to FEP and 6 (24%) to NIT. All 25 isolates 
were susceptible to ETP, IPM, MEM, AMK, and CST. 
 
Table A.1: Antimicrobial susceptibility profiles of ESBL-producing K. pneumoniae isolates (n=25) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MIC (mg/L) 
 
Categorical susceptibility (%) 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC 2 - 16 44 28 28 
TZP ≤4 - ≥128 64 16 20 
CXM ≥64   100 
CAE ≥64   100 
FOX ≤4 - 16 96 4  
CTX 2 - ≥64  8 92 
CAZ ≤1 - ≥64 44  56 
FEP ≤1 - ≥64 68 12 20 
ETP ≤0.5 100   
IPM ≤1 100   
MEM ≤0.25 100   
AMK ≤2 - 16  100   
GEN ≤1 - ≥16 28  72 
NAL ≤2 - ≥32 56  44 
CIP ≤0.25 - ≥4 48 16 36 
TGC ≤0.5 - ≥8 92 4 4 
NIT ≤16 - ≥512 24 24 52 
CST ≤0.5 100   
SXT ≤20 - ≥320 28  64 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.2 K. oxytoca 
The K. oxytoca isolate exhibited resistance to AMP, CXM, CAE, CTX, CAZ, FEP, 
GEN, and SXT (Table A.2). Intermediate resistance was detected to AMC and TZP. 
No resistance to FOX, ETP, IPM, MEM, AMK, NAL, CIP, TGC, NIT, or CST was 
detected.  
 
Table A.2: Antimicrobial susceptibility profiles of ESBL-producing K. oxytoca isolates (n=1) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MICs (mg/L) 
 
Categorical susceptibility (%) 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC 16  100  
TZP 32  100  
CXM  ≥64   100 
CAE ≥64   100 
FOX ≤4 100   
CTX ≥64   100 
CAZ 16   100 
FEP ≥64   100 
ETP ≤0.5 100   
IPM ≤1 100   
MEM ≤0.25 100   
AMK 16 100   
GEN ≥16   100 
NAL 4 100   
CIP ≤0.25 100   
TGC 1 100   
NIT ≤16 100   
CST ≤0.5 100   
SXT ≥320   100 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.3 E. coli 
Of the 21 E. coli isolates, 21 (100%) exhibited resistance to AMP, CXM, CAE and 
SXT, 4 (19%) to AMC, 2 (9.5%) to FOX, CAZ and NIT, 19 (90.5%) to CTX, 3 (13.6%) 
to FEP, 4 (19%) to GEN, 14 (66.7%) to NAL and CIP (Table A.3). Of the 21 E. coli 
isolates, 10 (47.6%) were classified with intermediate resistance to AMC, 1 (4.8%) to 
FOX, AMK and NIT, and (9.5%) to CTX. All 21 E. coli isolates were susceptible to 
TZP, ETP, IPM, MEM, TGC and CST.  
 
 
 
Table A.3: Antimicrobial susceptibility profiles of ESBL-producing E. coli isolates (n=21) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MICs (mg/L) 
 
Categorical susceptibility % 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC 4 - ≥32 33.4 47.6 19 
TZP ≤4 100   
CXM ≥64   100 
CAE ≥64   100 
FOX ≤4 – ≥64 85.7 4.8 9.5 
CTX 2 – ≥64  9.5 90.5 
CAZ ≤1 - ≥64 91  9 
FEP ≤1 - ≥64 86.4  13.6 
ETP ≤0.5 100   
IPM ≤1 100   
MEM ≤0.25 100   
AMK ≤2 - 32 95.2 4.8  
GEN ≤1 - ≥16 81  19 
NAL ≤2 - ≥32 33.3  66.7 
CIP ≤0.25 - ≥4 33.3  66.7 
TGC ≤0.5 – 1 100   
NIT ≤16 – 128 85.7 4.8 9.5 
CST ≤0.5 100   
SXT ≥320   100 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.4 E. cloacae 
Of the 4 E. cloacae isolates, 4 (100%) exhibited resistance to AMP, AMC, CXM, 
CAE, FOX, CTX and SXT, 3 (75%) to CAZ, 1 (25%) to FEP, 2 (50%) to GEN, NAL 
and CIP (Table A.4). Of the 4 E. cloacae isolates, 3 (75%) were classified with 
intermediate resistance to TZP and NIT. No resistance to ETP, IPM, MEM, AMK, 
TGC, or CST was detected.  
 
Table A.4: Antimicrobial susceptibility profiles of ESBL-producing E. cloacae isolates (n=4) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MICs (mg/L) 
 
Categorical susceptibility % 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC ≥32   100 
TZP ≤4 - 64 25 75  
CXM ≥64   100 
CAE ≥64   100 
FOX ≥64   100 
CTX ≥64   100 
CAZ ≤1 - ≥64 25  75 
FEP 2 - ≥64 75  25 
ETP ≤0.5 100   
IPM ≤1 100   
MEM ≤0.25 100   
AMK ≤2 - 16 100   
GEN ≤1 - ≥16 50  50 
NAL 16 - ≥32 50  50 
CIP 0.5 - ≥4 50  50 
TGC 1  100   
NIT 32 - 64 25 75  
CST ≤0.5 100   
SXT ≥320   100 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.5 C. freundii 
Of the 4 C. freundii isolates, 4 (100%) exhibited resistance to AMP, CXM, CAE, CTX 
and SXT, 3 (75%) to AMC, CAZ, GEN and NAL, 2 (50%) to FOX and CIP, and 1 
(25%) to FEP (Table A.5). Of the 4 C. freundii isolates, 1 (25%) was classified with 
intermediate resistance to AMC, and 2 (50%) to TZP. No resistance to ETP, IPM, 
MEM, AMK, TGC, NIT or CST was detected.  
 
Table A.5: Antimicrobial susceptibility profiles of ESBL-producing C. freundii isolates (n=4) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MICs (mg/L) 
 
Categorical susceptibility % 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC 16 - ≥32  25 75 
TZP 4 - 64 50 50  
CXM ≥64   100 
CAE ≥64   100 
FOX ≤4 - ≥64 50  50 
CTX ≥64   100 
CAZ 2 - ≥64 25  75 
FEP 2 - ≥64 75  25 
ETP ≤0.5 100   
IPM ≤1 100   
MEM ≤0.25 100   
AMK 4 - 16 100   
GEN ≤1 - ≥16 25  75 
NAL 4 - ≥32 25  75 
CIP ≤0.25 - ≥4 50  50 
TGC ≤0.5  100   
NIT ≤16 100   
CST ≤0.5 100   
SXT ≥320   100 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.6 E. aerogenes 
The E. aerogenes isolate was resistant to AMP, AMC, CXM, CAE, FOX, CTX, CAZ, 
FEP, GEN, and SXT (Table A.6). This isolates exhibited intermediate resistance to 
TZP and NIT. No resistance to ETP, IPM, MEM, AMK, NAL, CIP, TGC, or CST was 
detected.  
 
Table A.6: Antimicrobial susceptibility profiles of ESBL-producing E. aerogenes isolates (n=1) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MICs (mg/L) 
 
Categorical susceptibility % 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC ≥32   100 
TZP 32  100  
CXM ≥64   100 
CAE ≥64   100 
FOX ≥64   100 
CTX ≥64   100 
CAZ 16   100 
FEP ≥64   100 
ETP ≤0.5 100   
IPM ≤1 100   
MEM ≤0.25 100   
AMK ≤2 100   
GEN ≥16   100 
NAL 16 100   
CIP 1 100   
TGC ≤0.5 100   
NIT 64  100  
CST ≤0.5 100   
SXT ≥320   100 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.7 P. mirabilis 
The P. mirabilis isolate was resistant to AMP, CXM, CAE, CTX, CAZ, FEP, NAL, 
NIT, CST, TGC and SXT (Table A.7). This isolate exhibited intermediate resistance 
to AMK, and GEN. No resistance to AMC, TZP, FOX, ETP, IPM, MEM, and CIP was 
detected.  
 
Table A.7: Antimicrobial susceptibility profiles of ESBL-producing P. mirabilis isolates (n=1) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MICs (mg/L) 
 
Categorical susceptibility % 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC 8 100   
TZP ≤4 100   
CXM ≥64   100 
CAE ≥64   100 
FOX ≤4 100   
CTX 16   100 
CAZ ≥64   100 
FEP 32   100 
ETP ≤0.5 100   
IPM ≤1 100   
MEM ≤0.25 100   
AMK 32  100  
GEN 8  100  
NAL ≥32   100 
CIP 1 100   
TGC 4   100 
NIT 256   100 
CST ≥16   100 
SXT ≥320   100 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.8 S. marcescens 
Of the 2 S. marcescens isolates, both exhibited resistance to AMP, AMC, CXM, 
CAE, CTX, CAZ, GEN, NIT and CST, 1 (50%) to TZP, FEP and SXT (Table A.8). Of 
the 2 C. freundii isolates, 1 (50%) was classified with intermediate resistance to TZP 
and FEP, and 2 (100%) to FOX. No resistance to ETP, IPM, MEM, AMK, NAL, CIP, 
or TGC was detected.  
 
Table A.8: Antimicrobial susceptibility profiles of ESBL-producing S. marcescens isolates (n=2) 
determined by Vitek® 2 system. 
 
Antimicrobial 
agent 
MICs (mg/L) 
 
Categorical susceptibility % 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC ≥32   100 
TZP 64 - ≥128  50 50 
CXM ≥64   100 
CAE ≥64   100 
FOX 16  100  
CTX ≥64   100 
CAZ 16   100 
FEP 16 - 32  50 50 
ETP ≤0.5 100   
IPM ≤1 100   
MEM ≤0.25 100   
AMK 16 100   
GEN ≥16   100 
NAL ≤2 - 4 100   
CIP ≤0.25 100   
TGC ≤0.5 100   
NIT 256   100 
CST ≥16   100 
SXT ≤20 - ≥320 50  50 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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Carbapenem-resistant isolates 
A.1.9 A. baumannii 
Of the 14 A. baumannii isolates, 14 (100%) exhibited resistance to AMP, AMC, TZP, 
CXM, CAE, FOX, CTX, CAZ, FEP, IPM, MEM, NIT and SXT, 9 (64.3%) to ETP and 
TGC, 3 (21.4%) to AMK, 12 (85.8%) to GEN, 13 (92.9%) to NAL and CIP (Table 
A.9). Of the 14 A. baumannii isolates, 1 (7.1%) was classified with intermediate 
resistance to GEN. All 14 isolates were susceptible to CST. 
 
Table A.9: Antimicrobial susceptibility profiles of carbapenem-resistant A. baumannii isolates 
(n=14) determined by Vitek® 2 system. 
 
Antimicrobial agent MIC (mg/L) 
 
Categorical susceptibility (%) 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC ≥32   100 
TZP ≥128   100 
CXM ≥64   100 
CAE ≥64   100 
FOX ≥32   100 
CTX ≥64   100 
CAZ ≥64   100 
FEP ≥64   100 
ETP 0.064 - >32 35.7  64.3 
IPM 16 - 64   100 
MEM 16 - 64   100 
AMK 16 - ≥64 78.6  21.4 
GEN 4 - ≥16 7.1 7.1 85.8 
NAL ≤2 - ≥32 7.1  92.9 
CIP ≤0.25 - ≥4 7.1  92.9 
TGC ≤0.5 - ≥8 35.7  64.3 
NIT ≥512   100 
CST ≤0.5 100   
SXT ≥320   100 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.10 K. pneumoniae 
Of the 10 K. pneumoniae isolates, 10 (100%) exhibited resistance to AMP, AMC, 
TZP, CXM, CAE, FOX, CTX, CAZ, FEP, ETP, IPM, MEM, NAL, CIP, NIT and SXT, 7 
(70%) to GEN, and 3 (30%) to TGC (Table A.10). All 10 isolates were susceptible to 
AMK and CST. 
 
Table A.10: Antimicrobial susceptibility profiles of carbapenem-resistant K. pneumoniae isolates 
(n=10) determined by Vitek® 2 system. 
 
Antimicrobial agent MIC (mg/L) 
 
Categorical susceptibility (%) 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC ≥32   100 
TZP ≥128   100 
CXM ≥64   100 
CAE ≥64   100 
FOX ≥32   100 
CTX ≥64   100 
CAZ ≥64   100 
FEP ≥64   100 
ETP 2 - >32   100 
IPM 8 - 32   100 
MEM 16 - 32   100 
AMK 16  100   
GEN 4 - ≥16 30  70 
NAL ≥32   100 
CIP  ≥4   100 
TGC ≤0.5 - ≥8 70  30 
NIT ≥512   100 
CST ≤0.5 100   
SXT ≥320   100 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
 
 
. 
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A.1.11 P. aeruginosa 
Of the 9 P. aeruginosa isolates, 9 (100%) exhibited resistance to AMP, AMC, CXM, 
CAE, FOX, CTX, MEM, NAL, TGC and NIT, 5 (55.6%) to TZP, FEP and ETP, 1 
(11.1%) to CAZ, 8 (88.9%) to IPM, 4 (44.4%) to AMK and CIP, 7 (77.8%) to GEN 
and SXT (Table A.11). All 9 isolates were susceptible to CST. 
 
Table A.11: Antimicrobial susceptibility profiles of carbapenem-resistant P. aeruginosa isolates 
(n=9) determined by Vitek® 2 system. 
 
Antimicrobial agent MIC (mg/L) 
 
Categorical susceptibility (%) 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC ≥32   100 
TZP 8 - ≥128 44.4  55.6 
CXM ≥64   100 
CAE ≥64   100 
FOX ≥32   100 
CTX ≥64   100 
CAZ 2 - ≥64 88.9  11.1 
FEP 2 - ≥64 44.4  55.6 
ETP 0.032 - >32 44.4  55.6 
IPM 1 - 64 11.1  88.9 
MEM 16 - 64   100 
AMK ≤2 - ≥64 55.6  44.4 
GEN 2 - ≥16 22.2  77.8 
NAL ≥32   100 
CIP ≤0.25 - ≥4 55.6  44.4 
TGC ≥8   100 
NIT ≥512   100 
CST ≤0.5 100   
SXT 40 - ≥320 22.2  77.8 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.12 E. cloacae 
Of the 4 E. cloacae isolates, 4 (100%) exhibited resistance to AMP, AMC, TZP, 
CXM, CAE, FOX, CTX, CAZ, FEP, IPM, NAL, TGC and NIT, 3 (75%) to ETP, GEN, 
CIP and SXT (Table A.12). Of the 4 E. cloacae isolates, 1 (25 %) was classified with 
intermediate resistance to ETP. All 4 isolates were susceptible to AMK and CST. 
 
Table A.12: Antimicrobial susceptibility profiles of carbapenem-resistant E. cloacae isolates (n=4) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MIC (mg/L) 
 
Categorical susceptibility (%) 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC ≥32   100 
TZP ≥128   100 
CXM ≥64   100 
CAE ≥64   100 
FOX ≥32   100 
CTX ≥64   100 
CAZ ≥64   100 
FEP ≥64   100 
ETP 1 - 4  25 75 
IPM 16 - 32   100 
MEM 16 - 32   100 
AMK 8 100   
GEN ≤1 - ≥16 25  75 
NAL ≥32   100 
CIP ≤0.25 - ≥4 25  75 
TGC ≥8   100 
NIT ≥512   100 
CST ≤0.5 100   
SXT 40 - ≥320 25  75 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.13 E. asburiae 
The E. cloacae isolate exhibited resistance to AMP, AMC, TZP, CXM, CAE, FOX, 
ETP, IPM and MEM (Table A.13). This isolate was susceptible to CTX, CAZ, FEP, 
GEN, AMK, NAL, CIP, TGC, NIT and SXT.  
 
Table A.13: Antimicrobial susceptibility profiles of carbapenem-resistant E. asburiae isolates (n=1) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MIC (mg/L) 
 
Categorical susceptibility (%) 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC ≥32   100 
TZP ≥128   100 
CXM ≥64   100 
CAE ≥64   100 
FOX ≥32   100 
CTX ≤1 100   
CAZ ≤1 100   
FEP ≤1 100   
ETP 4    100 
IPM 8   100 
MEM 32   100 
AMK ≤2 100   
GEN ≤1 100   
NAL 8 100   
CIP ≤0.25 100   
TGC 1 100   
NIT 64 100   
CST ≤0.5 100   
SXT ≤20 100   
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
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A.1.14 E. coli 
The E. coli isolate exhibited resistance to AMP, AMC, CXM, CAE, FOX, CTX, CAZ, 
FEP, ETP, IPM, MEM, GEN, NAL, CIP and NIT (Table A.14). This isolate was 
susceptible to TZP, AMK, TGC and CST.  
 
Table A.14: Antimicrobial susceptibility profiles of carbapenem-resistant E. coli isolates (n=1) 
determined by Vitek® 2 system. 
 
Antimicrobial agent MIC (mg/L) 
 
Categorical susceptibility (%) 
Susceptible Intermediate Resistant 
AMP ≥32   100 
AMC ≥32   100 
TZP <4 100   
CXM ≥64   100 
CAE ≥64   100 
FOX ≥32   100 
CTX ≥64   100 
CAZ ≥64   100 
FEP ≥64   100 
ETP 12   100 
IPM 4   100 
MEM 32   100 
AMK 16  100   
GEN ≥16   100 
NAL ≥32   100 
CIP ≥4   100 
TGC ≤0.5  100   
NIT ≥512   100 
CST ≤0.5 100   
SXT ≥320   100 
Abbreviations: AMP = ampicillin; AMC = amoxicillin-clavulanic acid; CXM = cefuroxime; CAE = 
cefuroxime axetil; FOX = cefoxitin; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; ETP = 
ertapenem; IPM = imipenem; MEM = meropenem; AMK = amikacin; GEN = gentamicin; NAL = 
nalidixic acid; CIP = ciprofloxacin; TGC  = tigecycline; NIT = nitrofurantoin; CST = colistin; SXT = 
trimethoprim-sulfamethoxazole. Blank indicates not detected. MICs interpreted according to the CLSI 
guidelines (2013). 
 
 
 
 
 
 
 
 
 
 
175 
 
 
Figure A.1: CTX-M group I: CTX-M-3 variant DNA sequence of CTX-M-3 variant from a carbapenem-susceptible E. 
cloacae isolate CS28 aligned with a GenBank CTX-M-3 sequence (sequence corresponding to position 637 – 
1091 of blaCTX-M-3 with accession number: HQ214051.1). Sequence identity = 99%.  
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Figure A.2: DNA sequence of CTX-M-15 variant from a carbapenem-susceptible K. pneumoniae isolate CS8 aligned with a GenBank CTX-M-15 sequence 
(sequence corresponding to position 2209 - 2663 of blaCTX-M-15 with accession number: KF055402.1). Sequence identity = 99%.  
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Figure A.3: DNA sequence of CTX-M-14 variant from a carbapenem-susceptible K. pneumoniae isolate CS11 aligned 
with a GenBank CTX-M-14 sequence (sequence corresponding to position 139 – 571 of blaCTX-M-14 with 
accession number: AB545871.1). Sequence identity = 99%.  
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Figure A.4: DNA sequence of TEM-1 variant from a carbapenem-susceptible K. pneumoniae isolate 
CS25 aligned with a GenBank TEM-1 sequence (sequence corresponding to position 
814 – 1622 of blaTEM-1 with accession number: KF268357.1). Sequence identity = 93%.  
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Figure A.5: DNA sequence of SHV-1 variant from a carbapenem-susceptible K. pneumoniae isolate 
CS17 aligned with a GenBank SHV-1 sequence (sequence corresponding to position 42 
– 850 of blaSHV-1 with accession number: GU064389.1). Sequence identity = 99%.  
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Figure A.6: DNA sequence of SHV-11 variant from a carbapenem-susceptible K. pneumoniae 
isolate CS11 aligned with a GenBank SHV-11 sequence (sequence corresponding to 
position 42 – 847 of blaSHV-11 with accession number: GU064392.1). Sequence identity = 
99%.  
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Figure A.7: DNA sequence of OXA-1 variant from a carbapenem-susceptible E. cloacae isolate CS26 aligned with a 
GenBank OXA-1 sequence (sequence corresponding to position 358 – 775 of blaOXA-1 with accession number: 
GQ336886.1). Sequence identity = 99%.  
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Figure A.8: DNA sequence of QnrS1 variant from a carbapenem-susceptible E. cloacae isolate CS28 aligned with a 
GenBank QnrS1 sequence (sequence corresponding to position 167 – 526 of qnrS1 with accession number: 
HM125705.1). Sequence identity = 100%.  
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Figure A.9: DNA sequence of Aac(6’)-lb-cr variant from a carbapenem-susceptible K. pneumoniae isolate CS18 aligned 
with a GenBank Aac(6’)-lb-cr sequence (sequence corresponding to position 15 – 460 of aac(6’)-lb-cr with 
accession number: JQ065040.1). Sequence identity = 99%.  
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Figure A.10: DNA sequence of CTX-M-1 variant from E. coli ST131-negative isolate PE13 aligned with a GenBank CTX-M-1 sequence 
(sequence corresponding to position 2225 - 2679 of blaCTX-M-1 with accession number: HF549090.1). Sequence identity = 
99%.  
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Figure A.11: DNA sequence of OXA-23 variant from a carbapenem-resistant A. baumannii isolate CR3 aligned with a GenBank 
OXA-23 sequence (sequence corresponding to position 12 - 471 of blaOXA-23 with accession number: JQ409995.1). 
Sequence identity = 99%.  
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Figure A.12: DNA sequence of OXA-51 variant from a carbapenem-resistant A. baumannii isolate CR2 aligned with a GenBank 
OXA-51 sequence (sequence corresponding to position 40 - 353 of blaOXA-51 with accession number: JX305940.1). 
Sequence identity = 99%.  
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Figure A.13: DNA sequence of OXA-58 variant from a carbapenem-resistant A. baumannii isolate CR13 aligned with a GenBank 
OXA-58 sequence (sequence corresponding to position 13 - 561 of blaOXA-58 with accession number: JQ409994.1). 
Sequence identity = 99%.  
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Figure A.14: DNA sequence of ISAba1 from a carbapenem-resistant A. baumannii CR1 aligned with a GenBank ISAba1 sequence 
(sequence corresponding to position 616 - 1109 of ISAba1 with accession number: JN696403.1). Sequence identity = 
94%.  
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Figure A.15: DNA sequence of ISAba1-OXA-23 from a carbapenem-resistant A. baumannii isolate CR1 
aligned with a GenBank ISAba1-OXA-23 sequence (sequence corresponding to position 812 - 
1960 of ISAba1-blaOXA-23 with accession number: GQ861439.1). Sequence identity = 97%.  
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Figure A.16: DNA sequence of QnrB2 variant from a carbapenem-resistant E. cloacae isolate CR35 aligned with a GenBank 
QnrB2 sequence (sequence corresponding to position 166 – 607 of qnrB2 with accession number: 
HM125701.1). Sequence identity = 96%. 
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